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Abstract  
External beam radiotherapy (EBRT) plays a vital role in the treatment of cancer, with 
close to half of all cancer patients receiving EBRT at some point over their course of 
treatment. Although EBRT is a well-established form of treatment, there are a number of 
ways in which EBRT could still be improved in terms of quality and efficiency for 
treatment planning and radiation dose delivery. This thesis reports a series of 
improvements made to EBRT.  
First, we developed and evaluated a new treatment planning technique called unified 
intensity-modulated arc therapy (UIMAT) which combines the optimization and delivery 
of rotational volumetric modulated arc therapy (VMAT) and fixed-gantry intensity-
modulated radiation therapy (IMRT). When retrospectively compared to clinical 
treatment plans using VMAT or IMRT alone, UIMAT plans reduced the dose to nearby 
critical structures by as much as 23% without compromising tumour volume coverage. 
The UIMAT plans were also more efficient to deliver. The reduction in normal tissue 
dose could help lower the probability of treatment-related toxicities, or alternatively 
could be used to improve tumour control probability, via dose escalation, while 
maintaining current dose limits for organs at risk. 
Second, we developed a new fast inverse direct aperture optimization (FIDAO) algorithm 
for IMRT, VMAT, and UIMAT treatment planning. FIDAO introduces modifications to 
the direct aperture optimization (DAO) process that help improve its computational 
efficiency. As demonstrated in several test cases, these modifications do not significantly 
impact the plan quality but reduced the DAO time by as much as 200-fold. If 
implemented with graphical processing units (GPUs), this project may allow for 
applications such as on-line treatment adaptation.  
Third, we investigated a method of acquiring tissue density information from cone-beam 
computed tomography (CBCT) datasets for on-line dose calculations, plan assessment, 
and potentially plan adaptation using FIDAO. This calibration technique accounts for 
 iii 
 
patient-specific scattering conditions, demonstrated high dosimetric accuracy, and can be 
easily automated for on-line plan assessment.  
Collectively, these three projects will help reduce the normal tissue doses from EBRT, 
improve the planning and delivery efficiency, and pave the way for application like on-
line plan assessment and adaptive radiotherapy in response to anatomical changes.  
Keywords: 
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Cone Beam Computed Tomography;   
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Chapter 1 – Introduction  
1.1 Cancer statistics  
Cancer is a highly prevalent disease and a leading cause of death worldwide [1-5]. In 
2018, the Canadian Cancer Society projects that about one in two Canadians will be 
diagnosed with cancer at some point in their lifetime, and about one in four Canadians 
will die with this disease [1]. Fortunately, the cancer mortality rates are declining in many 
countries – including Canada – due to earlier detection and intervention, greater access to 
treatment, and from advancements in cancer treatments, including radiation therapy [4,5].  
1.2 Radiation Therapy Overview 
Radiation therapy plays a vital role in the treatment of cancer, with more than half of 
all cancer patients receiving radiation therapy at some point over their course of treatment 
[3,5]. In radiation therapy, the patient is exposed to one or more sources of ionizing 
radiation (i.e. high-energy x-rays, gamma rays, and/or charged particles). This ionizing 
radiation can penetrate through the patient’s body, damaging and killing cells along its 
trajectory [6,7]. The goal of radiation therapy is to preferentially deliver radiation to the 
tumour volume while minimizing the amount of healthy tissue exposed and collaterally 
damaged by treatment. 
A commonly used metric in radiation therapy is the absorbed dose. Absorbed dose 
measures the amount of energy (in joules, J) that is deposited per unit mass of an 
absorber (in kilogram, kg), by ionizing radiation [6]. Absorbed dose is measured in the SI 
unit Gray (Gy), where 1 Gy = 1 J/kg. The higher the absorbed dose in a volume, the more 
likely that lethal cell damage will occur in that volume, and the more likely that cells 
within that volume will transform or perish [7]. Therefore, the goal of radiation therapy is 
to achieve a high absorbed dose in defined target regions containing cancerous tissue, and 
a lower absorbed dose in regions containing normal tissue. 
Radiation treatments are often administered over multiple treatment sessions. The 
motivation for this fractionation comes from various radiobiological principles [7]. For 
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instance, healthy tissue can repair faster from radiation damage than most cancerous cells 
[7]. Therefore, by administering the treatment over multiple treatment sessions, we can 
offer the healthy tissue more repair than cancerous cells. Furthermore, between treatment 
sessions, the tumour volume can re-oxygenate, and its cells can enter into more 
radiosensitive phases of the cell division cycle. As a result, the tumour volume becomes 
more susceptible to radiation damage in future treatment sessions, and the therapeutic 
ratio can be improved with fractionated-radiotherapy. A typical radiation treatment will 
deliver 60 Gy to the tumour volume over 30 sessions (i.e. in 2 Gy / fraction over 30 
fractions).  
Radiation therapy can be administered in one of two ways: externally, through a 
treatment known as external beam radiotherapy (EBRT), or internally, through a 
procedure known as brachytherapy [6]. In brachytherapy, radioactive sources are 
permanently or temporarily implanted in the patient, within or in close contact with the 
tumour volume [6]. As the radionuclide decays, it emits ionizing gamma rays and/or 
charged particles capable of damaging the nearby cells [6,7]. By placing the 
radionuclides near or within the tumour volume, the absorbed dose is highest in the 
cancerous tissue and reduces rapidly in the distal healthy tissue. Due to the invasiveness 
of this procedure, brachytherapy is often only performed in a subset of patients where the 
surgical procedure is well tolerated or minimally invasive (e.g. cervical, esophageal, or 
localized prostate cancer) [6]. Instead, most cancer patients are treated using EBRT. This 
thesis will focus exclusively on EBRT. In EBRT, beams of high-energy x-rays or charged 
particles are generated by a medical linear accelerator and directed towards the patient’s 
cancerous tissue [6]. While medical linear accelerators (also referred to as a linacs) can 
be used to deliver megavoltage electron or x-ray beams, this thesis will deal exclusively 
with x-ray beams. A medical linear accelerator and its treatment head (collimator) is 
shown in Figure 1.1. To reach deeply seated tumours, the x-ray beam must first travel 
through – and deposit dose into – healthy tissue. Due to the dosimetric properties of x-
rays, more dose will be deposited in the shallow healthy tissue than in the deep-seated 
cancerous tissue [6]. To minimize the healthy tissue dose, EBRT treatments will use 
multiple cross-fired beams, delivered from various gantry, couch and collimator angles, 
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that intersect at the tumour volume. By doing this, less dose is deposited in the healthy 
tissue, while a high cumulative dose is deposited in the cancerous tissue. Components 
within the collimator, such as the jaws and multileaf collimator (MLC) shown in Figure 
1.1, can also be used to attenuate and shape the beams. The plan beams can be optimized 
to limit normal tissue dose and to improve the cumulative dose received by the target 
volume [6]. In order to determine which beam configuration, beam shapes, and exposure 
times to use for each patient, a treatment planning procedure is required as described in 
the following section.  
 
Figure 1.1: Picture of a linac [left] and the linac’s treatment head (collimator) [right]. 
Note that these images have been recolored to help identify each component. [left] The 
patient lies on the treatment couch (orange) during treatment. Ionizing radiation is 
delivered from the gantry (green) towards the patient, as illustrated by the yellow cone. 
The gantry (and therefore the beam) can fully rotate around the patient, while the couch 
can be rotated, elevated, and repositioned as well. Some linacs possess onboard imaging 
capabilities for patient positioning and setup. The x-ray source and detector of this linac’s 
imaging unit is highlighted blue and red, respectively. [right] The beam can be attenuated 
and shaped using the jaws (blue) and the multileaf collimator (MLC, purple) within the 
collimator of the linac. The rotation angle of the collimator can also be adjusted. 
 4 
 
1.3 EBRT Treatment Process 
The EBRT treatment planning process consists of the following major steps: (1) 
image acquisition, (2) delineation of target volumes and organs at risk (contouring), (3) 
beam selection, (4) plan optimization, (5) plan evaluation, (6) quality assurance, and (7) 
plan delivery. Details of each step that are relevant to this thesis, are provided in the 
following subsection. 
1.3.1 Image Acquisition 
Treatment planning begins by acquiring three-dimensional (3D) image sets of the 
patient. To calculate the absorbed dose from EBRT treatment in the patient, 3D maps of 
the tissue electron density (in electrons per cm3) are needed [8-10]. These maps can be 
easily generated from the pixel values (Hounsfield Units (HU)) of x-ray computed 
tomography (CT) scans [9,10]. These CT scans are acquired in the intended treatment 
position and will include any immobilization equipment that will be for treatment. For 
instance, personalized immobilization masks are often used for patients with brain and 
head-and-neck cancer to hold their head in the same reproducible position during the CT 
scan and in each of the treatment sessions. These masks are securely fastened to the 
couch of the linac. Similarly, abdominal compressors may be used in patients with lung 
cancer to help suppress respiratory tumour motion during the CT scan and treatment. 
These CT scans are often referred to as the ‘planning CT’ or ‘CT-sim’ as they are used to 
plan and simulate the treatment.  
In some cases, it may not be possible to differentiate healthy tissue from cancerous 
tissue on the planning CT images, as the borders of the tumour may not be well defined 
on this type of scan. Moreover, additional information such a metabolic activity or water 
diffusivity may be helpful for differentiating cancerous lesions from healthy tissue, 
staging the cancer, or visualizing nearby critical structures (e.g. hippocampus). Therefore, 
additional scans of the patient may be acquired using other imaging modalities such as 
magnetic resonance imaging (MRI) and positron emission tomography (PET) [11].  
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1.3.2 Contouring and Prescription  
The image sets (planning CT, MRI, PET) of the patient are imported into a 
commercial treatment planning system (TPS). If MRI or PET scans were acquired of the 
patient, these image sets are co-registered with the patient’s planning CT using rigid or 
deformable image registration (DIR) techniques [12]. The patient’s tumour(s), organs, 
and healthy tissue are then delineated on the planning CT with the assistance of the co-
registered MRI or PET scans [13]. The delineated tumour – as it is visible on the MRI, 
PET, and/or CT scan – is referred to as the gross tumour volume (GTV).  
Cancerous lesions are typically encapsulated by microscopic disease that cannot be 
clearly visualized on MRI, PET, or CT scans. To ensure that all cancerous tissue is 
treated, a treatment margin is added to the GTVs. This expansion of the GTV is referred 
to as the clinical target volume (CTV) [13].  
Some patients may have their gross tumour(s) surgically resected prior to radiation 
therapy. If no gross tumour is left behind from surgery, the tumour bed will be contoured 
instead and labelled as the CTV [13]. 
In some patients, there may be concerns that the disease has spread into the nearby 
lymphatic tissue; even when there is no clear GTV in these regions. In these cases, the 
lymphatic tissue may be delineated and treated prophylactically [13]. This is done to 
mitigate the risk of local reoccurrence and the risk of the disease spread (metastasis) to 
other regions of the body.  
Lastly, a margin is added to the CTVs to account for the interfraction variability in 
patient positioning, intrafraction motion such as breathing, and the general uncertainties 
associated with treatment delivery. This expansion of the CTV is called the planning 
target volume (PTV). Each PTV is prescribed a specific absorbed dose level. Primary 
PTVs containing the GTV will be prescribed a high absorbed dose that will result in a 
high tumour control probability (e.g. 70 Gy). Meanwhile, PTVs containing the lymphatic 
tissue will typically be treated with a lower absorbed dose (e.g. 56 Gy). Finally, the 
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radiotherapy plan is normalized so that 95% of primary PTV is covered by 100% of the 
prescription dose. 
1.3.3 Beam Selection 
In this step, a treatment planner specifies what type of beam the linac will deliver (x-
rays or electrons); the energy of each beam; the gantry, collimator, and couch angles of 
the beams; and how the linac will deliver this radiation. While there are many EBRT 
techniques available today, such as electron beams and 3D conformal radiotherapy, the 
majority of advanced EBRT treatments use x-ray beams delivered via one of two delivery 
techniques: fixed-gantry intensity-modulated radiation therapy (IMRT) and rotational 
volumetric modulated arc therapy (VMAT).  
In fixed-gantry IMRT, the gantry, couch and collimator angles will remain fixed 
while the x-ray beam is being delivered. However, during beam delivery, the linac can 
alter the shape of the beam using the MLC and jaws shown in Figure 1.1 [14]. The MLC 
(and in some cases, jaws) can move while the beam is being delivered, in a technique 
known as sliding-window IMRT. Alternatively, the jaws and MLC can only be moved 
when the beam is shut off, known as step-and-shoot IMRT [6]. By modulating the shape 
of the beam during treatment, the net intensity (or fluence) delivered from each gantry 
angle is spatially varied, hence the name intensity-modulated radiation therapy. This 
intensity modulation can be used to improve PTV dose coverage and to minimize the 
dose to organs-at-risk (OAR) along the beam trajectories [6]. With the wise selection of 
gantry angles, IMRT can generally minimize the healthy tissue exposure and generate 
steep dose gradients to spare nearby critical structures, as demonstrated by the whole 
breast radiotherapy case in Figure 1.2. 
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Figure 1.2: Axial view of a left-sided whole breast radiotherapy plan using two parallel 
and opposing IMRT beams. These beams are visualized as the red and green cones 
intersecting with the patient. With this beam setup, dose is limited primarily to the breast 
tissue. Meanwhile, the steep dose gradient (illustrated by the isodose lines, with each colour 
indicating the region receiving the corresponding dose (or more) in the legend on the right) 
generated by the beam edge is used to spare the nearby lung and heart.  
In VMAT, radiation is delivered as the linac gantry continuously rotates the beam 
around the patient. Along the arc trajectory, the beam’s dose-rate (i.e. the beam flux) and 
shape is modulated [15-16]. The treatment planner specifies the arcs to be used in the 
treatment plan and their arc range. While VMAT has limited intensity-modulation at any 
given gantry angle, the wide range of deliverable angles allows for more conformal dose 
distributions when treating quasi-spherical target volumes, like the prostate PTV shown 
in Figure 1.3. The wide range of deliverable angles in VMAT may result in a large 
volume of healthy tissue receiving low levels of dose, whereas the limited number of 
beams used by fixed-gantry IMRT may result in a smaller volume of healthy tissue being 
exposed but receiving higher levels of dose (as illustrated by the isodose lines in Figure 
1.2). VMAT treatments are also typically more efficient to deliver than fixed-gantry 
IMRT. 
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Figure 1.3: Axial view of a prostate radiotherapy plan using a single 360° VMAT arc 
(beam is not shown to improve visibility). With its wide range of deliverable angles, 
VMAT can produce dose distributions that are very conformal to the PTV.  
1.3.4 Plan Optimization 
It will be helpful for this section to first go over how medical linear accelerators are 
instructed to deliver IMRT and VMAT treatment plans. During delivery, a linac follows a 
series of programmed instructions known as control points (CP) [17]. Each CP specifies 
the position of each machine components (i.e. the couch position and angle, the gantry 
angle, the collimator angle, each jaw position, and each MLC leaf position) and the 
cumulative number of monitor units (MUs) that the machine is to deliver by the next CP. 
Note that the MU is a calibrated radiation unit that is measured by a monitoring ion 
chamber inside the linac head during beam delivery [6]. MU is calibrated to deliver a 
certain dose to a reference point in a water phantom under specific condition. 
Specifically, one MU is typically calibrated to deliver one cGy to a reference point in a 
water phantom at depth 5 cm and source to detector distance 100 cm for a beam with a 
field size of 10x10 cm2. In step-and-shoot IMRT, the linac moves the components to the 
positions specified in the first CP. It then delivers the number of MUs specified for the 
first CP, while holding each machine component stationary. Once the MUs have been 
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delivered, the linac moves the components to the positions specified in the next CP, then 
delivers the MUs specified for that CP. Conversely, in VMAT and sliding-window 
IMRT, the linac moves the machine components between the positions specified in the 
first and second CP while delivering the number of MUs that are to be delivered by the 
second CP. It continues transitioning the components and delivering the MUs 
simultaneously until the last CP is reached.  
The goal of plan optimization is to determine what the CPs parameters of the 
treatment plan should be. This process begins with the treatment planner creating a list of 
plan objectives (sometimes referred to as IMRT objectives). This list will consist of, for 
instance, a homogeneous prescribed absorbed dose to each PTV and a maximum dose 
permitted for each OAR. A weighting factor is also assigned to each of the planning 
objectives, indicating the relative importance of the objective.  
When optimizing the treatment plan, each IMRT objective is represented by a scalar 
objective function [18]. This function reaches a global minimum value of zero when the 
3D dose distribution of the plan satisfies the corresponding IMRT objective. The goal of 
plan optimization is to determine the CP parameters whose 3D dose distribution 
minimizes the weighted sum of these objective functions (i.e. that simultaneously 
satisfies as many of the IMRT objectives as possible). Unfortunately, these objective 
functions often have multiple minima, and so there is a risk that conventional 
deterministic optimization methods like gradient-descent could become trapped at a local 
minimum (i.e. at a sub-optimal solution). This issue can be avoided by using stochastic 
optimization techniques, such as simulated annealing, which can ‘escape’ from local 
minima [19]. However, stochastic optimization methods are typically much slower than 
deterministic methods, and so most commercial treatment planning systems use 
deterministic optimization algorithms (as described in Chapter 3 and Chapter 4). Briefly, 
these optimization algorithms perform the following IMRT/VMAT treatment planning 
procedure which will initialize the CP parameters as close to the global minimum of the 
objective function as possible. 
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IMRT plan optimization begins with fluence map optimization (FMO). FMO 
optimizes each beam’s fluence map based on the planning objectives [20]. A more 
detailed summary of FMO can be found in Chapter 3.2.1. FMO tells us what the ideal 
beam fluence should be after a beam is delivered, but it does not tell us how many CPs 
are needed or what the CP parameters should be to generate the optimal fluence map. To 
get this CP information, an aperture-sequencing algorithm is executed on the optimized 
fluence maps [14]. These sequencing algorithms decompose the fluence map into a 
collection of segments, with each segment having a single homogeneous intensity. These 
segments can be easily converted into equivalent CP information. Usually, the number of 
CPs needed to faithfully recreate the optimal fluence map, is too high for delivery to be 
practical [19]. Therefore, sequencing algorithms are typically forced to approximate the 
ideal fluence map using a limited number of CPs. Due to this approximation, plan quality 
often degrades after aperture sequencing. To recoup this plan degradation, direct aperture 
optimization (DAO) are typically used [19,21-27]. These DAO algorithms iteratively 
optimize the MLC, jaw, and MUs values of each CP while also taking into consideration 
the delivery limitations of the specific linear accelerator. A more detailed introduction to 
DAO can also be found in Chapter 3.2.2. Some DAO algorithms optimize the aperture 
shapes after FMO and aperture sequencing [22], while others incorporate the aperture 
sequencing step into the FMO algorithm [23]. Both types of DAO use the same planning 
objectives as FMO. The result of these DAO algorithms is the CPs necessary for 
achieving the desired planning objectives. 
The plan optimization algorithm used for VMAT treatment planning is dependent on 
the commercial TPS [16,28,29]. For this thesis, only the SmartArc VMAT planning 
algorithm is introduced [29]. Upon starting VMAT optimization, SmartArc performs 
FMO and aperture sequencing at fixed-gantry angles every 24 degrees between the user-
specified starting and stopping angle. It then selects the two CPs with the highest number 
of open leaf pairs from each beam, while discarding all the rest of CPs. The selected CPs 
are then redistributed around their original gantry position. Additional CPs are then 
created between the selected and repositioned CPs, via linear interpolation, until a 
minimum angular spacing between consecutive CPs (typically 2° or 4°) is achieved. This 
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process is referred to as arc sequencing and is illustrate in Figure 1.4. DAO is then 
performed on the CPs of the VMAT arc, using the same planning objectives as before. 
Note, the DAO algorithms used for VMAT also incorporate any VMAT related delivery 
constraints, such as the maximum dose rate and gantry rotation speed.  
 
Figure 1.4: Illustration of the SmartArc planning process. FMO and aperture sequencing 
is performed at 24° increments. The two CPs with the highest number of open leaf pairs 
are selected from each beam, while the rest (CPs 1a & 2a) are discarded. The selected 
CPs are then repositioned along the arc (crosses). Additional CPs are generated via linear 
interpolation (circles) until a maximum distance between consecutive CPs (typically 4°) 
is achieved. This figure is reproduced from Bzdusek et al. [29], with permission from 
John Wiley and Sons (Appendix B.1). 
The accuracy and efficiency of plan optimization relies heavily on the dose calculation 
algorithm that is used for plan optimization [10]. High dosimetric accuracy is needed so 
that the plan parameters are correctly optimized, and the optimization converges to the 
users-specified plan objectives. However, the dose calculation should be sufficiently fast 
for the optimization to complete in a practical amount of time. A common approach is to 
perform an accurate but less efficient dose calculation (e.g. collapsed cone convolution 
(CCC)) in the middle of the optimization. Then, during DAO, the algorithm uses a fast 
but less accurate dose engine (e.g. singular value decompositions (SVD)) to ‘perturb’ the 
dose distribution, based on the difference between the current plan parameters and plan 
parameters at the time of the accurate dose calculation [22,30]. This allows for fast 
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optimization without a substantial decrease in the dosimetric accuracy. At the end of 
optimization, a more accurate dose calculation algorithm such as CCC will be used again 
for the final dose computation of the plan. 
1.3.5 Plan Evaluation 
The plan quality will be evaluated once plan optimization is completed. The 
following tools are commonly used to assess EBRT plan quality: (1) the 3D dose 
distributions, (2) cumulative dose-volume histograms (DVH), and (3) dose metrics [6].  
3D dose distributions and isodose lines (as shown in Figure 1.2 and Figure 1.3) can 
be used to evaluate the conformity of the dose distribution to the PTVs and doses to 
organs at risk.  
Cumulative DVHs gives a compact summary of the 3D dose distribution for selected 
regions of interest (ROIs). Each DVH is plotted with the volume (absolute or relative) of 
a ROI on the vertical axis that is receiving more than or equal to the dose on the 
horizontal axis. An example of a DVH for a VMAT lung case is shown in Figure 1.5. 
Each of the PTV and OAR volumes are plotted separately on the DVH. Ideally, PTV 
DVHs will be as close to the top right as possible, indicating a high dose to as much of 
the PTV as possible. Conversely, all OAR DVHs should be bunched as close to the 
bottom left as possible, indicating that as little of the OAR is exposed to as low of a dose 
as possible. Many planning objectives, like the minimum and maximum dose, can be 
visualized with point markers on the DVH plot. 
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Figure 1.5: A sample dose-volume histogram from VMAT lung case. Common dose 
metrics for the lungs, esophagus and PTV are labelled. 
Dose metrics are typically points on the DVH (e.g. the maximum dose as described 
above) or quantify some property about a DVH (e.g. conformity of the PTV coverage). 
Common dose metric include: the mean dose (?̅?), the maximum point dose (𝐷𝑚𝑎𝑥), the 
minimum dose received by 𝑥 volume in cubic centimeters (𝐷𝑥 𝑐𝑐), the minimum dose 
received by 𝑥 % of the volume (𝐷𝑥%), and the percent volume receiving 𝑥 dose or more 
(𝑉𝑥 𝐺𝑦). Various dose metrics have been labelled on the DVH in Figure 1.5. Several dose 
metrics have been correlated with patient outcome data [31]. For instance, the lungs 
𝑉20𝐺𝑦 (the volume of the lungs receiving 20 Gy or more, shown in Figure 1.5) has been 
shown to be predictive of the patient developing pneumonitis after radiotherapy [32]. It is 
recommended that the lung 𝑉20𝐺𝑦 be below 30% for treatment (it is about 7% in the plan 
shown in Figure 1.5).  
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If the dose distribution, the DVHs, or any of the dose metrics don’t meet the clinical 
goal (e.g. the 𝑉20𝐺𝑦 objective above), the plan will be re-optimized with modified 
planning objectives and/or objective weights. This cycle is repeated, in a trial-and-error 
approach, until a satisfactory treatment plan is achieved.  
1.3.6 Quality Assurance 
Once a satisfactory plan has been obtained, a series of quality assurance (QA) checks 
are performed to ensure that the treatment plan is safe, effective, and can be delivered 
accurately [33]. One QA test that will be relevant to this thesis is the patient-specific plan 
QA. First, the patient’s treatment plan is delivered to a phantom that can measure and 
record the cumulative dose at numerous points in space. Let the spatial location of these 
measurements be denoted by, 𝑟𝑚, and the dose that is recorded at these points be, 
𝐷𝑚(𝑟𝑚). The measured dose is then compared with the dose distribution calculated by the 
TPS, via a gamma analysis [34]. Specifically, let 𝐷𝑐(𝑟𝑐) be the dose calculated by the 
TPS at the location 𝑟𝑐. For each measurement point 𝑟𝑚, the gamma analysis will find the 
𝑟𝑐 that yields the lowest value to the function: 
Γ(𝑟𝑚, 𝑟𝑐) = √(
𝐷𝑐(𝑟𝑐) − 𝐷𝑚(𝑟𝑚)
ΔD
)
2
+ (
𝑑(𝑟𝑐, 𝑟𝑚)
Δ𝑑
)
2
. 
That is, 
𝛾(𝑟𝑚) =
min
𝑟𝑐
Γ(𝑟𝑚, 𝑟𝑐) . 
Note, 𝑑(𝑟𝑐, 𝑟𝑚) is the Euclidean distance between 𝑟𝑐 and 𝑟𝑚, and ΔD and Δ𝑑 are the dose 
difference and distance-to-agreement acceptance criteria set by the user. Any 
measurement points where 𝛾(𝑟𝑚) > 1 indicates a region where the measured dose and 
calculated dose disagree by more than the composite acceptance criteria. The gamma 
pass-rate gives the percentage of points where the measured dose agrees with calculated 
dose within the acceptance criteria. A common criteria is that 95% or more of the 
phantom dose measurements agree with the calculated dose, when the gamma analysis is 
performed with a 3% dose difference and 3 mm distance-to-agreement acceptance 
criteria.  
 15 
 
1.3.7 Plan delivery  
During a treatment session, the patient will be set up on the treatment couch (see 
Figure 1.1) in the same treatment position as the planning CT. Planar x-ray images or 
cone-beam computed tomography (CBCT) images may be acquired with linac’s on-board 
imaging system (shown in Figure 1.1) and compared with the planning CT, to ensure 
accurate patient positioning [6]. Alternative image guidance technique like megavoltage 
x-ray CT, MRI, or optical guidance systems may also be used, if available, for patient 
positioning [35]. Once the patient is in the planned treatment position, the linac will 
deliver the patient’s treatment plan. The patient will be treated with this plan, once or 
twice a day, Monday to Friday, for up to several weeks.  
Over the course of treatment, the patient may undergo anatomical changes such as 
weight loss or tumour regression [36]. These changes may impact the effectiveness of the 
patient’s immobilization equipment, leading to possible setup errors. Moreover, these 
changes may alter how radiation dose is distributed in the patient, leading to sub-optimal 
outcomes or unintended treatment-related side-effects [37].  
To ensure that the patient receives adequate treatment, the patient may be referred for 
a new planning CT when their immobilization equipment is no longer effective or if large 
anatomical changes are observed between the patient’s original planning CT and a CBCT 
acquired on-line. The patient’s new planning CT will be contoured and registered with 
the patient’s original planning CT. The patient’s plan will then be ‘copied’ onto the new 
planning CT for dose calculation and plan assessment. If the plan quality is deemed 
inadequate, a new treatment plan will be generated on an accelerated timeline. The 
patient will then resume treatment with this new treatment plan. This is the process of 
treatment plan adaptation 
1.4 Research Motivation  
There are a number of ways in which the EBRT process described above, could be 
altered to improve plan quality, planning efficiency, and delivery efficiency.  
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First, EBRT treatments typically use either IMRT or VMAT delivery techniques. 
However, due to the complementary dosimetric properties of VMAT and IMRT, there 
could be an advantage to combining both VMAT and IMRT together in the same plan, as 
opposed to using one or the other. Currently, TPS do not support the simultaneous 
optimization of VMAT and IMRT. Instead, hybrid VMAT-IMRT treatment plans can 
only be created by optimizing the VMAT and IMRT portions separately [38]. This calls 
into question whether the treatment plan is truly optimal, as the plan parameters are never 
truly optimized together at the same time. Moreover, this planning approach will require 
that the IMRT and VMAT beams be delivered separately, making treatment delivery 
much less efficient.  
Another source for improvement is the time spent optimizing IMRT, VMAT, as well 
as any future hybrid VMAT-IMRT treatment plans. Due to the computational complexity 
of the DAO problem, and the current trial-and-error approach to plan optimization, 
treatment planning can sometimes take several hours or even days to complete in some 
very complex cases. Furthermore, when there is limited time for treatment planning (e.g. 
for re-planning), sub-optimal treatment plans may be deemed acceptable for treatment, so 
that treatment delivery is uninterrupted. While newer TPS offer DAO algorithms that are 
implemented on fast parallelized graphical processing units (GPU), they are still not fast 
enough for applications like: (1) multi-criteria optimization [39,40] where numerous 
treatment plans are generated and compared, and (2) on-line adaptive radiotherapy (ART) 
where treatment re-planning is performed at the linear accelerator – while the patient is 
immobilized and awaiting treatment – using the 3D image sets acquired on-line (e.g. 
CBCT, MRI) [41,42]. 
Finally, even if fast DAO algorithms were available for on-line ART, another hurdle 
for ART is getting accurate electron density information from the 3D data sets acquired 
on-line, for dose calculations and plan optimization. For instance, MRI lacks a one-to-one 
correspondence between the voxel (3D pixel) intensity and electron density [43]. 
Meanwhile, patient-specific scattering conditions in CBCT can influence the accuracy of 
electron density maps [44]. Several methods of calibrating CBCTs for accurate dose 
calculation have been implemented, such as intensity-based deformable image 
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registration (DIR) algorithms that warp the accurate planning CT data onto the patient 
anatomy obtained from the CBCT. However, these DIR algorithms often introduce 
localized deformation errors which could potentially impact the densitometric, dosimetric 
and contouring accuracy within the region (see Chapter 5 for details). Therefore, more 
precise methods of acquiring electron density information from these image sets are still 
needed.  
Even if fast DAO algorithms are unavailable for on-line ART, these electron density 
maps will be helpful for on-line dose calculations and plan assessment to judge whether 
treatment re-planning is truly necessary. Specifically, the effectiveness of the patient’s 
immobilization equipment and the anatomical changes viewed on CBCT may not always 
be good indicators that treatment intervention and re-planning is necessary. It is not 
uncommon for a new planning CT to be acquired, contoured, and the plan copied over for 
plan assessment, only to find that the plan quality has not changed significantly to 
warrant re-planning. More importantly, these markers could be failing to identify patients 
that do need treatment intervention.  
The overarching goal of this research is to address these critical areas of improvement 
in EBRT. Note that this is by no means an exhaustive list of how EBRT could be 
improved for gains in clinical outcomes. Many other areas for improving EBRT and 
patient outcome are currently under investigation at institutions around the world, such as 
the use of heavy-ion beams (e.g. proton, carbon-ion) [6], hypo-fractionation treatment 
regimens for the treatment of primary and oligometastatic cancer [45,46], and 
immunotherapy and its possible synergistic effects with radiation therapy [47], to name a 
few.   
1.5 Research Hypothesis  
We hypothesize that a fast plan optimization algorithm that unifies rotational 
volumetric modulated arc therapy and fixed-gantry intensity-modulated radiation therapy 
will improve radiotherapy plan quality, planning and delivery efficiency, and will provide 
a stepping-stone towards future on-line (interactive) plan adaptation.  
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1.6 Chapter Objectives  
In Chapter 2, we evaluate a plan optimization algorithm called unified intensity-
modulated arc therapy (UIMAT) on complex head-and-neck cases. This UIMAT 
algorithm simultaneously optimizes both rotational VMAT and fixed-gantry IMRT 
delivery techniques and combines their delivery. That is, UIMAT sequences the plan CPs 
such that, at delivery, the linac will deliver just like a VMAT beam. However, when this 
UIMAT beam reaches a gantry angles selected for IMRT delivery, it will halt gantry 
rotation and begin delivering like a step-and-shoot IMRT beam. After delivering this 
IMRT portion, the UIMAT beam will resume VMAT delivery. Delivery efficiency is 
improved by combining VMAT and IMRT’s delivery in this way. Since this UIMAT 
algorithm was initially developed before entering this PhD program, details of this 
UIMAT plan optimization algorithm are provided in Appendix A.  
 In Chapter 3, a new DAO algorithm called fast inverse direct aperture optimization 
(FIDAO) is developed. FIDAO introduces modification to the equations used in DAO. 
These modifications greatly reduce the computation time of repeated calculations 
performed in the DAO process. By reducing the time of these calculations, DAO will be 
able to execute faster and improve the treatment planning efficiency, potentially allowing 
for on-line applications. Chapter 3 describes and evaluates this FIDAO algorithm for 
fixed-gantry IMRT treatment planning, while Chapter 4 evaluates FIDAO for rotational 
VMAT treatment planning. 
In Chapter 5, a patient-specific CBCT calibration technique for on-line dose 
calculation and plan assessment is developed. By performing dose calculations and plan 
assessment on-line with these CBCT datasets, we can better differentiate the patient that 
truly require treatment re-planning from those who do not, saving resources and time. 
Moreover, with a fast DAO algorithm like the one developed in Chapter 3 & Chapter 4, 
the treatment re-planning could be potentially performed on-line with the calibrated 
CBCTs. 
Finally, Chapter 6 summarizes the findings of this thesis, the potential clinical impact 
of these project, their limitations, future work, and specifically how these projects could 
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be combined as a package for an advanced on-line treatment planning and plan 
adaptation procedure. All of these developments are aimed at improving the clinical 
outcomes in patients treated with state-of-the-art radiation therapy. 
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Chapter 2 – Evaluation of unified intensity-modulated arc 
therapy (UIMAT) for the radiotherapy of head-and-neck 
cancer 
This chapter was adapted from the published article entitled “Evaluation of unified 
intensity-modulated arc therapy for the radiotherapy of head-and-neck cancer” by 
Michael MacFarlane, Douglas A. Hoover, Eugene Wong, Nancy Read, David Palma, 
Varagur Venkatesan, Alex Hammond, Jerry J. Battista, and Jeff Z. Chen, Radiotherapy 
and Oncology, 119 (2): 331-336 (2016). Permission to reproduce this article was granted 
by Elsevier and is provided in Appendix B.2. Supplemental tables and figures for this 
chapter are provided in Appendix C. 
2.1 Introduction 
Volumetric modulated arc therapy (VMAT) and fixed-gantry intensity-modulated 
radiation therapy (IMRT) are two commonly used external beam radiotherapy techniques 
for the treatment of cancers. Although these two delivery modalities are often treated in 
practice and literature as disparate or competing techniques, they are in fact both 
mechanically and dosimetrically complementary to each another. 
The fixed-angle delivery used in IMRT allows for the creation of steep dose gradients 
at the field edges and highly modulated intensity patterns from each beam direction. With 
the wise selection of beam orientations, substantial sparing of select organs at risk (OAR) 
is possible with this technique [1,2]. However, for more rotationally symmetric target 
volumes, a larger number of beams may be required to achieve sufficient dose coverage 
and conformity while still sparing the surrounding OARs, resulting in reduced delivery 
efficiency. In such cases, the rotational delivery of VMAT is preferred as the wide range 
of deliverable angles can create very conformal dose distributions in a timely and 
efficient manner [3-7]. However, the requirements of continuous gantry motion and high 
delivery efficiency limit the degree of intensity modulation achievable at any given beam 
angle. 
Many groups have demonstrated that the combination of IMRT and VMAT within a 
single plan provides a therapeutic advantage over treatments using either IMRT or 
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VMAT alone, as it utilizes the dosimetric advantages of both techniques [8-13]. This 
could be particularly advantageous in complex sites such as the head and neck where, in 
general, no consistent dosimetric advantage is observed between VMAT and IMRT [14]. 
It should be noted that with these previous hybrid techniques, IMRT and VMAT have not 
been fully integrated during either the inverse-optimization or beam delivery process. 
Recently, our group developed a method called unified intensity-modulated arc 
therapy (UIMAT) which permits the simultaneous inverse optimization and concurrent 
delivery of VMAT and IMRT in a single arc [15]. Specifically, during the arc delivery, 
the gantry rotation can be reduced to a near-stop in order to deliver IMRT beam segments 
at opportune gantry angles. Details of this UIMAT algorithm can be found in Appendix 
A. This current study evaluates the potential benefit of UIMAT for the radiotherapy of 
complex head-and-neck cancer, compared to strictly VMAT or IMRT treatment plans. 
This site was selected based on promising preliminary results obtained in the previous 
feasibility study [15]. 
2.2 Methods and materials 
Thirty previously treated head-and-neck cases were arbitrarily selected for this study. 
Fifteen of these cases were treated with dual-arc VMAT while the other fifteen cases 
were treated with a variable number of step-and-shoot (SS) IMRT beams. No factors 
related to the patient, primary disease site, or the prescribed dose was considered during 
the selection. A summary of the selected cases is provided in Supplementary Table 2.1. 
UIMAT plans were generated for each patient using custom scripts developed for 
Pinnacle3 v9.6 Radiation Therapy Planning System (Philips Healthcare, Fitchburg, USA). 
Technical details of the UIMAT method were previously described by Hoover et al. [15] 
and can be found in Appendix A however, the method can be roughly divided into five 
stages: 
(1) Fluence Map Optimization: Multiple static beams are evenly distributed along the 
arc range and their fluences are optimized. 
 26 
 
(2) MLC Sequencing: Optimized fluences are converted into deliverable MLC 
segments. 
(3) UIMAT Sequencing (Re-assignment): Deliverable beams are sequenced via a script 
into VMAT or IMRT phases based on the number of MLC segments in a beam. Beams 
with fewer segments are converted to VMAT phases, while beams with more segments 
are converted to IMRT phases with near-constant gantry angles as shown in Figure 2.1. 
(4) Direct Aperture Optimization (DAO): Both VMAT and IMRT phases are 
optimized simultaneously using Pinnacle’s DAO algorithm.  
(5) Unification: The optimized VMAT and IMRT phases, which are treated as separate 
beams within Pinnacle, are merged by script into a single UIMAT arc for final dose 
calculation and delivery.  
 
Figure 2.1: Illustration showing IMRT phases (lavender) and VMAT phases (orange) 
generated by the UIMAT script.  
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All UIMAT plans were created by a single planner (MM) and treatment planning 
times were recorded. Planning objectives for each UIMAT plan were copied from the 
clinical plan and set so that 95% of the planning target volume (PTV) would receive at 
least 95% of the prescription dose, while OAR doses were kept as low as achievable. 
Without exception, all OAR doses in both clinical and UIMAT plan were kept below our 
institutional standards, which originate from recommendations by Radiation Therapy 
Oncology Group (RTOG) clinical trials (RTOG 0225, 0513, 0522, 0615, and 0619), and 
Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC) guidelines 
[16]. 
UIMAT plans were optimized using the same (or very similar) objectives as the 
clinical plans. OAR objectives were set to reduce global OAR doses as opposed to the 
dose to any specific endpoint. Individual dose objectives were made more stringent if 
their relative contribution to the total objective function approached zero. In this way, the 
dose to all OARs was pushed as low as possible, in an unbiased manner. No explicit 
attempt was made to surpass the clinical plan; rather, UIMAT optimization was 
continued until the plan reached its highest potential. This is similar to how our clinical 
cases are planned. 
The completed UIMAT plans were then evaluated against the clinically delivered 
plans in terms of target volume coverage, conformity index (CI), as well as clinically 
relevant OAR dose metrics. Wilcoxon signed rank tests were performed in SPSS (IBM 
Corp., Armonk, USA) to test for statistically significant differences between the UIMAT 
plans and the clinically delivered plans. The threshold for statistical significance was set 
to 5%. For plans with multiple PTVs (each having a different dose level), the average of a 
PTV metric was used in the analysis. For instance, if a plan had a PTV70Gy with a mean 
dose of 102% (relative to 70 Gy), and a PTV56Gy with a mean dose of 110% (relative to 
56Gy), then the PTV mean dose used in the analysis would be 106%. 
The conformity index used here is similar to the one introduced by Oozeer et al. [17]: 
𝐶𝐼 = (𝐶𝑜𝑣𝑒𝑟 𝑓𝑎𝑐𝑡𝑜𝑟) × (𝑆𝑝𝑖𝑙𝑙 𝐹𝑎𝑐𝑡𝑜𝑟) 
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= (
𝑉95(𝑃𝑇𝑉)
𝑉𝑃𝑇𝑉
) × (
𝑉95(𝑃𝑇𝑉)
𝑉95(𝐵𝑜𝑑𝑦)
) (1) 
where V95(PTV) and V95(Body) are the volumes of the PTV and body, respectively, 
receiving at least 95% of the prescription dose, and VPTV is the volume of the PTV. This 
equation was defined initially for a single dose level. To handle the case where multiple 
dose levels exist, the PTV volume with a lower prescription dose will also include all 
higher dose PTV volumes. For example, for a plan with PTV70Gy, PTV63Gy, and PTV56Gy, 
to calculate the conformity index for the PTV with the lowest prescription dose (56 Gy), 
the PTV in equation (1) will be the union of the three PTV volumes. 
Treatment plans were validated with an ArcCheck phantom (Sun Nuclear Corp., 
Melbourne, USA), using a TrueBeam linear accelerator (Varian Medical Systems, Palo 
Alto, USA) operating in clinical mode. Absolute dose distributions were compared 
between plans and ArcCheck measurements, using gamma parameter thresholds of 3% 
dose difference and 3 mm distance-to-agreement [18]. Delivery times were also measured 
during the ArcCheck delivery. 
2.3 Results 
The median (range) time required to generate a UIMAT plan was 3 (1.5-6) hours, 
which is comparable to the typical clinical planning time logged at our institution. 
Dosimetric comparisons for individual VMAT and IMRT cases are tabulated respectively 
in Supplementary Table 2.2 and Supplemental Table 2.3 (available online at 
www.thegreenjournal.com). In Table 2.1, median and ranges of the target and OAR dose 
metrics are compared for UIMAT plans against the stand-alone clinical IMRT plans, 
VMAT plans, and both clinical IMRT or VMAT plans.  
Conformity indices were found to be lower in IMRT and UIMAT when compared to 
VMAT. A slight improvement in the dose coverage (D95) was observed for UIMAT 
relative to the IMRT (98.0% vs 96.7%, respectively, p < 0.01), but not when comparing 
UIMAT to the VMAT (98.2% vs 98.0%, respectively, p = 0.70). The mean PTV doses 
were slightly higher in UIMAT relative to VMAT (102.3% vs 101.5%, respectively, p < 
0.01) and to IMRT (102.2% vs 101.8%, respectively, p = 0.01).  
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Median OAR dose metrics were universally reduced by the application of UIMAT. 
On average, OAR max doses were reduced by 5.4 Gy when compared to VMAT, and 5.3 
Gy when compared to IMRT. Similarly, OAR mean doses were reduced, on average, by 
2.5 Gy when compared to VMAT, and 3.9 Gy when compared to IMRT. All dose metrics 
were significantly reduced with the exception of the mean larynx and mean parotid doses 
when compared to VMAT. Average OAR dose-volume histograms are shown in Figure 
2.2. Average OAR dose-volume histograms between just the VMAT and UIMAT 
techniques, as well as between IMRT and UIMAT techniques, are provided in 
Supplemental Figure 2.1. Sample dose distributions of two representative cases are 
shown in Figure 2.3. 
In terms of deliverability, a significant reduction of the median delivery time was 
observed for UIMAT plans compared to the IMRT plans (147 s vs 269 s, p = 0.001), 
while no significant difference was observed between UIMAT and VMAT median 
delivery times (135s vs 168s, p = 0.39). A significant reduction in median monitor units 
(MU) was observed for UIMAT compared to IMRT (449 MU vs 596 MU, p < 0.01) and 
to VMAT (486 MU vs 635 MU, p < 0.01). Median IMRT QA pass rates were found to be 
significantly lower with UIMAT when compared to VMAT (97.5% vs. 98.8 %, p = 0.03) 
and IMRT (97.6 % vs. 99.2 %, p = 0.02). 
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Figure 2.2: Comparison of average DVHs for various organs at risk. The clinical average 
DVH is plotted with the dashed line while the UIMAT average DVH is plotted with a 
solid line. 
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Table 2.1: Median (Min, Max) metric value between our UIMAT plans and the clinically delivered plans. Summaries are 
provided for VMAT cases (patients 1 – 15), IMRT cases (patients 16 – 30), and all cases. PTV mean doses and D95s (dose to 
95% of the PTV) are given as percentages of the prescribed dose to the PTV. Reported max dose is the dose to 2% of the 
volume. Statistically significant differences are indicated by *. 
 Region 
of 
Interest  
  
VMAT Only (Cases: 1-15) IMRT Only (Cases: 16-30) All Cases (Cases: 1-30) 
Metric  VMAT UIMAT P IMRT UIMAT P Clinical UIMAT P 
PTV 
CI 
0.73 
(0.51,0.92) 
0.70 
(0.46, 0.87) 
0.003* 
0.67 
(0.15,0.81) 
0.67 
(0.14, 0.83) 
0.256 
0.69 
(0.15,0.92) 
0.69 
(0.14, 0.87) 
0.086 
Mean (%) 
101.5 
(100.7,104.3) 
102.3 
(100.7, 105.6) 
0.001* 
101.8 
(100.3,104.6) 
102.2 
(101.3, 104.3) 
0.011* 
101.7 
(100.3,104.6) 
102.3 
(100.7, 105.6) 
< 0.001* 
D95 (%) 
98.0 
(95.8,100.8) 
98.2 
(94.9, 100.2) 
0.695 
96.7 
(94.9,98.7) 
98.0 
(95.6, 99.5) 
0.004* 
97.5 
(94.9,100.8) 
98.1 
(94.9, 100.2) 
0.01* 
Norm. Tiss. Mean (Gy) 
6.4  
(1.0, 11.2) 
6.2 
(1.0, 10.5) 
0.691 
7.4  
(4.2, 13.4) 
7.4 
(3.5, 13.8) 
0.069 
7.2 
(1.0. 13.4) 
7.2 
(1.0, 13.8) 
0.086 
Oral Cavity Mean (Gy) 
29.2  
(4.7, 44.0) 
21.3 
(3.0, 43.0) 
0.002* 
33.9 
(14.0, 61.3) 
27.5 
(10.0, 57.7) 
0.001* 
30.3  
(4.7, 61.3) 
23.2 
(3.0, 57.7) 
< 0.001* 
Lt. Parotid Mean (Gy) 
25.3  
(2.0, 43.9) 
22.6 
(2.0, 44.3) 
0.173 
29.1  
(3.4, 52.0) 
26.7 
(2.6, 48.3) 
0.005* 
28.0 
(2.0, 52.0) 
26.1 
(2.0, 48.3) 
0.001* 
Rt. Parotid Mean (Gy) 
27.2  
(1.3, 60.9) 
25.5 
(1.1, 60.8) 
0.071 
27.2  
(4.7, 58.6) 
18.4 
(2.7, 58.3) 
0.001* 
27.2  
(1.3, 60.9) 
23.6 
(1.1, 60.8) 
< 0.001* 
Larynx Mean (Gy) 
33.8  
(0.2, 65.8) 
26.2 
(0.2, 67.1) 
0.173 
37.4  
(0.7, 71.3) 
30.9 
(0.6, 70.6) 
0.002* 
35.3  
(0.2, 71.3) 
29.3 
(0.2, 70.6) 
0.001* 
Cord Max (Gy) 
35.8  
(7.3, 41.6) 
29.4 
(5.6, 40.0) 
0.001* 
35.3  
(25.3, 41.5) 
30.3 
(15.9, 39.6) 
0.001* 
35.6  
(7.3, 41.6) 
29.9 
(5.6, 40.0) 
< 0.001* 
Brainstem Max (Gy) 
25.7  
(4.3, 57.3) 
11.7 
(2.8, 56.9) 
0.001* 
25.4  
(3.4, 46.9) 
22.2 
(4.5, 41.0) 
0.001* 
25.6  
(3.4, 57.3) 
21.2 
(2.8, 56.9) 
< 0.001* 
Lt. Cochlea Max (Gy) 
11.9  
(2.3, 64.6) 
5.9 
(1.6, 65.5) 
0.011* 
8.5  
(0.7, 59.9) 
5.9 
(0.6, 56.3) 
0.001* 
10.2  
(0.7, 64.6) 
5.9 
(0.6, 65.5) 
< 0.001* 
Rt. Cochlea Max (Gy) 
16.1  
(1.2, 50.0) 
8.2 
(1.0, 50.0) 
0.001* 
9.5  
(0.9, 25.2) 
5.7 
(0.9, 17.7) 
0.001* 
12.2  
(0.9, 50.0) 
6.8 
(0.9, 50.0) 
< 0.001* 
Abbreviations: Norm. Tiss., normal tissue (defined as external contour minus the PTV & OAR volumes); Rt, right; Lt, left; 
D95, dose to 95% of the volume. †P-values were calculated using the Wilcoxon signed-rank test.  
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Figure 2.3: Comparison of dose distributions between: (a) the clinical VMAT plan (left) 
and UIMAT plan (right) for patient 1 with PTV64Gy in red and PTV60Gy in light green 
color wash; (b) the IMRT plan (left) and the UIMAT plan (right) for patient 29 with 
PTV70Gy in red, PTV63Gy in green, and PTV56Gy in cyan color wash.  
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2.4 Discussion 
The UIMAT technique exhibited many promising features, most notable being its 
ability to reduce the dose to organs at risk (see Table 2.1). This is also evident from the 
average DVH comparisons and sample dose distribution comparisons in Figure 2.2 and 
Figure 2.3, respectively, where improved sparing of the various organs at risk can be 
observed. In addition to this, Table 2.1 and Figure 2.2 shows that UIMAT was able to 
reduce the dose to organs at risk without increasing the dose to the rest of the normal 
tissue (defined here as all tissue outside of the reported PTVs and OARs), suggesting that 
the reduction in OAR dose did not result from the redistribution of dose to unspecified 
normal tissue, but rather from improved utilization of dose delivery. This reduction in 
OAR dose has the potential to lower both the severity and frequency of toxicities 
attributed to head-and-neck radiotherapy such as xerostomia, stomatitis, and 
sensorineural hearing loss. Alternatively, these improvements in dose delivery could 
allow for further dose escalation while maintaining a similar toxicity profile observed 
today. 
Some small variability was seen in the conformity indices for the target volumes, with 
UIMAT conformity generally lying between that of IMRT and VMAT. This is not 
entirely surprising given that UIMAT is a mixture of these two techniques. This could 
also be a result of optimization technique, for example by imposing a higher priority on 
OAR sparing compared to conformity. This result was not universally observed though, 
as can be seen from the individual patient results in Supplementary Table 2.2 and 
Supplemental Table 2.3. In addition to its dosimetric advantages, UIMAT plans required 
fewer MUs and had comparable delivery times to VMAT. 
Several areas of improvement for the UIMAT algorithm have been identified during 
this retrospective planning study. For instance, the current algorithm does not enforce a 
minimum MU or MLC segment area during plan optimization. As a result, UIMAT plans 
may be susceptible to dosimetric errors introduced by small-field dosimetry and small 
MU delivery [19-21]. This is likely the source of the lower IMRT QA gamma pass rates 
observed relative to the clinical plans. To improve UIMAT delivery accuracy, future 
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versions of the UIMAT algorithm may implement a filtration step, in which small fields 
are removed, or a direct aperture optimization algorithm that enforces a minimum 
segment area.  
As with any retrospective planning study, this work was susceptible to certain biases 
such as providing more resources to a new treatment technique compared with the 
standard one. To combat this, treatment planning times were limited to a maximum of 6 
hours (for the most complex cases) in order to match clinical time constraints. While it 
may appear that reusing the clinical objectives for UIMAT optimization gave our planner 
a head start, this was not the case. Most of the plan setup is automated within our 
institution, whereas our UIMAT method is still a manual process, and so any amount of 
time gained by copying (rather than populating) the objective list was easily lost in the 
UIMAT plan setup. The selection of endpoints may also be viewed as a source of bias. 
The metrics that have been reported here are, what we believe to be, the most clinically 
relevant based on literature as well as local standards. Additional efforts to avoid bias 
were made by preventing the planner from “over-optimizing” certain objectives. For 
example, an objective’s dose or weight was only modified when the objective’s relative 
contribution to the total objective function approached zero. Furthermore, we attempted 
to minimize the global dose to all OARs (including those which were not reported here) 
as a medical dosimetrist would, without favoring the specific endpoints presented in this 
work. This can be observed from the comparison of average dose-volume histograms in 
Figure 2.2. 
The clinical and UIMAT plans presented here were also not selected based on multi-
criteria optimization (MCO) or Pareto fronts. Therefore, the presented plans may not 
represent the Pareto-optimal solutions and one could question whether the observed 
dosimetric advantages result from suboptimal clinical beam configurations rather than 
from the superiority of our UIMAT technique. Although Pareto fronts have been 
previously implemented within Pinnacle [22], such an investigation is beyond the scope 
and capabilities of the current study. Notwithstanding, the clinical and UIMAT plans 
likely represent near-Pareto optimal solutions, since OAR dose objectives were pushed 
until further dose reduction in OARs would compromise target volume coverage. 
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This technique has a similar treatment planning and delivery processes as VMAT, 
which would allow cancer clinics to easily transition from VMAT to UIMAT. For 
example, a planner need only select the starting and stopping angles for the UIMAT plan, 
similar to VMAT planning, as the beam angles for static delivery are chosen 
automatically by the algorithm. Similarly, a radiation therapist would not need to perform 
any additional steps for UIMAT setup and delivery than what is currently required for 
stand-alone VMAT. Of course, UIMAT would require standard commissioning and 
testing prior to clinical implementation. 
2.5 Conclusion 
Compared to stand-alone VMAT or IMRT for head-and-neck cancer, UIMAT plans 
exhibited comparable target volume coverage and dose conformity while significantly 
reducing the dose to the surrounding organs at risk. Furthermore, UIMAT plans required 
only a single arc and fewer MUs on average than either VMAT or IMRT plans. We 
expect that this technique will also yield dosimetric benefits for other complex treatment 
sites. 
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Chapter 3 – A fast inverse direct aperture optimization 
algorithm for intensity-modulated radiation therapy 
This chapter was adapted from the published article entitled “A fast inverse direct 
aperture optimization algorithm for intensity-modulated radiation therapy” by Michael 
MacFarlane, Douglas Hoover, Eugene Wong, Pedro Goldman, Jerry J. Battista, and Jeff 
Z. Chen, Medical Physics 2019; 46(3): 1127-39. Permission to reproduce this article was 
granted by John Wiley and Sons and is provided in Appendix B.3. Supplemental tables 
and figures for this chapter are provided in Appendix D. 
3.1 Introduction 
Direct aperture optimization (DAO) is a frequently used tool in external beam 
radiotherapy treatment planning [1-9]. A DAO algorithm optimizes the beam aperture 
shapes [i.e. multi-leaf collimator (MLC) positions] and intensities based on the treatment 
planning objectives while adhering to any dosimetric or machine-specific delivery 
constraints.  
Due to the size and complexity of the DAO problem, it may take several hours to 
attain an optimal treatment plan using a DAO algorithm, particularly when dealing with a 
large high-resolution dataset or when multiple optimization trials are needed to 
adequately satisfy the clinical treatment objectives. Treatment plans may therefore be left 
at a sub-optimal solution when there is insufficient time for treatment planning. 
Furthermore, applications such as online treatment planning and adaptation for changing 
patient anatomy may be impractical as an updated treatment plan is needed within 
minutes while the patient remains immobilized on the treatment unit.  
A major source of computational inefficiency in DAO comes from the repeated 
evaluation of the objective function and its gradient vector [7,9-12]. To calculate these 
components, the DAO algorithm must first compute the 3D dose distribution based on the 
plan parameters of the current iteration. This computation involves several gigabytes 
worth of dose data, which often results in a computational bottleneck in the optimization 
process. This bottleneck can be mitigated by performing the calculation in parallel over 
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multiple central or graphical processing units (CPU/GPUs) [7,9-12]. However, the 
computational speed gained by parallelizing these calculations is still insufficient for 
emerging applications such as online or real-time plan optimization.  
In this work, we propose reformulating the objective function used in DAO so that 
the computational workload associated with evaluating the objective function and 
computing its gradient vector is greatly reduced. Specifically, we adapted the objective 
function used in a previously developed fluence map optimization algorithm called Fast 
Inverse Dose Optimization (FIDO) to optimize the aperture shapes and intensities of 
IMRT beams [13,14]. The number of operations performed when evaluating the adapted 
FIDO objective function and its gradient vector is substantially lower than that of the 
conventional objective function, resulting in substantially faster plan optimization.  
For clarity, a brief summary of the FIDO algorithm is provided in the following 
section. We then describe the proposed fast inverse direct aperture optimization (FIDAO) 
algorithm. Finally, we present the results of a treatment planning study comparing a 
prototype FIDAO algorithm with a conventional DAO algorithm. For simplicity, both 
DAO algorithms use a singular value decomposition (SVD) dose computation algorithm 
but note that a more sophisticated and accurate dose calculation algorithm can also be 
used. 
3.2 Materials and Methods 
3.2.1 Introduction to FIDO 
In fluence map optimization (FMO), each beam is decomposed into an array of 
smaller, finite-sized pencil-beams. Each pencil-beam is assigned a unique index, 𝑖, and 
intensity, 𝜏𝑖. A large but sparse pencil-beam-based dose matrix, 𝒅, is then computed 
using any dose calculation algorithm and it is stored in memory. The dose matrix element 
𝒅𝑥𝑖 specifies the dose deposited to voxel 𝑥 per unit intensity of pencil-beam 𝑖. During 
optimization, the FMO algorithm can compute the 3D dose distribution by multiplying 
this pre-calculated pencil-beam dose matrix with a vector containing the pencil-beam 
intensities.  
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FMO algorithms optimize the beam fluence maps by finding the minimum solution of 
an objective function (𝑓) such as the following, 
𝑓(𝜏) = 𝑝𝑝𝑡𝑣 ∑ (∑𝒅𝑥𝑖𝜏𝑖 − 𝑑𝑝𝑡𝑣
𝑖
)
2
𝑥∈𝑃𝑇𝑉
+ 𝑝𝑜𝑎𝑟 ∑ (∑𝒅𝑥𝑖𝜏𝑖
𝑖
)
2
𝑥∈𝑂𝐴𝑅
, (1) 
where 𝑝𝑅𝑂𝐼 is the penalty weight assigned to each region of interest’s (ROI) objective 
(PTV or OAR), and 𝑑𝑝𝑡𝑣 is the dose prescribed to the planning target volume (PTV). This 
objective function approaches a global minimum when the dose to each voxel in the PTV 
approaches the prescribed dose, while the dose to all surrounding organs at risk (OAR) is 
as close to zero as possible. Notice, however, that a minimum could be obtained by 
combining positive and negative pencil-beam intensities. Since negative pencil-beam 
intensities represent a non-physical process (the removal of radiation from the patient), 
most FMO algorithms include a non-negative pencil-beam intensity constraint, resulting 
in the following FMO problem, 
minimize
𝜏
      𝑝𝑝𝑡𝑣 ∑ (∑𝒅𝑥𝑖𝜏𝑖 − 𝑑𝑝𝑡𝑣
𝑖
)
2
𝑥∈𝑃𝑇𝑉
+ 𝑝𝑜𝑎𝑟 ∑ (∑𝒅𝑥𝑖𝜏𝑖
𝑖
)
2
,
𝑥∈𝑂𝐴𝑅
 (2) 
subject to     𝜏𝑖 ≥ 0. 
The solution to this FMO problem can be found through a variety of iterative 
constrained optimization techniques [3,11,12,15]. However, solving this FMO problem 
with an iterative method can be very inefficient. This is due to the frequency with which 
these constrained optimization algorithms must compute the objective function value 
(and its gradient vector if the algorithm is gradient-based) as it must first compute the 
product of the very large pencil-beam dose matrix, 𝒅, and the vector containing the 
pencil-beam intensities, 𝜏, of the current iteration.  
In FIDO, the objective function was reformulated as the following: [13,14] 
𝑓(𝜏) = 𝑝𝑝𝑡𝑣 ∑ (∑𝒅𝑥𝑖𝜏𝑖 − 𝑑𝑝𝑡𝑣
𝑖
)
2
𝑥∈𝑃𝑇𝑉
+ 𝑝𝑜𝑎𝑟 ∑ ∑𝒅𝑥𝑖
2 𝜏𝑖
2
𝑖𝑥∈𝑂𝐴𝑅
. (3) 
In this formulation, the OAR objective function (which is the primary culprit leading to 
negative pencil-beam weights) can no longer approach its minimum through the use of 
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negative pencil-beam intensities. Instead, the OAR objective can only reach its minimum 
when all pencil-beams depositing dose to the OAR have null intensity. Additional 
regulative objectives can be added to the objective function to further suppress the use of 
negative pencil-beam intensities by the PTV objective; however, previous experience has 
found that these additional regulation terms are unnecessary [14]. 
Given that the FIDO objective function (Equation 3) is purely quadratic and that 
constraints are not likely needed, its minimum can be found by differentiating with 
respect to each pencil-beam’s weight and setting each equation to zero (which is 
equivalent to Newton’s Method in Optimization) [15]. The resulting system of equations 
can be written as, 
𝜶𝜏 = 𝛽,            (4) 
where 
𝜶𝑗𝑖 = 𝑝𝑝𝑡𝑣 ∑ 𝒅𝑗𝑥
𝑇
𝑥∈𝑃𝑇𝑉
𝒅𝑥𝑖 + 𝑝𝑜𝑎𝑟 𝛿𝑖𝑗 ∑ 𝒅𝑗𝑥
𝑇
𝑥∈𝑂𝐴𝑅
𝒅𝑥𝑖 
𝛽𝑗 = 𝑝𝑝𝑡𝑣 𝑑𝑝𝑡𝑣 ∑ 𝒅𝑗𝑥
𝑇
𝑥∈𝑃𝑇𝑉
. 
This matrix equation can be efficiently solved via matrix inversion to give the globally-
optimal and physically-feasible fluence maps. 
Multiple optimizations are often necessary to fine-tune the PTV coverage and/or 
OAR sparing. To minimize the amount of work performed in subsequent optimizations, 
FIDO stores each ROI’s contribution to 𝛽 and 𝜶. When the OAR and/or PTV weights are 
adjusted in subsequent optimizations, the FIDO matrix equation can be quickly computed 
by rescaling and summing these stored matrices. 
3.2.2 FIDAO Formulation 
The relationship between voxel dose and MLC position is non-linear, and by 
extension the objective function too will vary non-linearly with MLC-position. The MLC 
positions are also subject to numerous mechanical delivery constraints. Therefore, it is 
not possible to optimize the MLC positions by solving a single matrix equation as we had 
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with the pencil-beam intensities in FIDO [15]. Instead, we are forced to use an iterative 
constrained optimization technique as in the conventional FMO methods. Fortunately, as 
will be discussed shortly, we can improve the efficiency of computing the objective 
function value and its gradient vector by using a FIDO-like objective function. To do this, 
we first need a method of converting the beam aperture information into equivalent 
fluence maps. 
Numerous DAO algorithms convert the plan’s MLC positions, 𝑙, and aperture 
intensity, ?⃗⃗⃗?, into equivalent fluence maps, 𝜏(𝑙, ?⃗⃗⃗?), so that the pre-calculated pencil-beam 
dose matrix, 𝒅, can continue to be used during optimization, to compute the objective 
function value and its gradient vector [3,9]. One method of converting the aperture 
parameters into equivalent fluence maps is through the following approximate 
relationship:  
𝜏𝑗(𝑙, ?⃗⃗⃗?) ≈∑𝑻𝑗𝜈(𝑙) 𝑤𝜈
𝜈
, (5) 
where 𝑤𝜈 is the intensity of aperture 𝜈, and 𝑻𝑗𝜈(𝑙) is a non-convex piecewise linear 
function describing the fractional transmission through pencil-beam 𝑗 by aperture 𝜈 
[9,16]. An illustration of this transmission matrix is shown in Figure 3.1. If pencil-beam 𝑗 
is completely blocked by aperture 𝜈, or if the pencil-beam belongs to another beam and 
therefore cannot be exposed by this beam’s aperture, then the fractional transmission 𝑻𝑗𝜈 
will be 0 (e.g. pencil-beams 1-3 in Figure 3.1). Conversely, if pencil-beam 𝑗 belongs to 
the same beam as the aperture and is completely exposed by the aperture, then the 
transmission matrix element will have value 1 (e.g. pencil-beam 8 in Figure 3.1). Finally, 
if pencil-beam 𝑗 is partially exposed by the aperture, the fractional exposed area of the 
pencil-beam is assigned to the transmission matrix (e.g. pencil-beams 7 and 11 in Figure 
3.1). By multiplying this transmission matrix with a vector containing the aperture 
intensities, we can approximate the fluence map produced when delivering all the beam’s 
apertures. This conversion of the aperture information into equivalent fluence will be 
sufficiently accurate so long as the size of the pencil beams are not too large. Otherwise, 
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the fractional transmission may not adequately model the true fluence produce by 
delivering the plan apertures. 
 
Figure 3.1: Illustration of the transmission matrix. The left grid shows the index that 
each pencil-beam was assigned (1-16) during FMO. The right grid shows the pencil-
beam array superimposed with MLC of the first aperture (shown in blue). The 
corresponding values assigned to the first column of the transmission matrix, due to the 
first apertures shape, is provided in the right array. 
Using the equivalent fluence maps from Equation 5, the standard FMO problem from 
Equation 2 can be converted into the following generalized DAO problem: 
minimize
𝑙, ?⃗⃗⃗?
      𝑝𝑝𝑡𝑣 ∑ (∑𝒅𝑥𝑖𝜏𝑖(𝑙, ?⃗⃗⃗?) − 𝑑𝑝𝑡𝑣
𝑖
)
2
𝑥∈𝑃𝑇𝑉
+ 𝑝𝑜𝑎𝑟 ∑ (∑𝒅𝑥𝑖𝜏𝑖(𝑙, ?⃗⃗⃗?)
𝑖
)
2
𝑥∈𝑂𝐴𝑅
, (6) 
subject to      𝜏𝑖(𝑙, ?⃗⃗⃗?)  =∑𝑻𝑖𝜈(𝑙) 𝑤𝜈
𝜈
, 
𝑤𝜈 ≥ 0, 
𝑪(𝑙) ≥ ?⃗?, 
where the aperture intensities, like the pencil-beam intensities, must be positive and the 
constraint, 𝑪(𝑙) ≥ ?⃗?, describes all boundary, linear, and nonlinear machine-based 
delivery constraints on the MLC (e.g. the minimum leaf gap, position limits, leaf 
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interdigitation, or minimum open-area). Similarly, the equivalent fluence maps from 
Equation 5 can be used with the FIDO objective function in Equation 3 to construct the 
following aperture-based FIDO problem:  
minimize
𝑙, ?⃗⃗⃗?
      𝑝𝑝𝑡𝑣 ∑ (∑𝒅𝑥𝑖𝜏𝑖(𝑙, ?⃗⃗⃗?) − 𝑑𝑝𝑡𝑣
𝑖
)
2
𝑥∈𝑃𝑇𝑉
+ 𝑝𝑜𝑎𝑟 ∑ ∑𝒅𝑥𝑖
2 𝜏𝑖
2(𝑙, ?⃗⃗⃗?)
𝑖𝑥∈𝑂𝐴𝑅
, (7) 
subject to      𝜏𝑖(𝑙, ?⃗⃗⃗?)  =∑𝑻𝑖𝜈(𝑙) 𝑤𝜈
𝜈
, 
𝑤𝜈 ≥ 0, 
𝑪(𝑙) ≥ ?⃗?. 
Like the FMO problem (Equation 2), these DAO problems can be solved using an 
iterative (often gradient-based) constrained optimization technique [1-10]. However, 
these DAO algorithms will be inefficient from repeatedly computing the product of the 
large pencil-beam dose matrix and the effective fluence maps produced by the plan 
parameters of the current iteration.  
Another way of evaluating the objective function is through its Taylor series 
expansion. Specifically, since the objective function is purely quadratic with respect to 
the pencil-beam intensity, its value can be computed without approximation using a 
second-order Taylor series expansion, such as the following expansion centered at 𝜏 = 0: 
𝑓(𝜏) = 𝑓(0) + ∇𝑓(0) ⋅ 𝜏 +
1
2
 𝜏𝑇 𝐇[𝑓] 𝜏, 
where ∇𝑓(0) denotes the gradient vector of the objective function evaluated at 𝜏 = 0 and 
𝐇[𝑓] denotes the Hessian matrix of the objective function. It is advantageous to use this 
Taylor series expansion as the Hessian matrix will often be several orders of magnitude 
smaller than the pencil-beam dose matrix. Therefore, fewer operations will be performed 
when evaluating the objective functions with its Taylor series expansion as opposed to its 
non-expanded form. Furthermore, since the Hessian matrix is also symmetric, we can 
reduce the amount of computer memory taken up during optimization, and possibly avoid 
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any von Neumann bottlenecks (where the computation is limited by the data transfer 
rates) during optimization [12]. 
While the Taylor series expansion may reduce the number of operations performed 
when evaluating the objective function, it does require us to compute the objective 
function’s Hessian matrix prior to optimization which could be computationally intensive 
in itself. This is where using the FIDO objective function becomes advantageous. First, 
note that the Hessian matrix of the FIDO objective function is proportional to the 𝜶 
matrix in Equation 4, [15] while the Hessian matrix of the standard objective function is, 
𝐇[𝑓] = 𝑝𝑝𝑡𝑣 ∑ 𝒅𝑗𝑥
𝑇
𝑥∈𝑃𝑇𝑉
𝒅𝑥𝑖 + 𝑝𝑜𝑎𝑟 ∑ 𝒅𝑗𝑥
𝑇
𝑥∈𝑂𝐴𝑅
𝒅𝑥𝑖 . 
Notice that, while similar, the equations for 𝜶 and the standard objective function’s 
Hessian matrix differ by a Krönecker-delta function in the OAR term. This means that 
the OAR objectives will contribute to every element in the Hessian matrix of the standard 
objective function, whereas the OAR objectives will only contribute to the diagonal 
elements of the 𝜶 matrix in FIDO. As a result, we can compute the Hessian matrix of the 
FIDO objective function far more efficiently than that of the standard objective function, 
especially when large OARs such as the normal unspecified tissue have planning 
objectives. Additional modifications can be made to the FIDO objective function so that 
dose-volume objectives can be included in the optimization. These modifications take 
into consideration the total number of operations performed when updating 𝜶 and 𝛽 
matrices during optimization and will be discussed in further detail in the following 
section. 
The Taylor series expansion of the FIDO objective function can be written as, 
𝑓(𝜏) = 𝑓(0) + 𝜏 ⋅ ( 𝛂 𝜏  − 2𝛽 ), (8) 
where 𝑓(0) is a constant. Since this constant term will have no effect on the optimal 
solution, it can be omitted from computations during the optimization. Therefore, like 
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Equation 7, a fast inverse direct aperture optimization (FIDAO) problem can be 
formulated as the following generalized problem:  
minimize
𝑙, ?⃗⃗⃗?
     𝜏(𝑙, ?⃗⃗⃗?) ⋅ ( 𝛂 𝜏(𝑙, ?⃗⃗⃗?)  − 2𝛽 ), (9) 
subject to      𝜏𝑖(𝑙, ?⃗⃗⃗?)  = ∑𝑻𝑖𝜈(𝑙) 𝑤𝜈
𝜈
, 
𝑤𝜈 ≥ 0, 
𝑪(𝑙) ≥ ?⃗?. 
If we are using a gradient-based optimization technique, the derivatives of the 
objective function with respect to each aperture 𝜇’s intensity, 𝑤𝜇, and with respect to the 
leaf position of each leaf k in each aperture 𝜇, 𝑙𝑘
(𝜇)
, can be computed using the following:  
∂𝑓 
𝜕𝑤𝜇
= 2∑𝑻𝜇𝑗
𝑇 (𝑙)
𝑗
( 𝛂 𝜏(𝑙, ?⃗⃗⃗?)  − 𝛽)
𝑗
,            (10𝑎)
∂𝑓
𝜕𝑙𝑘
(𝜇)
= 2 ∑𝑤𝜇
𝜕𝑻𝜇𝑗
𝑇 (𝑙)
𝜕𝑙𝑘
(𝜇)
𝑗 
  ( 𝛂 𝜏(𝑙, ?⃗⃗⃗?)  − 𝛽)
𝑗
.             (10𝑏)
 
For convenience, the pencil-beam array is aligned with the MLC leaf banks as shown in 
Figure 3.1. Therefore, any leaf motion will either expose or block the pencil-beam(s) that 
currently coincide with the MLC leaf position (for instance, pencil-beam 7 or 11 in 
Figure 3.1) and we can use the following piecewise approximation when evaluating 
Equation 10b for each leaf in each aperture, [9,16] 
𝜕𝑻𝜇𝑗
𝑇 (𝑙)
𝜕𝑙𝑘
(𝜇)
= {
±
1
ℎ𝑝𝑏
, 𝑙𝑒𝑎𝑓 𝑘 𝑜𝑓 𝑎𝑝𝑒𝑡𝑢𝑟𝑒 𝜇 (𝑙𝑘
(𝜇)) 𝑐𝑜𝑖𝑛𝑐𝑖𝑑𝑒𝑠 𝑤𝑖𝑡ℎ 𝑝𝑒𝑛𝑐𝑖𝑙 𝑏𝑒𝑎𝑚 𝑗
0,                                                                  𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒                     
 (11) 
with ℎ𝑝𝑏 being the width of the pencil-beams. The sign (±) of this piecewise function will 
depend on whether the differentiated leaf 𝑘 is a member of the left or right leaf bank, and 
whether a change in its position in the positive direction of motion will lead to the 
coinciding pencil-beam becoming more exposed or blocked. If a leaf resides exactly 
between two pencil beams (e.g. the leaf between pencil beam 2 and 6 in Figure 3.1), the 
leaf will be considered to coincide with the pencil beam on the right unless the leaf is on 
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the right boundary of the calculated pencil beam array (e.g. the leaf on the edge of pencil 
beam 16 in Figure 3.1) in which case it will be considered to coincide with the pencil 
beam on the left [16]. 
3.2.3 Dose-volume objectives 
Often a treatment plan must satisfy a variety of clinical dose-volume objectives such 
as a minimum PTV dose or a maximum dose to some volume of an OAR. Dose-volume 
objectives are typically included as a separate term in the objective function, such as the 
following for a minimum PTV dose objective: 
𝑓𝑚𝑖𝑛−𝑑𝑣ℎ
(𝑝𝑡𝑣) (𝜏) = 𝑝𝑝𝑡𝑣 ∑ Θ(𝑑𝑚𝑖𝑛 −∑𝑑𝑥𝑖𝜏𝑖
𝑖
)(𝑑𝑚𝑖𝑛 −∑𝑑𝑥𝑖𝜏𝑖
𝑖
)
2
𝑥∈𝑃𝑇𝑉
, 
where Θ is the Heaviside function and 𝑑𝑚𝑖𝑛 is the minimum threshold dose [16]. Note 
that a similar equation is used for maximum dose objectives in the PTV and OARs.  
 Like the standard objective function (Equation 1), these dose-volume objective 
functions will contribute to every element in the Hessian matrix and gradient vector. 
Moreover, their contribution to the Hessian matrix and gradient vector will have to be 
updated throughout the optimization, as the dose distribution changes and non-compliant 
voxels begin to comply with the dose-volume objectives and vice versa. This repeated 
computation of the Hessian matrix and gradient vector could be very time-consuming and 
so we propose the following approach.  
Similar to the original FIDO publication, we use a voxel-based OAR penalty weight, 
𝑝𝑜𝑎𝑟(𝑥), and prescribed dose, 𝑑𝑝𝑡𝑣(𝑥), in the FIDO objective function (Equation 3) to 
include dose-volume objectives [14]. The amount that these terms are varied by is based 
on: (1) whether the voxel is contributing to the violation of a dose-volume objective, (2) 
the amount of dose or volume that the voxel or ROI is violating a dose-volume objective 
by, and (3) the penalty weight assigned to the dose-volume objective. Details on how the 
prescribed dose and OAR penalty weight are spatially varied can be found in Section 
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3.6Appendix, along with examples demonstrating its effectiveness. By doing this, the 
equations for 𝜶 and 𝛽 become, 
𝜶𝑗𝑖 = 𝑝𝑝𝑡𝑣 ∑ 𝒅𝑗𝑥
𝑇
𝑥∈𝑃𝑇𝑉
𝒅𝑥𝑖 +  𝛿𝑖𝑗 ∑ 𝑝𝑜𝑎𝑟(𝑥) 𝒅𝑗𝑥
𝑇
𝑥∈𝑂𝐴𝑅
𝒅𝑥𝑖  
𝛽𝑗 = 𝑝𝑝𝑡𝑣  ∑ 𝑑𝑝𝑡𝑣(𝑥) 𝒅𝑗𝑥
𝑇
𝑥∈𝑃𝑇𝑉
. 
By spatially varying these specific terms, we can include dose-volume objectives in 
the optimization while also minimizing the number of elements in 𝜶 and 𝛽 that need to 
be updated during optimization. Specifically, we only need to update the diagonal 
elements of the 𝜶 matrix when OAR dose-volume objectives are included, and the 
elements of 𝛽 only when PTV dose-volume objectives are included. A similar approach 
was used in the original FIDO algorithm to enforce minimum and maximum point dose 
objectives [14]. Specifically, after solving the FIDO matrix equation (Equation 4), the 
FIDO algorithm would re-compute and solve the matrix equation a second time with a 
spatially varying prescribed dose and penalty weights based on the previous solution to 
the FIDO matrix equation [14]. With sufficient weighting of the dose-volume objectives, 
the second solution to the FIDO matrix equation will improve the maximum or minimum 
point dose objectives. 
3.2.4 Implementation & testing of the prototype algorithm 
A proof-of-concept FIDAO algorithm was developed in MATLAB v9.4 (Mathworks 
Inc, Natick, MA) using an open-source treatment planning toolkit called matRad v2.2. 
[16]. This toolkit includes a graphical user interface for creating and evaluating the 
treatment plan, a singular value decomposition (SVD) dose computation algorithm for 
calculating the pencil-beam dose matrix, MLC leaf-sequencing algorithms for generating 
apertures from fluence maps, and sample datasets. It also includes a built-in experimental 
DAO algorithm, which we used as an independent benchmark for our FIDAO algorithm 
[16]. 
The prototype FIDAO algorithm used the open-source interior-point optimization 
(IPOPT) package to solve the FIDAO problem in Equation 9 [15]. This IPOPT package 
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was made available through the computational infrastructure for operations research 
(COIN-OR) initiative [17]. This algorithm was selected so that a fair comparison could 
be made between our FIDAO algorithm and matRad’s DAO algorithm, as it too uses the 
same IPOPT package to solve the standard DAO problem in Equation 6. Our goal for this 
planning study was to compare the time it took each algorithm to converge to similar 
plans, using the same optimization algorithm but different equations for the objective 
function and its gradient vector. Therefore, the same planning objectives, starting 
apertures, convergence criteria, delivery constraints, and optimization settings were used 
by both algorithms.  
IMRT treatment plans were created on the Common Optimization for Radiation 
Therapy (CORT) datasets that were included with the matRad toolkit [16,18]. This library 
includes the AAPM TG-119 box phantom (shown in Figure 3.2 below) as well as sample 
prostate, liver, and head-and-neck clinical cases. The voxel size for dose calculations and 
plan evaluation were: 3x3x2.5 mm3 in the TG-119 case, 3x3x3 mm3 in the prostate case, 
3x3x2.5 mm3 in the liver case, and 3x3x5 mm3 in the head-and-neck case. Pencil beams 
were set to 5x5 mm2 in size. The couch and gantry angles were set to the suggested 
values in the CORT study for IMRT treatment [18].  
For the planning study, the plans first underwent FMO optimization using matRad’s 
built in FMO algorithm and the planning objectives listed in Table 3.1 [16]. The plan 
then underwent aperture sequencing using matRad’s leaf-sequencing algorithm [19]. The 
matRad leaf-sequencing algorithm was modified slightly so that the total number of 
apertures in a plan could be restricted. Specifically, if the sequencer produced more 
apertures than a user-defined limit, the apertures with the smallest open area were 
discarded. The maximum number of apertures in the plan was set to 10 times the number 
of beams.  
After aperture sequencing, one copy of the post sequencing plan underwent DAO 
with the standard DAO algorithm implemented in matRad, and another copy underwent 
DAO with the FIDAO algorithm. Both algorithms used the same planning objectives 
listed in Table 3.1. Identical objective penalty weights were also used in both plans, 
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except for the TG-119 phantom case, where marginally higher OAR penalty weights 
were necessary in the FIDAO plan to achieve similar OAR sparing as the standard DAO 
plan. 
Table 3.1: Optimization objectives used by both algorithms. 
No. Site 
Beams 
(Apertures) Optimization Objectives 
1. TG-119 5 (50) • Uniform 50 Gy dose to the C-shaped Target. 
• Minimal dose to the core OAR and body. 
• Maximum point dose of 50 Gy in the body, and 25 Gy in the core OAR.  
2. Liver 7 (70) • Uniform 45 Gy dose to the PTV. 
• Minimal dose to the healthy liver, heart & normal tissue. 
• Maximum point dose of 40 Gy in the normal tissue. 
3. Prostate 5 (50) • Uniform 68 Gy and 56 Gy dose to the PTV and Nodes. 
• Minimal dose to the rectum, bladder & normal tissue. 
• Maximum point dose of 50 Gy in the normal tissue, rectum, and 
bladder. 
4. HN 10 (100) • Uniform dose to each PTV (70 Gy, 63 Gy, and 56 Gy). 
• Minimal dose to the cord, brainstem, parotid glands & normal tissue. 
Prior to DAO, FIDAO computed and stored each ROI’s contribution to 𝜶 and 𝛽. 
Furthermore, FIDAO also performed aperture weight optimization prior to DAO by 
solving the matrix equation, 
?⃗⃗⃗? = (𝑻𝑇𝜶 𝑻)−1 (𝑻𝑇𝛽). 
This FIDO-like aperture weight optimization equation is acquired by setting Equation 
10a to zero. Its solution gives the optimal aperture weights based on the aperture 
information approximated by 𝑻. This aperture weight optimization was performed prior 
to DAO in an effort to reduce the number of iteration performed in FIDAO, as the 
equation and its solution can be computed efficiently and the solution will place the plan 
significantly closer to a minimum of the objective function. 
During DAO, both algorithms enforced a non-negative aperture weight constraint and 
position limits on the MLC leaves. These constraints are linear and are enforced during 
each iteration of the optimization [17]. Both methods used the default IPOPT termination 
criteria that came with the matRad software (v2.2.0) [16,17]. The maximum number of 
iterations was set to 500 and the threshold for termination was set to 1x10-8. 
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If dose-volume objectives were included in the optimization, FIDAO would update 𝜶 
and 𝛽 twice during the optimization; once at the beginning of the optimization and a 
second-time after half of the maximum number of iterations were completed. If the 
optimization exited before the half-way point, the update would be performed then, and 
the optimization would automatically be executed a second time. 
These optimizations were performed on the same desktop computer running 
Windows 10 with an Intel i7-4790 (3.6 GHz) CPU and 16 GB of RAM. To the best of 
our knowledge, no CPU or GPU parallelization was utilized in matRad’s DAO 
algorithm’s code [16]. Similarly, no parallel processing was used in FIDAO’s code. The 
FIDAO and matRad optimized plans were then compared based on their dose-volume 
histograms, 3D dose distributions, and optimization time. 
3.3 Results 
Details about the test cases and the algorithms’ performance are listed in Table 3.2. 
Note that the size of the square Hessian matrix (𝜶) is proportional to the number of pencil 
beams (column 3) in the plan, while the size of the pencil-beam dose matrix is the 
number of pencil beams x the number of voxels (column 4). Also, note that the listed 
computation times for FIDAO’s 𝜶 and 𝛽 (column 7) refers only to their initial 
computation time prior to DAO. The time spent updating 𝜶 and 𝛽 when dose-volume 
objectives were present is included in the total FIDAO optimization time (column 8).  
Table 3.2: Information related to the size of the optimization problem, and each algorithm’s 
performance.  
No. Site 
Pencil 
Beams 
Voxels 
[x 106] 
Non-zero  
dxi [x 106] 
Voxels in 
PTV [x103] 
𝛂, β⃗⃗ 
Initialization  
Optimization Time (Iter.) 
FIDAO  Standard  
1. TG-119   1,857 3.60   91.8  7.5   2.1 s 0.3s (17)   56.7 s (50) 
2. Liver   1,971 7.91 159.0  7.0   4.5 s 2.0s (28) 134.1 s (57) 
3. Prostate   3,034 3.05 159.6 16.3   6.2 s 2.5s (26) 180.6 s (107) 
4. HN 13,749 1.72 235.5 30.6 60.6 s 6.7s (20) 469.4 s (245) 
Abbreviations: Iter, Iterations. 
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Dose-volume histograms (DVH) and sample dose distributions for each site are 
shown in Figure 3.2 through Figure 3.5. To demonstrate the effectiveness of these DAO 
algorithms, Figures 3.2-3.5 also include sample dose distributions and DVHs of the plan 
before DAO (post FMO and aperture sequencing). In the prostate, liver and head-and-
neck cases, there were too many critical structures to display all the DVHs in one plot. 
Therefore, additional DVHs are available for these cases in Supplemental Figure 3.1 
through Supplemental Figure 3.3. PTV and OAR dose metrics are also supplied in 
Supplemental Table 3.1 and Supplemental Table 3.2, respectively. As demonstrated by 
the comparisons of the dose-volume histograms and the sample dose distributions, 
FIDAO and standard DAO algorithm converged to nearly identical plans. However, 
FIDAO obtained the optimal solution substantially faster than the standard DAO 
algorithm in matRad (approximately 70-200 times faster; or up to 23 times faster when 
including the pre-calculation times for the 𝜶 and 𝛽 matrices), and in fewer iterations. 
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Figure 3.2: Dose-volume histograms (upper) and sample dose-distributions (lower) of 
the AAPM TG-119 phantom plan after undergoing FMO and aperture sequencing (dotted 
line) and when optimized with the FIDAO (solid line) and the standard (dashed line) 
DAO algorithms. The cross-section of the axial, sagittal, and coronal planes are shown as 
dashed lines on the dose distributions. 
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Figure 3.3: Dose-volume histograms (upper) and sample dose-distributions (lower) of 
the prostate case after undergoing FMO and aperture sequencing (dotted line) and when 
optimized with the FIDAO (solid line) and the standard (dashed line) DAO algorithms. 
The cross-section of the axial, sagittal, and coronal planes are shown as dashed lines on 
the dose distributions. 
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Figure 3.4: Dose-volume histograms (upper) and sample dose-distributions (lower) of 
the liver case after undergoing FMO and aperture sequencing (dotted line) and when 
optimized with the FIDAO (solid line) and the standard (dashed line) DAO algorithms. 
The cross-section of the axial, sagittal, and coronal planes are shown as dashed lines on 
the dose distributions. 
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Figure 3.5: Dose-volume histograms (upper) and sample dose-distributions (lower) of 
the head-and-neck case after undergoing FMO and aperture sequencing (dotted line) and 
when optimized with the FIDAO (solid line) and the standard (dashed line) DAO 
algorithms. The cross-section of the axial, sagittal, and coronal planes are shown as 
dashed lines on the dose distributions. 
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3.4 Discussion 
The algorithms used for DAO and FMO are computationally demanding. This is 
primarily due to the repeated use of the pencil-beam dose matrix, 𝒅, to evaluate the 
objective function and compute its gradient vector during optimization. As shown in 
Table 3.2, this matrix has millions of elements and takes several gigabytes of memory to 
store. The size of this matrix not only impacts the amount of memory required to perform 
FMO or DAO, but also the time it takes to execute a computation involving it, as the 
computation speed will be limited by the rate at which the computer can transfer the dose 
matrix elements from memory to the processor’s arithmetic unit as well as the 
processor’s clock speed [10,12]. In response to this limit, many academic and 
commercial groups have developed FMO and DAO algorithms that utilize the multiple 
processors available on modern CPUs and GPUs [7,9-12]. With these multicore units, the 
computation can be performed in parallel, allowing for the individual computations and 
the overall optimization to be completed faster. Others have also developed using a novel 
non-voxel-based broad-beam (NVBB) framework when deriving the DAO problem, 
which eliminates the pencil-beam dose matrix from the DAO problem entirely [20,21].  
In this work, we extended a previously developed FMO algorithm called FIDO to 
perform DAO. This algorithm uses the objective function’s Hessian matrix and a 
reference gradient vector (or 𝜶 and 𝛽 as they were denoted in the original FIDO papers), 
via second-order Taylor series expansion, to compute the objective function value and its 
gradient vector during optimization [13-15]. Using the 𝜶 and 𝛽 matrices is advantageous 
as they often have considerably fewer elements than the pencil-beam dose matrix, and 
therefore any computations involving them will have smaller data transfer overheads and 
require fewer operations. This can be illustrated with some of the values found in Table 
3.2. If the pencil-beam dose matrix is stored in a compressed sparse row or column 
format, the number of operations performed during matrix-vector multiplication with the 
pencil-beam dose matrix (e.g. 𝒅𝜏 in the standard objective function) is proportional to the 
number of non-zero elements in the matrix [22]. On the other hand, the same operation 
with 𝜶 (e.g. 𝜶𝜏 in the FIDAO objective function) is proportional to the squared number 
of pencil-beams in the plan. From Table 3.2, we can see that the squared number of 
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pencil-beams in each plan is substantially smaller than the number of non-zero element in 
the pencil-beam dose matrix. As a result, FIDAO could evaluate the objective function 
value or compute its gradient vector substantially faster, resulting in an overall faster 
optimization.  
While a similar algorithm could have been formulated from the standard objective 
function’s (Equation 1) Hessian matrix and gradient vector, this formulation would likely 
have been less efficient than FIDAO due to the computation times for the Hessian matrix. 
Notice from Table 3.2 that a relatively large amount of time is spent pre-calculating 𝜶 
and 𝛽. This time is mostly spent on computing the PTV component of 𝜶, as the PTV 
objectives contributes to every element in 𝜶 whereas the OAR objectives only contribute 
to the diagonal elements of 𝜶. The fact that the OARs only contribute to the diagonal 
elements of 𝜶 is a result of the reformulation of the OAR objective function in FIDO. If 
we were to use the standard objective function, the OARs would then contribute to every 
element in 𝜶, which would substantially increase the computation time for the Hessian 
matrix especially when very large OARs have planning objectives such as the normal 
unspecified tissue. Furthermore, if we were to use the standard equations for dose-volume 
objectives, we would have to update every element in 𝜶 and 𝛽 as opposed to just 𝛽 and 
the diagonal elements of 𝜶 when using the spatially varying penalty weight and 
prescribed dose in FIDO. Collectively, this makes computing and updating the Hessian 
matrix and gradient vector of the FIDO objective function substantially easier than with 
the standard objective function. 
If given the same penalty weight, 𝑝𝑜𝑎𝑟, and effective fluence map, 𝜏, the standard 
equation for the OAR objective will contribute more to the objective function value than 
the reformulated FIDO equation. That is, 
𝑝𝑜𝑎𝑟∑(∑𝑑𝑥𝑖
𝑖
𝜏𝑖)
2
𝑥
≥ 𝑝𝑜𝑎𝑟∑∑𝑑𝑥𝑖
2
𝑖
𝜏𝑖
2
𝑥
. 
This inequality means that FIDAO may need a higher OAR penalty weight than the 
standard objective function in order to achieve similar OAR sparing, as was observed in 
the TG-119 phantom case from this study. Moreover, this reformulation could cause 
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FIDAO to be less sensitive to OAR maximum doses as FIDAO penalizes the individual 
dose contributed by each pencil beam instead of the net dose contributed by all pencil 
beams. This can be counteracted by spatially increasing the OAR penalty weight in 
voxels with a net dose above some tolerance dose, as demonstrated in Figure 3.6 in the 
Appendix. 
The optimization times obtained with FIDAO are similar to the reported optimization 
times of GPU-based DAO algorithms. For instance, Men et al. showed that their GPU-
based DAO algorithm could optimize an IMRT treatment plan in 0.7s to 3.8s, whereas 
our FIDAO algorithm could optimize a plan in 0.3s to 6.7s without any parallelization 
[7]. Note that the fast optimization times reported in their study can be partially attributed 
to the down-sampling of unspecified tissue (i.e. voxels that were outside the PTV or 
contoured OARs), which resulted in much smaller pencil-beam dose matrices than in our 
present study. For instance, the number of non-zero elements in 𝒅 in their study was at 
least 25 times smaller than in this study. Therefore, their GPU-based DAO algorithm 
would take considerably longer if executed on the same cases reported here. That said, 
our FIDAO algorithm does require an additional 2 to 60 s to pre-compute 𝜶 and 𝛽 
whereas the GPU-based method does not. This computation, however, can be parallelized 
in addition to the evaluation of FIDAO’s objective function and the computation of its 
gradient vector.  
Note that the much better OAR sparing in the post sequencing prostate plan (Figure 
3.3) and head-and-neck plan (Figure 3.5) was only achievable due to the severe and 
clinically unacceptable under-dosing of the PTVs (more than 25% under-dosing for D95 
of PTVs). The plans obtained with FIDAO and the standard DAO algorithm are more 
clinically relevant as they provide the best possible OAR sparing achievable while also 
obtaining a clinically acceptable level of PTV coverage. 
It is well known that gradient-based DAO methods may become trapped at a local 
minimum due to the non-convex nature of the objective function. However, this problem 
can be minimized by starting the DAO at a good starting point as done in many 
commercial treatment planning systems. For instance, we can first perform fluence map 
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optimization with FIDO which finds the global minimum of the objective function. After 
MLC leaf sequencing, we can then fine-tune these apertures using FIDAO. We can also 
employ stochastic optimization methods like simulated annealing and genetic algorithms 
in lieu of a gradient-based approach, as these algorithms can escape from local minima. 
For this proof-of-concept study, we chose to use a gradient-based optimization method 
due to its accessibility and the wide-spread use of gradient-based DAO methods in 
commercial treatment planning systems. However, similar performance improvements 
should be expected when using FIDAO with any stochastic, greedy, or other first-order 
optimization methods due to the much more efficient evaluation of the expanded FIDO 
objective function compared to the standard objective function. 
FIDAOs optimization time is minimally impacted by the size or resolution of the dose 
grid. Specifically, only the initial computation and updating of the 𝜶 and 𝛽 matrices will 
be affected by the resolution or size of the dose grid, whereas the computation of the 
objective function value and its gradient vector during optimization is only affected by 
the number of pencil-beams in the plan. This makes FIDAO very desirable for optimizing 
stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) treatment 
plans, where an isotropic high-resolution dose grid size of 2 mm or less is recommended  
[23]. Conversely, it is unclear whether FIDAO may be suitable for optimizing volumetric 
modulated arc therapy (VMAT) plans, as VMAT plans typically have tens of thousands 
of pencil-beams which could drastically decrease the efficiency of evaluating the FIDAO 
objective function. Moreover, interior point methods are known to be inefficient for 
large-scale optimization problems such as those in VMAT planning, so a different 
optimization method may also be necessary. This will need to be assessed in a future 
study that incorporates VMAT-related delivery constraints such as the maximum MLC 
distance due to maximum MLC-travel speeds and gantry-rotation speeds. 
3.5 Conclusions 
In this work, a fast inverse direct aperture optimization (FIDAO) algorithm was 
developed based on the fast inverse dose optimization (FIDO) method. A prototype of 
this algorithm was developed in MATLAB and compared against an independent DAO 
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algorithm on four test cases. In all four cases, the prototype algorithm produced 
comparable step-and-shoot IMRT plans with gains of 70-200 times in optimization speed. 
The study demonstrates promising speed enhancements for direct aperture optimization 
using FIDAO without necessitating parallel computing strategies. 
3.6 Appendix 
Let 𝑑(𝑥) be the dose deposited to voxel 𝑥, and let 𝑝𝑑𝑣ℎ and 𝑑𝑡𝑜𝑙 be the objective 
penalty weight and tolerance dose assigned to a dose-volume objective. Also, let 
Δ𝑑(𝑥) = 𝑑(𝑥) − 𝑑𝑡𝑜𝑙 and 𝑚(𝑥) denote the percent that the voxel dose is above or below 
the tolerance dose, 
𝑚(𝑥) = |
Δ𝑑(𝑥)
𝑑𝑡𝑜𝑙
|. 
If a maximum or minimum point dose objective is applied to the PTV, FIDAO uses a 
spatially varying prescription dose to increase or decrease the dose in non-compliant 
voxels. By varying the prescription dose instead of the penalty weight, FIDAO can avoid 
having to recompute the full Hessian matrix. Specifically, the prescription dose of voxels 
above or below the threshold point dose will vary according to: 
𝑑𝑝𝑡𝑣(𝑥) =
{
 
 
 
 (1 ± (
𝑝𝑑𝑣ℎ
𝑝𝑝𝑡𝑣
)𝑚(𝑥))  𝑑𝑝𝑡𝑣,    𝑖𝑓 𝑚(𝑥) < 0.03
(1 ± (
𝑝𝑑𝑣ℎ
𝑝𝑝𝑡𝑣
)0.03)  𝑑𝑝𝑡𝑣,    𝑖𝑓 𝑚(𝑥) > 0.03
,  
while all other voxels will maintain the user prescribed 𝑑𝑝𝑡𝑣 dose [14]. Note that the ± 
sign will be positive if it’s a minimum dose objective, and negative if it’s a maximum 
dose objective. This equation is equivalent to increasing or decreasing the prescription 
dose by up to 3%, when the penalty weight of the dose-volume objective is the same as 
𝑝𝑝𝑡𝑣. If the dose-volume objective is weighted more than the homogeneity objective 
(𝑝𝑑𝑣ℎ > 𝑝𝑝𝑡𝑣), the prescription dose will be varied by more than 3% and vice versa.  
If a maximum point dose objective is applied to an OAR, the OAR objective penalty 
weight 𝑝𝑜𝑎𝑟(𝑥) for voxels above the tolerance dose is varied by, 
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𝑝𝑜𝑎𝑟(𝑥) =
{
 
 
 
 (1 + (
𝑝𝑑𝑣ℎ
𝑝𝑜𝑎𝑟
)
Δ𝑑(𝑥)
𝑑1
)𝑝𝑜𝑎𝑟 ,      𝑖𝑓 Δ𝑑(𝑥) < 𝑑𝑡ℎ𝑟𝑒𝑠ℎ
(1 + (
𝑝𝑑𝑣ℎ
𝑝𝑜𝑎𝑟
)
𝑑𝑡ℎ𝑟𝑒𝑠ℎ
𝑑1
)𝑝𝑜𝑎𝑟 ,   𝑖𝑓 Δ𝑑(𝑥) > 𝑑𝑡ℎ𝑟𝑒𝑠ℎ
, 
where 𝑑𝑡ℎ𝑟𝑒𝑠ℎ is a threshold dose chosen to be 9 Gy, and 𝑑1 = 1 Gy so that the 
penalty weight remains dimension-less. This equation is equivalent to increasing the 
penalty weight by up to a factor of 10 when the penalty weight of the dose-volume 
objective is the same as 𝑝𝑜𝑎𝑟. If the dose-volume objective is weighted more than the 
OAR objective (𝑝𝑑𝑣ℎ > 𝑝𝑜𝑎𝑟), the penalty weight will be increased by more than a factor 
of 10 [14]. 
If the minimum (or maximum) dose-volume objective for the PTV is volume based, 
the prescribed dose is increased (or decreased) more for voxels that are closer to the 
threshold dose. Similarly, if the dose-volume objective for an OAR is volume based, the 
penalty weight is increased more for voxels that are closer to the threshold dose.  
Figure 3.6 shows the DVHs of the prostate case from this study after FIDAO 
optimization with (solid line) and without (dashed line) a minimum PTV dose objective 
(upper), a maximum dose objective to 50% of the rectum and bladder (middle), and a 
maximum rectum point dose objective (lower). 
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Figure 3.6: Dose-volume histograms of the prostate case after DAO with FIDAO with 
(solid) and without (dashed) a minimum 64.6 Gy PTV dose objective (upper), a 
maximum 35 Gy dose objective to 50% of the rectum and bladder (middle), and a 
maximum 60 Gy point dose objective to the rectum (lower) as indicated by the circles 
and arrow markers. 
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Chapter 4 – A fast inverse direct aperture optimization 
algorithm for volumetric modulated arc therapy 
This chapter describes initial work on a FIDAO algorithm for VMAT planning. It will 
be converted to a manuscript for a technical note entitled “A fast inverse direct aperture 
optimization algorithm for volume-modulated arc therapy” by Michael MacFarlane, 
Douglas Hoover, Eugene Wong, Jerry J. Battista, and Jeff Z. Chen.  
4.1 Introduction 
In a recent article, our group developed a new direct aperture optimization (DAO) 
algorithm called fast inverse direct aperture optimization (FIDAO) [1]. FIDAO extends a 
previously implemented fluence map optimization algorithm called fast inverse dose 
optimization (FIDO) for DAO [1-3]. Specifically, instead of using the conventional 
objective function, FIDAO used a modified quadratic objective function (similar to 
FIDO) to efficiently compute the objective function value and gradient vector during 
DAO.  
The advantage of FIDAO is that the number of operations (𝑚) performed when 
evaluating the modified quadratic objective function is proportional to the squared 
number of pencil beams in the plan, whereas the number of operations (𝑛) performed 
when evaluating the conventional objective function is proportional to the number of 
non-zero elements in a pre-calculated dose matrix. For fixed-gantry intensity-modulated 
radiotherapy (IMRT), 𝑚 ≪ 𝑛, as a result FIDAO executes up 200-times faster when 
compared to standard DAO methods as described in Chapter 3 [1]. No significant 
differences in plan quality was observed between the plans optimized with FIDAO and 
the standard method.  
For volume-modulated arc therapy (VMAT) plans, the number of pencil beams in a 
plan can be significantly larger than in IMRT plans. As a result, it is possible for 𝑚 ~ 𝑛 
or 𝑚 > 𝑛, especially if the pre-calculated dose matrix is down-sampled in unspecified 
normal tissue, as is done by some DAO algorithms for optimization [4,5]. Furthermore, 
VMAT uses a different planning procedure than IMRT and requires additional 
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constraints, which could possibly impact the performance of FIDAO. Therefore, the goal 
of this work was to extend FIDAO for VMAT planning, and to evaluate whether FIDAO 
can also offer a performance advantage for VMAT treatment planning, as it did for fixed-
field IMRT. 
4.2 Methods and Materials 
A prototype FIDAO algorithm for VMAT treatment planning was developed in 
MATLAB v9.4 (Mathworks Inc, Natick, MA) using the open-source treatment planning 
toolkit matRad (v2.2 – dev_VMAT build) [6,7]. This version of the matRad toolkit 
includes an implementation of the SmartArc VMAT planning algorithm [7,8]. 
Specifically, to generate a VMAT plan, this algorithm first performs fluence map 
optimization (FMO) and aperture sequencing on a set of coarsely equispaced beams [9]. 
The sequenced apertures are then redistributed along the arc trajectory at a finer angular 
spacing (typically 4°). Afterwards, the arc undergoes DAO where VMAT-related 
delivery constraints are enforced. 
VMAT treatment plans were created on the AAPM TG-119 phantom dataset as well 
as the sample prostate and liver cancer cases that are supplied with the matRad toolkit 
[6,10]. The voxel size of these datasets was 3x3x2.5 mm3 in the TG-119 case, 3x3x3 
mm3 in the prostate case, and 3x3x2.5 mm3 in the liver case. The dose calculation matrix, 
𝒅𝑥𝑖, was pre-calculated using matRad’s singular value decomposition (SVD) dose 
computation algorithm [11]. The size of the pencil beams was set to 5x5 mm2. To 
improve the standard DAO and FMO algorithms speed, the dose calculation matrix was 
down-sampled by a factor of 2 in the unspecified normal tissue. Note, however, that the 
full (non-down-sampled) dose calculation matrix was used, after optimization, for the 
final dose calculations and plan evaluation. In all three cases, the plans underwent FMO 
at an angular spacing of 28°, followed by aperture sequencing and arc sequencing with a 
4° angular spacing. The planning objectives that were used in each plan are listed in 
Table 4.1. After arc sequencing, the plans underwent DAO using either the standard 
VMAT DAO algorithm that was included with the matRad toolkit, or the FIDAO 
algorithm.  
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The standard DAO algorithm used an interior-point optimization method to solve: 
minimize
𝑙, ?⃗⃗⃗?
      𝑓1(𝑙, ?⃗⃗⃗?) 
subject to     𝑪(𝑙, ?⃗⃗⃗?) ≥ ?⃗? 
[6,12]. In this problem, 𝑙 and ?⃗⃗⃗? stand for the aperture leaf positions and weights 
respectively, 𝑓1(𝑙, ?⃗⃗⃗?) is the conventional objective function [6], and 𝑪(𝑙, ?⃗⃗⃗?) ≥ ?⃗? are the 
constraints which include a non-negative aperture weight constraint, boundary limits on 
the leaf positions, minimum and maximum leaf travel speed of 0 cm/s and 6 cm/s, 
minimum and maximum gantry rotation speed of 0 °/s and 6 °/s, and a minimum and 
maximum monitor unit (MU) dose rate of 75 MU/min and 600 MU/min, respectively [7]. 
These were the default machine-based delivery constraint that came with the matRad 
toolkit.  
FIDAO used the same interior-point optimization method to solve its DAO problem. 
Compared to the standard DAO algorithms, FIDAO had the following changes: (1) prior 
to optimization, FIDAO computed and stored the modified objective function’s Hessian 
matrix (𝜶) and 𝛽 via Equation 4 in Chapter 3.2.1; (2) Equations 8 & 10 in Chapter 3.2.2 
were used for computing the objective function value and its gradient vector, 
respectively; and (3) if dose-volume objectives were included in the optimization, an 
intermediate recalculation of the Hessian matrix would be performed as describe in 
Chapter 3.2.3.  
Effectively, FIDAO and the standard DAO algorithm are the same as they were in 
Chapter 3, with the exception that both VMAT DAO problems are limited to a single 
aperture at each gantry angle per arc, and that the DAO problems in this study include 
additional VMAT-related delivery constraints such as maximum gantry-rotation speed 
and dose rate. 
Planning was performed on the same desktop computer running Windows 7 with an 
Intel i7-3930K (3.2 GHz) CPU and 64 GB of RAM. To the best of our knowledge, no 
CPU or GPU parallelization was utilized in matRad’s DAO algorithm’s code [6,7]. 
Similarly, no parallel processing was used in the code for FIDAO. The total optimization 
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time and number of iterations were recorded for both FIDAO the standard DAO 
algorithm. The FIDAO and matRad optimized plans were also compared based on their 
dose-volume histograms and 3D dose distributions.  
Table 4.1: Optimization objectives used by both algorithms. 
No. Site 
Beams 
(Apertures) Optimization Objectives 
1. TG-119 1 360° Arc 
(91) 
• Uniform 50 Gy dose to the C-shaped Target. 
• Minimal dose to the core OAR and body. 
• Maximum point dose of 50 Gy in the body, and 25 Gy in the core OAR.  
2. Liver 1 360° Arc 
(91) 
• Uniform 45 Gy dose to the PTV. 
• Minimal dose to the healthy liver, heart & normal tissue. 
• Maximum point dose of 40 Gy in the normal tissue. 
3. Prostate 1 360° Arc 
(91) 
• Uniform 68 Gy and 56 Gy dose to the PTV and Nodes. 
• Minimal dose to the rectum, bladder & normal tissue. 
• Maximum point dose of 50 Gy in the normal tissue, rectum, and 
bladder. 
4.3 Results 
Details about the test cases and the algorithms’ performance are listed in Table 4.2. 
Note that the size of the Hessian matrix (𝜶) is proportional to the squared number of 
pencil beams (column 3) in the plan, while the size of the pencil-beam dose matrix is the 
number of pencil beams times the number of voxels (column 4). Also, note that the listed 
computation times for FIDAO’s 𝜶 and 𝛽 (column 7) refers to their one-time initial 
computation time prior to DAO. The time spent updating 𝜶 and 𝛽 when dose-volume 
objectives were present is included in the total FIDAO optimization time (column 8). 
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Table 4.2: Information related to the size of the optimization problem, and each algorithm’s performance.  
No. Site 
Pencil 
Beams 
Voxels 
[x 106] 
Non-zero  
dxi [x 108] 
Voxels in 
PTV [x103] 
𝛂, β⃗⃗ 
Initialization  
Optimization Time (Iter.) 
FIDAO  Standard  
1. TG-119 32,123 3.60 4.88 7.5 40.9 s 
64.9 s 
(245) 
602 s  
(275) 
2. Liver 20,293 7.91 8.38 7.0 18.7 s 
25 s  
(85) 
803 s 
(159) 
3. Prostate 52,234 3.05 10.52 16.3 197.8 s 
98.6 s 
(174) 
754.3 s 
(149) 
Abbreviations: Iter, Iterations. 
Sample dose-volume histograms (DVH) for each case are shown in Figure 4.1-Figure 
4.3. To demonstrate the effectiveness of these DAO algorithms, Figure 4.1-Figure 4.3 
also include DVHs of the plan prior to DAO (post FMO, aperture and arc sequencing).  
As demonstrated by the comparison of DVHs, FIDAO and the standard DAO 
algorithm converged to plans of similar quality. In the liver case however, the FIDAO 
plan spared the stomach slightly more whereas the standard DAO plan spared the spinal 
cord slightly more. Similarly, in the prostate case, the standard DAO plan and FIDAO 
plan spared the femoral heads and rectum slightly differently. In terms of optimization 
time, FIDAO obtained its solutions about 7-32 times faster than the standard DAO 
algorithm, or 2.5-18.3 times faster if the one-time calculation time for 𝜶 and 𝛽 is 
included. 
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Figure 4.1: Dose-volume histograms of the AAPM TG-119 phantom plan after 
undergoing FMO and aperture sequencing (dotted line) and when optimized with the 
FIDAO (solid line) and the standard (dashed line) DAO algorithms. 
 
Figure 4.2: Dose-volume histograms of the liver plan after undergoing FMO and 
aperture sequencing (dotted line) and when optimized with the FIDAO (solid line) and 
the standard (dashed line) DAO algorithms. 
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Figure 4.3: Dose-volume histograms of the prostate plan after undergoing FMO and 
aperture sequencing (dotted line) and when optimized with the FIDAO (solid line) and 
the standard (dashed line) DAO algorithms. 
4.4 Discussion 
In this work, we extended FIDAO for VMAT treatment planning and evaluated its 
performance relative to a standard VMAT DAO algorithm in three cases. As shown in 
Table 4.2, FIDAO reduced the optimization time for VMAT by up to a factor of 18 
(when the pre-calculation times for 𝜶 and 𝛽 are included). The plan quality obtained with 
FIDAO was on par with the standard DAO method, although some minor differences 
could be observed when using the same planning objectives (Figure 4.1 - Figure 4.3). 
The source of FIDAO’s superior performance lies in the lower computational cost of 
computing FIDAO’s objective function value and gradient vector. As discussed in the 
introduction, the number of operations (𝑚) performed when evaluating FIDAO’s 
objective function is proportional to the squared number of pencil beams in the plan 
(Table 4.2, column 3 squared), whereas the number of operations (𝑛) performed when 
evaluating the conventional objective function is proportional to the number of non-zero 
elements in a pre-calculated dose matrix (Table 4.2, column 5). In most cases, 𝑚 is much 
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lower than 𝑛, meaning that FIDAO can compute its objective function value and gradient 
vector more efficiently. Moreover, FIDAO’s gradient vector can be computed with little 
additional cost once the objective function value is computed, and vice versa, by storing 
the result of 𝒂𝜏 − 𝛽. This cannot be done when using the standard objective function.  
 The optimization times observed in this study are approaching the reported 
optimization times by commercial treatment planning systems, and by Men et al. for their 
GPU-based DAO algorithm, for VMAT planning [13]. For instance, Men et al. reported 
VMAT optimization times in the range of 18 – 31 s when parallelized on an NVIDIA 
Tesla C1060 GPU, whereas we observed optimization times of 25 – 98.6s, on a standard 
desktop CPU, without any parallelization. There are a few key differences between our 
study and Men et al. that are worth noting. First, the plans optimized by Men et al. are 
considerably smaller than the test cases presented in this study. The largest plan in their 
patient cohort had 5.5x107 non-zero elements in its dose calculation matrix, whereas the 
smallest plan in this study has 4.8x108 non-zero elements. Therefore, it would likely take 
considerably longer than 18 – 31 s for their algorithm to execute on the cases presented in 
this study. Secondly, the algorithm implemented by Men et al. is a column generation 
approach that sequentially adds apertures to the plan based on a pricing problem [5,13]. It 
does not perform DAO after aperture and arc sequencing as is done in SmartArc (Philips 
Healthcare, Fitchburg, USA) and the algorithm implemented in this study. Therefore, to 
make a fair comparison, we should also incorporate the 𝜶 computation times (column 7 
of Table 4.2) and the approximate 120 s that was spent on FMO, aperture and arc 
sequencing performed in our method. While this adds a considerable amount of time to 
FIDAO’s overall planning time, note that the 𝜶 calculation can be accelerated greatly 
with GPUs (Equation 4 in Chapter 3.2.1 is a data-heavy computation) and we can 
eliminate most of the FMO time by performing FMO with FIDO [2,3]. Therefore, 
collectively, we anticipate that FIDAO would take less time than the algorithm developed 
by Men et al. when implemented on the same system and tested on the same cases.  
While the time complexity (number of operations) of FIDAO may be lower, the 
spatial complexity (memory usage) of FIDAO is considerably higher. Specifically, 
FIDAO requires us to compute and store the objective function’s Hessian matrix (𝜶). 
 75 
 
When stored in a compressed upper or lower triangular format (notice 𝜶 is symmetric) at 
double precision, the Hessian matrix for the TG-119, liver and prostate cases took an 
additional 4.1 GB, 1.6 GB, and 10.9 GB of memory, respectively. Furthermore, we were 
unable to optimize the head-and-neck cancer case that is included with the matRad toolkit 
due to the memory limitations of our system [6,10]. For a full 360° arc, this head-and-
neck case contained 130,676 pencil beams, so the Hessian matrix would require an 
additional 68.3 GB of memory, which is more memory than our machine possessed. This 
highlights a potential limitation of current implementation of FIDAO. This may 
particularly be an issue when we attempt to use FIDAO for non-coplanar VMAT, which 
may have even more pencil beams in its plan. In a future study, we will investigate 
whether low-rank approximations of the Hessian matrix could be used to help reduce the 
memory used in FIDAO [14]. Furthermore, we will implement FIDAO within a 
commercial treatment and compare the FIDAO optimization to a clinically relevant DAO 
algorithm as opposed to the research DAO algorithm used in this and the previous study. 
Finally, we will parallelize FIDAO’s computations on a GPU and evaluate its 
performance.  
4.5 Conclusion 
In this work, a prototype FIDAO algorithm for VMAT planning was developed and 
compared to a standard DAO algorithm. In the three cases that were tested, FIDAO 
produced plans of similar quality in at least half the time. This study demonstrates 
promising speed enhancement for the DAO of VMAT plans using FIDAO. Further 
opportunities for speed gain are possible with parallel processing technology.  
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Chapter 5 – Patient-specific calibration of cone-beam 
computed tomography images for dose tracking and 
treatment plan assessment 
This chapter was adapted from the published article entitled “Patient-specific 
calibration of cone-beam computed tomography data sets for radiotherapy dose 
calculations and treatment plan assessment” by Michael MacFarlane, Daniel Wong, 
Douglas A. Hoover, Eugene Wong, Carol Johnson, Jerry J. Battista, and Jeff Z. Chen, 
Journal of Applied Clinical Medical Physics, 19 (2): 249-257 (2018). Permission to 
reproduce this article was granted by John Wiley and Sons and is provided in Appendix 
B.4. Supplemental data for this chapter is provided in Appendix E. 
5.1 Introduction 
Radiation treatments generally span several weeks and during this time, changes in 
patient weight, tumour volume and organ positioning can occur [1]. These changes may 
substantially alter the radiation dose distribution within the patient, potentially resulting 
in degraded plan quality and suboptimal clinical outcomes [2].  
To ensure that a patient receives adequate treatment, a new re-planning CT (reCT) 
data set may be acquired to dosimetrically assess plan quality and to evaluate whether 
treatment re-planning has become necessary. Unfortunately, this workflow is often 
inefficient as it is difficult to distinguish a priori which patients require a reCT from 
those who do not. A promising solution is to use cone-beam computed tomography 
(CBCT) image sets to dosimetrically assess plan quality, since these image sets are 
already routinely acquired prior to treatment for patient setup and monitoring. However, 
to perform dose calculations, accurate tissue density information must be extracted from 
the CBCT voxel values. 
Normally, tissue density information is obtained through CT calibration curves, 
which are generated by scanning a plastic phantom containing various inserts of known 
electron density [3]. For CBCT scans, the Hounsfield Units (HU) of an image set are 
highly dependent on many factors, including the size and material of the phantom, the 
materials placed in the phantom, and the imaging protocol used [4-7]. Furthermore, 
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scattering conditions often differ between phantoms and patients when using a cone-
beam geometry. Due to this variability, HU-to-density calibration curves obtained with 
phantoms for CBCT lack sufficient robustness to be applicable to all patients and across 
all anatomical sites [6]. Consequently, alternative methods of inferring tissue density 
have been suggested, such as: (1) population-based calibration curves [6,7], (2) multi-
level thresholding or bulk assignment of the HU or density values [7-10], and (3) voxel-
to-voxel mapping using deformable image registration (DIR) [10-12].  
Although these CBCT calibration techniques have demonstrated some promising 
results, each method may have limitations in certain situations. For instance, population-
based calibration methods require unique calibration curves for each treatment site, and 
for each imaging protocol used. Bulk assignment techniques are dependent on the 
accuracy of automatic segmentation or thresholding of tissue regions, correct density 
assignments, or the time allotted to manually correct improperly delineated volumes. 
Similarly, DIR methods depend on the accuracy of the DIR algorithms, as regional DIR 
errors may significantly distort local anatomy and hence affect the density and dose 
evaluation within the region [13]. This may be particularly problematic in sites such as 
the pelvis and thorax where large deformation errors frequently occur. Moreover, 
regional DIR errors could also alter the delineation of critical structures, thereby further 
affecting organ dose assessment and dose-volume metrics.  
To potentially resolve these limitations, we began development on an alternative 
patient-specific CBCT calibration (PSC) technique that, while using DIR algorithms, is 
less sensitive to DIR uncertainties. Briefly, rather than mapping CT numbers voxel-by-
voxel with DIR, we generate a systematic but patient-specific calibration curve for each 
CBCT slice after registering CBCT to planning CT with DIR (see next section for 
details). This slice-specific calibration curve is then applied to the CBCT slice to convert 
the voxel values to their ‘planning CT equivalent’ values, without altering the patient 
geometry through regional DIR errors. Calibration curves are generated on a per-slice 
basis since scattering conditions may vary axially and thereby affect the relationship 
between CBCT and planning CT HU values. 
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To evaluate whether this new PSC method improves dosimetric accuracy, we 
performed a retrospective patient study of 15 head-and-neck clinical cases, and a 
phantom study. The dosimetric accuracy of this PSC method was compared to a re-
planning CT (serving as the gold standard) and to other CBCT calibration methods 
implemented in literature (DIR mapping and bulk density assignment).  
5.2 Materials and Methods 
5.2.1 Patient Selection 
Fifteen head-and-neck cancer patients were selected at random from our institution 
database, all of whom had completed their treatment course and were referred for a reCT 
study at some point during their treatment course. This tumour site was selected due to 
the high frequency of treatment re-planning. In order to minimize the dosimetric error 
resulting from anatomical differences, CBCTs acquired around the acquisition date of the 
reCT were reviewed and the CBCT with the most acceptable anatomical agreement with 
the reCT image set was selected. Patient and treatment related information are 
summarized in Supplemental Table 5.1. 
5.2.2 Imaging 
All CT and CBCT images were acquired as part of the patient’s routine treatment 
course. 
Original planning CT and re-planning CT images were acquired on a Philips 
Brilliance Big Bore 16-slice CT scanner (Philips Healthcare, Cleveland, OH). CT images 
were acquired with a full-fan 120 kVp beam. The scanning parameters used to acquire 
each planning and re-planning CT, can be found in Supplemental Table 5.2 and 
Supplemental Table 5.3, respectively. The CT images were reconstructed using the 
device’s default filtered back-projection algorithm, with a default slice thickness of 3 mm 
and slice size of 512 x 512. The voxel size varied between image sets as the CT operator 
would select the smallest field of view (FoV) required to cover the patient [14]. 
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CBCT images were acquired with either a Varian Truebeam or Clinac iX On-Board 
Imaging (OBI) system (Varian Medical Systems, Palo Alto, CA). CBCT scans were 
acquired with either a standard (20 mA) or low dose (10 mA) protocol using a full-fan 
100 kVp beam with a full bow-tie filter. The scanning parameters used to acquire each 
CBCT can be found in Supplemental Table 5.4. CBCT scans were reconstructed by the 
treatment unit’s OBI software (v 2.0-2.1) which uses a Feldkamp-Davis-Kress (FDK) 
reconstruction algorithm with a Ram-Lak filter [15,16]. Image slices were 384 x 384 in 
size when acquired with the Clinac iX’s system, and 512 x 512 when acquired with the 
Truebeam’s system. 
5.2.3 Creation of calibrated CBCT image sets 
Figure 5.1 outlines the general steps performed for each calibration method in this 
study. Details specific to each method will be described below. 
 
Figure 5.1: Schematic of the process used to generate a calibrated CBCT data set for 
dose calculation (left). The gold standard reCT data set is rigidly registered with the final 
calibrated CBCT data set for comparison (right). 
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5.2.4 Patient-specific calibration (PSC) Method 
The CBCT image sets were imported into a research version of the Pinnacle treatment 
planning system (v9.7, Philips Healthcare, Fitchburg, WI) along with the patient’s 
original treatment planning CT data set (containing the CT scan, treatment plan, contours, 
and points of interest). The CBCT image set was first rigidly registered with the planning 
CT image set. The planning CT image set was then deformably registered to the CBCT 
image set using a fast-symmetric Demon’s algorithm implemented in Pinnacle [17], 
resulting in a deformed planning CT image set that was registered with the CBCT image 
set. The resulting deformed planning CT and the CBCT image sets were exported to 
Matlab (v2015a, MathWorks Inc, Natick, MA) for the patient specific calibration.  
A correlation plot of the voxel values was then generated for each slice between the 
deformed planning CT and CBCT image sets (Figure 5.2a). While deformation errors 
may have affected the correlation of HU values for some voxel pairs (such as those 
highlight by the arrows in Figure 5.2a), most voxels within the slice will have been 
properly mapped by the DIR algorithm to planning CT HU values. Therefore, a strong 
relationship between the planning CT and CBCT HU values could be regressed from 
these correlation plots. With this relationship, we could scale the CBCT HU values to 
their CT-equivalent values without introducing the regional DIR errors. 
Linear calibration curve specific to each slice were obtained by least-squares fitting of 
the correlation plots, and applied to each slice of the CBCT data set. These calibration 
curves were slice-specific since scatter conditions will vary between slices of the CBCT, 
and therefore the relationship between CBCT and planning CT HU values (the model 
parameters regressed) may change. 
As a final image processing step, the calibrated CBCT images were merged with the 
original planning CT images to extend the FoV, as shown in Figure 5.2b. Before 
merging, the calibrated CBCT images were rigidly registered with the original planning 
CT (using R1 in Figure 5.1) and resampled with a linear interpolation algorithm so that 
the resolution of the CBCT matched that of the planning CT. Regions that were outside 
of the calibrated CBCT FoV or truncated during reconstruction were substituted with 
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voxel values from the original planning CT images. Slices on the superior/inferior border 
with poor correlation between the voxel values of the CBCT and the deformed planning 
CT image set (R2 < 0.8) were also replaced by the planning CT images. This usually 
occurred in the shoulder region where the CBCT FoV was insufficient to cover the whole 
patient, resulting in large deformation errors. By removing these slices, we could improve 
the anatomical matching at the junction of the CBCT and the original planning CT image 
set. 
 
Figure 5.2: Illustration of the patient-specific calibration (PSC) method. a) An HU 
correlation plot is generated for each slice, between corresponding voxels of the CBCT 
and the deformed planning CT. Despite the presence of DIR errors (highlighted by the 
arrows), a strong slice-specific linear calibration curve of the CBCT HU values to the 
planning CT HU values, can be obtained by least square fitting. b) Once the linear 
mappings are applied, the calibrated CBCT image set is then rigidly registered, resampled 
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and merged with the original planning CT image set to extend its field-of-view. Slices 
with poor correlation between the CBCT and the deformed planning CT voxel values (R2 
< 0.8; outside of dashed lines) were replaced by the original planning CT. 
5.2.5 Voxel-to-voxel DIR method 
For the DIR method, the deformable image registration proceeded exactly as it did for 
the PSC method. Provided there are no significant DIR errors, a deformed planning CT 
will match the target CBCT while containing HU values from the source planning CT. 
Therefore, the deformed planning CT data set can be directly used to calculate the dose 
received at the time of treatment. After DIR, the deformed planning CT image set has the 
same dimensions and coordinates as the CBCT image set. Therefore, the deformed 
images were also rigidly registered, resampled, and merged with the original (un-
deformed) planning CT images to extend the field-of-view. Like the PSC method, the 
same slices on the superior/inferior border with poor correlation between the voxel values 
of the CBCT and the deformed planning CT (R2 < 0.8) were replaced by the planning CT 
slices. 
5.2.6 Density-override method 
In the density-override method, the CBCT image set was first rigidly registered with 
the original planning CT image set. Regions where soft tissue had become air (e.g. 
weight loss) or where air had been replaced by soft tissue (e.g. closed air cavity) were 
manually delineated on the original planning CT image set and assigned either water or 
air equivalent densities, accordingly. With these modifications, the major anatomical 
changes can be accounted for on the planning CT dataset, while continuing to use the 
original planning CT’s HU values for dose calculations. This technique is similar to the 
algorithm implemented by van Zijtveld et al. [8] and is illustrated in Figure 5.3. 
5.2.7 Gold standard (reCT) for dose evaluation 
The CBCT image sets calibrated by each method were imported back into the 
research version of Pinnacle, along with the patient’s re-planning CT data set (including 
contours). The calibrated CBCTs inherit the coordinate system of the original planning 
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CT study, which may not be registered with the re-planning CT. Therefore, for accurate 
plan dose comparison, each of the image sets was rigidly registered with the reCT image 
set (R2 in Figure 5.1), taking care to match the original plan isocenter to the same 
anatomical location. The original treatment plan was then transferred to the reCT data set 
and dose was recomputed while maintaining the original beam layout and monitor units 
per beam. Dose was calculated on each data set using Pinnacle’s Adaptive Collapsed 
Cone Convolution algorithm with inhomogeneity corrections [18]. The dose grid was set 
to cover the entire patient CT images with 3 mm resolution in all directions. To minimize 
dosimetric errors, regions with metal streaking artifacts were delineated on each image 
set and assigned tissue equivalent densities for dose computation. Dose-volume metrics 
evaluating tumour volume coverage and organ-at-risk (OAR) exposure were tabulated 
and served as the gold standard results. 
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Figure 5.3: Illustration of the density-override method. Regions of weight loss (shown in 
a teal colourwash) were assigned a density of 0 g/cm3 for dose calculations. 
5.2.8 Contouring and dose metrics 
The contours from the reCT data set were rigidly copied onto each calibrated CBCT 
image set based on the rigid registration R2. If necessary, these contours were manually 
adjusted to match the patient anatomy as seen on the calibrated image set. Dose metrics 
evaluating tumour volume coverage and organ-at-risk (OAR) exposure were again 
tabulated and compared to the gold standard results. 
5.2.9 Gamma analysis 
Dose distributions computed on each of the calibrated image sets were compared to 
the gold standard dose distribution using the SlicerRT extension (v 0.18.0) of 3D Slicer 
(v 4.6.2) [19,20]. A 3D gamma analysis was restricted to a region inside the original 
CBCT volume and excluded voxels within 3 mm of the surface so that uncertainties in 
surface dose were omitted. The analysis was performed with a low-dose threshold of 10% 
(relative to the maximum point dose on the reCT data set), and acceptance criteria of 3% 
dose-difference and 3 mm distance-to-agreement. The gamma pass rate (percentage of 
voxels with γ < 1) was tabulated. 
5.2.10 Statistical Analysis 
A one-way repeated measures MANOVA was performed in the Statistical Package 
for the Social Sciences (SPSS v23, IBM Corp, Chicago, IL) to assess whether the image 
set used for dose calculations influenced the collective dose metric values. Univariate 
analysis followed when the MANOVA test was significant, along with post-hoc pair-wise 
Student’s t-tests when appropriate. A one-way repeated measure ANOVA was also 
performed to find statistical differences between the gamma pass rates. A 5% threshold 
for statistical significance (p = 0.05) was used. 
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5.2.11 Phantom Study 
A phantom study was also performed to assess the accuracy of the DIR and PSC 
CBCT calibration methods. A planning CT and CBCT (Clinac iX) scan were acquired of 
the CIRS 062 inner ‘head’ phantom with various material inserts (Computerized Imaging 
Reference Systems Inc, Norfolk, VA).  
To simulate weight loss with the phantom, a simulated reCT image set was created by 
reducing the planning CT’s in-plane dimensions by 5% (yielding an equivalent depth 
reduction of 4.5 mm) as shown in Figure 5.4. Similarly, the in-plane dimensions of the 
CBCT images were reduced by 5% to match the simulated reCT. 
The original planning CT, simulated reCT and CBCT image sets were imported into 
the research version of Pinnacle. The CBCT was then calibrated using both the DIR and 
the PSC CBCT calibration methods described above. Merging of the calibrated CBCT 
image sets with the original planning CT was not required as the CBCT FoV was 
sufficient to capture the entire phantom. The calibrated CBCT images were then rigidly 
registered with the reCT image set. The inserts in the phantom were manually delineated 
on each image set (as shown in Figure 5.4) and the average density and Sørensen-Dice 
similarity coefficient (compared to the reCT contour) were calculated for each insert and 
each image set. 
 
Figure 5.4: The image sets and contours produced for the phantom study. A simulated 
reCT was produced by reducing the Planning CT’s in-plane voxel size by 5%. The CBCT 
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voxel size was also adjusted by 5%. The CBCT was then calibrated using both the PSC 
and DIR methods. The inserts were delineated on each image and the average density and 
Dice Coefficient (relative to the reCT) was computed for comparison. 
5.3 Results 
Table 5.1 shows the difference of various dose metrics compared to the gold standard 
values, averaged over all patients and normalized to the prescription dose (due to 
different prescription doses between patients). Figure 5.5 and Figure 5.6 show the 
average dose-volume histogram of the 15 patients and a sample patient dose distribution, 
respectively. 
Table 5.1: Mean (standard deviation) dose metric differences 
compared to the gold standard reCT, normalized by the prescribed 
dose. Dose metrics that were significantly different to the reCT are 
indicated with the asterisk (p < 0.05) and dagger (p < 0.01). 
ROI 
Dose 
Metric 
PSC 
Method 
[%] 
DIR 
Method 
[%] 
Density-
Override 
[%] 
PTV 
D95% -1.1 (1.0) -0.9 (1.0) -0.8 (2.8) 
Mean -0.5 (0.8) -1.0 (0.8) † -1.5 (0.8) † 
D2% 0.0 (1.3) -0.8 (1.2) † -1.5 (1.3) † 
Brainstem D0.1cc 0.6 (1.0) 0.0 (1.2) -0.5 (1.5) 
Cord D0.1cc -2.0 (2.5) * -3.0 (3.3) † -3.4 (3.1) † 
Lt. Parotid Mean 0.7 (1.5) 0.3 (2.4) 0.5 (1.9) 
Rt. Parotid Mean 0.5 (2.2) 0.2 (3.1) -0.4 (2.4) 
Abbreviations: ROI, region of interest; PSC, patient-specific calibration; 
DIR, deformable image registration; DXX, minimum dose to the most 
irradiated XX volume, specified in percent or cubic centimeters (cc), as 
indicated. 
On average, dose metric differences were ≤ 1.1% for all three methods, with the PSC 
method providing marginally better agreement (-0.3 ± 1.0%, mean ± standard deviation) 
compared to the DIR (-0.7 ±1.1%) and density-override (-1.1 ± 1.2%) methods. 
Multivariate testing revealed that the image set used for dose calculation had a 
statistically significant effect on the dose metric values (p < 0.001). Further univariate 
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analysis and pair-wise t-testing found that the spinal cord maximum dose D0.1cc metric 
was systematically underestimated by all three methods (p < 0.05). Furthermore, both 
DIR and density-override methods also systematically underestimated both the PTV 
mean dose metric (p < 0.01) and D02 metric (p < 0.01), whereas the PSC method did not. 
The level of statistical significance of the Student’s t-test is indicated by asterisks (p < 
0.05) and daggers (p < 0.01) in Table 5.1. 
 
Figure 5.5: Average dose-volume histograms of fifteen plans, calculated with the gold-
standard reCT image set (dashed line), and the CBCT calibrated with the patient-specific 
calibrated method (PSC, solid line), and the DIR method (DIR, dotted line). 
The results of the 3D gamma analysis were found to be similar across all three 
techniques (p = 0.41), with the average (standard deviation) gamma pass rates of 95.0% 
(3.0%), 96.1% (3.3%), and 94.4% (4.4%) for the PSC, DIR, and density-override 
methods, respectively. 
Results from the CIRS phantom study are provided in Table 5.2. Relative to the reCT 
scan, the DIR calibrated CBCT provided very similar densities for every insert in the 
phantom. However, significant distortions were introduced into the image set as a result 
of the DIR errors, as evident by the Dice coefficient values and by visual inspection of 
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the deformed CT in Figure 5.4. Conversely, the PSC calibrated CBCT provides better 
anatomy matching than DIR, with higher Dice coefficients. Despite the presence of 
crescent artifacts, the PSC method also improves the average density accuracy for most 
materials, relative to the uncalibrated CBCT, as shown in Table 5.2. 
 
Figure 5.6: (Upper) Sample dose distributions from patient 1 for the plans calculated on 
the gold standard reCT (left), PSC calibrated CBCT (middle), and DIR calibrated CBCT 
(right) image sets. (Lower) Differences between the PSC, DIR calculated dose 
distribution and the reCT calculated dose distribution. 
On average, it took about 30 minutes to perform the full DIR and PSC calibration 
workflow, with the bulk of the time spent on dose calculations and transferring the image 
sets between systems for merging and/or calibration. Of those 30 minutes, under a minute 
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was spent running the DIR, and only a few seconds were spent calibrating and merging 
the CBCT with planning CT image set using the PSC method. The density-override 
techniques took longer (~50 minutes) because the contours delineating anatomical 
changes were generated manually. 
Table 5.2: The average density and Sørensen-Dice similarity coefficient 
(compared to the reCT) calculated for each insert in the CIRS 062 phantom, 
and for each image set. 
Material Computed Density [g/cm3] Dice Coefficient 
(True density [g/cm3]) DIR PSC CBCT PSC DIR 
Exhaled Lung (0.52) 0.53 0.52 0.47 0.98 0.96 
Adipose (0.93) 0.93 0.90 0.87 0.99 0.94 
Liver (1.05) 1.05 1.04 1.02 0.96 0.77 
Muscle (1.05) 1.05 1.04 1.00 0.97 0.73 
Inhaled Lung (0.24)  0.26 0.27 0.21 0.97 0.97 
Dense Bone (1.55) 1.55 1.58 1.57 0.86 0.80 
Breast 50/50 (0.96) 0.96 0.95 0.91 0.96 0.79 
Trabecular Bone (1.20) 1.19 1.21 1.20 0.94 0.92 
5.4 Discussion 
We have developed a patient-specific method of calibrating CBCTs for dose tracking 
and plan assessment and compared it with other methods for the head-and-neck site 
[8,11]. The results show that slightly better dosimetric agreement with the gold standard 
reCT can be obtained when using this patient-specific calibration (PSC) method, although 
each method demonstrated sufficient accuracy for plan re-assessment during 
radiotherapy.  
It is worth noting that the spinal cord dose was poorly estimated by all three methods 
(D0.1cc in Table 5.1, Figure 5.5). This was caused by a few select patients who had slight 
variations of the spinal cord positioning in regions of steep dose gradients (due to 
differences in setup between the reCT and the CBCT studies). It should also be noted that 
the gamma pass rates presented in this study are lower than other published results. For 
example, both van Zijtveld et al. [8] and Veiga et al. [11] reported similar gamma pass 
rates for the head-and-neck site when using a stricter 2%, 2 mm acceptance criteria. The 
difference in gamma pass rates could be attributed to differences in the study design. For 
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instance, Veiga et al. [11] performed their DIR method on simulated CBCTs, which were 
created by deforming the selected CBCT to match the reCT. 
The results from this study illustrate the pros and cons of the three CBCT calibration 
methods. While the density override method is easy to implement on available treatment 
planning systems, it cannot account for internal anatomical changes and it can be very 
time consuming to perform. Furthermore, the observed dosimetric accuracy of this 
technique is not as high as the other CBCT calibration techniques (Table 5.1). The DIR 
method is less sensitive to the CBCT artifacts (such as the crescent artifact visible in 
Figure 5.4) and provides sufficiently accurate tissue density and dosimetric information 
(Table 5.2, Figure 5.5). However, DIR methods may introduce distortions into the image 
through DIR errors (Figure 5.2a, Figure 5.4, Table 5.2) that can affect OAR delineations 
and their dosimetric evaluations (Table 5.1). On the other hand, the PSC method is less 
sensitive to regional DIR errors as it maintains the patient anatomy from the CBCT, 
resulting in higher Dice similarity coefficients as shown in Table 5.2. While the PSC 
method preserves the patient anatomy, it also preserves the noise and any artifacts present 
in the CBCT images (Figure 5.4). It also produces slightly less accurate densities than the 
DIR methods (Table 5.2). Neither of these limitations appeared to have considerable 
influence on the dosimetric performance of the PSC method (Table 5.1, Figure 5.5).  
While distortions introduced by DIR calibration did not have substantial influence on 
the dosimetric accuracy in the head-and-neck site studied here (Table 5.1, Figure 5.5 & 
Figure 5.6), the same may not be true in sites such as pelvis or thorax where large DIR 
distortions are commonplace at tissue-air interfaces, such as the bowel. Therefore, the 
PSC method could be potentially advantageous for these sites and will be investigated in 
the future.  
Based on Table 5.2, the PSC method improves the average density accuracy of the 
uncalibrated CBCT, for most materials inserted in the phantom. However, since there 
were relatively low amounts of high-density (bone) material in each slice, the calibration 
curves used by the PSC method were primarily fitted for lower density materials and not 
higher density materials. As a result, the density of higher density materials were not 
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corrected by the PSC method. A future version of this PSC method could potentially be 
improved by using a piece-wise continuous linear calibration curves that calibrates both 
lower and higher density materials separately. Furthermore, the limited FoV, noise, and 
artifacts present in CBCTs may pose additional challenges in sites such as the pelvis or 
thorax [21,22]. Therefore, more sophisticated methods of extending the CBCT field-of-
view (such as fusion-aligned reprojection techniques [23]), and reducing the noise and 
artifacts present in the CBCT, will be investigated in the future. The performance of this 
method will also need to be verified on other CBCT imaging systems, and in other 
treatment sites. 
Finally, in addition to calibrating CBCT for dose calculations, the calibration curves 
used in the PSC method can also be used to quickly identify regions of potential DIR 
error on a deformed CT. For example, if one highlights the voxels outside of the 95% 
confidence interval of the calibration curve, regions where the CBCT and the deformed 
CT differed substantially can be easily visualized. An example of this application is 
provided in Figure 5.7. 
5.5 Conclusion 
A patient-specific CBCT calibration method has been developed and tested for the 
head-and-neck site. Compared to a gold standard reCT dose distribution, average 
differences in dose metric values were ≤ 1.1% for all calibration methods tested, although 
the PSC method showed slightly better performance. Some advantages of the PSC 
method are that it preserves the patient anatomy, accounts for variable scattering per CT 
slice, can be uniquely applied to each patient, is computationally efficient, and may also 
be used to display errors introduced by DIR algorithms. 
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Figure 5.7: Illustration of how the linear calibration tool may be used to highlight 
regions of deformation error. The bottom frame shows the correlation plot generated for 
this slice. The linear mapping used to calibrate the slice is shown in orange, while the 
upper and lower bounds of the 95% confidence interval (CI) are shown as the dashed 
green lines. Data-points falling outside of the 95% CI are labelled in red and blue on the 
plot and are also highlighted on the top-right deformed planning CT to show regions 
where the CBCT (top-left) and deformed planning CT (top-middle) differ due to DIR 
errors. 
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Chapter 6 – Summary & Future Work 
6.1 Contributions and Findings  
This thesis presented a number of improvements to the EBRT planning process that 
enhance patient plan quality as well as the efficiency of the treatment planning and beam 
delivery procedures. This work also made progress towards long-awaited applications 
like on-line plan assessment and adaptive radiation therapy. 
In Appendix A, we presented initial work on a new treatment planning algorithm 
called unified intensity-modulated arc therapy (UIMAT) which combines the 
optimization and delivery of rotational VMAT and fixed-gantry IMRT. Specifically, 
UIMAT automatically selects which subset of gantry angles to deliver as fixed-gantry 
IMRT, and which arc ranges to deliver as rotational VMAT. It then simultaneously 
optimizes the VMAT and IMRT beams and merges their control point (CP) information 
for efficient delivery – merging the best qualities of these complementary techniques.  
A retrospective planning study of 15 lung, head-and-neck, and prostate cancer 
patients was performed, comparing the clinically approved treatment plans with the plans 
obtained with this UIMAT algorithm. The results of this planning study showed that 
UIMAT could obtain similar PTV coverage while also providing modest dose reductions 
to the surrounding OARs in the lung and prostate cases (as demonstrated by Figure A.4 & 
Figure A.5, respectively), and substantial dose reductions to OARs in head-and-neck 
cases (as demonstrated in Figure A.3). These findings motivated a larger retrospective 
planning study of 30 head-and-neck patients that was presented in Chapter 2. When 
compared to the clinically approved dual-arc VMAT or step-and-shoot IMRT plan, the 
UIMAT plans provided similar or better PTV coverage while also reducing the dose to 
nearly all OARs (Figure 2.2, Table 2.1). This OAR dose reduction was achieved without 
increasing the dose to unspecified normal tissue (i.e. by relocating the dose elsewhere). It 
was also found that UIMAT plans could be delivered more efficiently than clinical IMRT 
or VMAT plans, both in terms of average delivery time and total delivered MU.  
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This reduction in OAR dose means that UIMAT could potentially reduce the severity 
or frequency of treatment-related toxicities such as dry mouth (xerostomia), mouth sores, 
and difficulty swallowing (dysphagia) in head-and-neck cancer patients [1]. Conversely, 
the lower OAR doses could allow for dose escalation to the PTV to achieve even better 
tumour control while continuing to adhere to OAR dose limits.  
DAO algorithms are needed to create VMAT, IMRT, and UIMAT treatment plans. 
Due to the dimensionality and computational complexity of the DAO problem, and the 
current inefficient trial-and-error approach to plan optimization, treatment planning can 
sometimes take several hours or even days to complete in complex cases. Furthermore, 
when there is limited time for treatment planning (e.g. for re-planning), sub-optimal 
treatment plans may be accepted so as to not interrupt or delay treatment delivery. In 
Chapter 3 and Chapter 4, we developed and evaluated a new fast DAO algorithm called 
fast inverse direct aperture optimization (FIDAO). FIDAO extends a previously 
established FMO algorithm called fast-inverse dose optimization (or FIDO) for fast 
DAO. When compared to conventional DAO algorithm, FIDAO reduced DAO times by 
as much as 23 times in IMRT plans (Chapter 3) and by as much as 18 times in VMAT 
plans (Chapter 4). Similar plan quality was observed between the plans obtained with the 
standard DAO algorithm and FIDAO, though some minor (but clinically insignificant) 
differences could be observed between the VMAT plans. Given that UIMAT plans 
consist of just as many pencil beams as a VMAT plan, we anticipate that faster DAO will 
also be observed with a FIDAO algorithm implemented for UIMAT planning.  
FIDAO, like conventional DAO algorithms, is well suited for parallelization on 
GPUs. When compared to their runtimes on CPUs, standard DAO algorithms 
implemented on GPUs have achieved an average speed gain of about 37 times in IMRT 
and 15 times in VMAT [2,3]. If similar gains were to be obtained with FIDAO, the 
FIDAO optimization times could be in the millisecond range for IMRT plans, and in a 
few seconds range for VMAT plans. This could drastically reduce the time spent on 
treatment planning, allowing the treatment planner to focus on the plan quality instead of 
the plan deadline. It could also make applications like multicriteria optimization (MCO) 
faster and allow for new applications such as interactive treatment planning and on-line 
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adaptive radiotherapy. In order to perform on-line adaptive radiotherapy, accurate dose 
information is needed from image sets acquired on-line, which leads us to the final 
project. 
In Chapter 5, we developed a patient-specific CBCT calibration (PSC) technique for 
on-line dose calculations and plan assessment. This PSC method demonstrated high 
dosimetric accuracy when compared to the dose calculated with a gold-standard re-
planning CT data set, and when compared to other established CBCT calibration 
techniques. One of the key features of this PSC method is that it does not introduce 
geometric distortions (via deformation errors) and it accounts for slice-by-slice scattering 
conditions. Furthermore, this PSC technique can be used to flag regions of DIR error on 
deformed image sets. The calibrated CBCT could be used instead of acquiring a new 
planning CT, to assess whether treatment re-planning has become necessary due to 
anatomical changes such as weight-loss or tumour regression. This will help make sure 
that the patient receives their intended treatment and minimize the risk of a suboptimal 
clinical outcome. Moreover, this will help avoid unnecessary re-planning procedures that 
potentially waste resources and cause treatment delays. Finally, if combined with FIDAO 
and automated precise target/OAR delineation techniques, treatment re-planning could 
potentially take place on-line while the patient is immobilized and awaiting their 
treatment. 
In summary, this thesis has developed new methods of improving plan quality and 
delivery efficiency, improving planning efficiency, and assuring accurate EBRT 
treatment delivery in the presence of ongoing anatomical changes. It also brings 
applications like on-line adaptive radiotherapy within the realm of feasibility.  
6.2 Limitations and Future Work  
The future projects of FIDAO, UIMAT, and PSC are shown as a diagram in Figure 
6.1. The section number describing each future project is stated along each arrow. 
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Figure 6.1: Visual diagram of proposed future work. The section number describing each 
future project is stated along each arrow.  
6.2.1 UIMAT 
A.   Robustness 
The UIMAT algorithm presented in Section A.2.1 is only capable of producing 
hybrid VMAT-IMRT treatment plans, as well as single-arc VMAT treatment plans (when 
2 apertures are sequenced for every beam). However, a truly unified approach to VMAT 
and IMRT planning should be able to produce VMAT-only, IMRT-only, or hybrid 
treatment plans, should they be the optimal treatment method for the patient. 
Development is currently underway on a new, more robust UIMAT algorithm. Briefly, 
this new algorithm is inspired by recent work on beam orientation optimization using 
sparse optimization techniques [4,5]. Specifically, this UIMAT algorithm begins by 
performing FMO and aperture sequencing at 4° gantry angle increments. The goal of this 
step is to create a large collection of CPs at many gantry angles, as illustrated in Figure 
6.2a. Next an accelerated proximal gradient method optimizes the CP shapes and 
weights, while simultaneously minimizing a regularizer acting on the CP weights [6,7]. 
As this DAO progresses, the regularizer forces the DAO algorithm to eliminate CPs from 
the treatment plan, while simultaneously trying to improve the plan quality. The idea is 
that gantry angles that can use higher intensity-modulation to improve plan quality, will 
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retain their apertures, while all other gantry angles will have their CPs removed. This step 
is illustrated in Figure 6.2b. In cases where IMRT-only is the optimal treatment plan, we 
expect this DAO to only keep CPs at select gantry angles. Conversely, in cases where 
VMAT-only is the optimal treatment plan, we expect this DAO to eliminate CPs 
uniformly from all gantry angles.  
 
Figure 6.2: Illustration of the new UIMAT algorithm. A) FMO and aperture sequencing 
(each CP illustrated as a square) is performed at 4° increments. B) DAO with a CP 
weight regularizer is performed. As this DAO progresses, the regularizer eliminates CPs 
from the treatment plan. C) The results of this DAO are parsed and VMAT (green) or 
IMRT (purple) beams are sequenced using the CPs from B). A final DAO is then 
performed.  
When this DAO terminates, the treatment plan may still have too many apertures for 
treatment delivery to be practical. Therefore, the UIMAT algorithm next evaluates each 
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individual CP and gantry angle’s delivery efficiency and their contribution to the 
treatment plan. It then sequences VMAT arcs and/or IMRT beams from these CPs. This 
step is visualized in Figure 6.2c. The newly sequenced VMAT and IMRT beams then 
undergo a final DAO, without the CP weight regularizer described above, and where the 
VMAT- or IMRT-related delivery constraints are enforced.  
This new UIMAT algorithm is currently being implemented in MATLAB v9.4 
(Mathworks Inc, Natick, MA) using the open-source treatment planning toolkit matRad 
(v2.2 – dev_VMAT build) [8,9]. Preliminary results of this UIMAT algorithm on a 
prostate, head-and-neck, and a right-sided whole breast radiotherapy case are provided in 
Figure 6.3. The plans obtained with this new UIMAT algorithm were compared to 
conventional dual-arc VMAT plans in the prostate and head-and-neck cases, and a 
tangent-field IMRT plan in the whole breast radiation therapy case.  
In the whole breast radiotherapy case, the UIMAT algorithm produced a hybrid 
treatment plan using a single VMAT arc and two tangent IMRT beams (similar to the 
plan visualized in Figure 6.2c). Slightly lower OAR doses were obtained with the 
UIMAT algorithm, as visible from the DVHs. In the prostate case, the UIMAT algorithm 
also produced a dual 360° arc VMAT plan. However, the plan quality of the UIMAT plan 
was noticeably better, as can be seen by the DVH curves. Finally, in the head-and-neck 
case, the UIMAT algorithm produced a hybrid plan consisting of a single 360° VMAT 
arc and 5 IMRT beams. Superior OAR sparing was observed with the UIMAT plan, 
supporting the observations of the previous UIMAT studies. 
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Figure 6.3: Preliminary DVH [left] and sample dose distributions [right] from the new 
UIMAT algorithm.  
Further development is still needed for this algorithm. If the regularizer is not 
adequately enforced during the first DAO, the optimization will fail to eliminate enough 
CPs from the plan, and the subsequent beam sequencing step will create an impractical 
number of beams. Similarly, we have not yet settled on a single metric for determining a 
CP’s or gantry angle’s ‘contribution’ to the treatment plan. Currently, the algorithm looks 
at the median PTV voxel dose that is delivered from each gantry angle (as shown in 
Figure 6.2c) as a measure of each gantry angle’s contribution to the plan. Better metrics 
(such as the gantry angle’s relative contribution to the objective function value) may be 
suitable. 
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B.   Constraints 
As discussed in Section 2.4, the DAO algorithm currently used by UIMAT cannot 
enforce a minimum MU or MLC segment area during optimization. This could make 
UIMAT susceptible to dosimetric errors introduced by small field and small MU 
dosimetry and could explain why lower gamma passing rate were observed with UIMAT 
in the head-and-neck study [10-12]. Therefore, a future UIMAT algorithm should use a 
custom DAO algorithm – such as FIDAO – where these delivery constraints can be 
enforced.  
C.   Additional Applications for UIMAT 
Additional future work includes integrating FIDAO into this UIMAT algorithm. This 
fast UIMAT algorithm could then be implemented on GPUs, and potentially used for 
online adaptive radiotherapy using the PSC CBCT technique or other on-line 3D image 
sets. Finally, one can also investigate a UIMAT algorithm that uses non-coplanar arcs or 
that can select IMRT beams outside of the VMAT arc range. Moreover, one can 
investigate a UIMAT algorithm that also incorporates couch rotations during beam 
delivery (a 4𝜋 UIMAT algorithm) [13]. 
6.2.2 FIDAO 
A.   Memory 
FIDAO’s greatest limitation at the moment is the computer storage requirements for 
the Hessian matrix. As discussed in Section 4.4, we were unable to optimize a head-and-
neck VMAT plan as FIDAO’s Hessian matrix required much more memory (68 GB) than 
was available on the tested computer system (64 GB). This memory issue will continue to 
grow as we evaluate FIDAO on larger treatment plans, including non-coplanar VMAT 
and 4𝜋 plans (where the couch is also allowed to rotate during beam delivery [13]). This 
is because the size of the Hessian matrix grows quadratically with the number of pencil 
beams in the plan. This storage issue can potentially be mitigated by using a low-rank 
approximation of the Hessian matrix, via singular value decomposition (SVD) [14]. 
Specifically, SVD can help identify a set of vectors whose memory requirements are 
much smaller, and whose product closely approximates the full Hessian matrix. 
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Alternatively, FIDAO could perform successive optimizations on a random sampling of 
the plan parameters, allowing for smaller Hessian matrices during each individual 
optimization cycle. With this memory issue resolved, future studies will continue to 
develop and evaluate FIDAO’s performance on larger co-planar and non-coplanar 
VMAT plans, UIMAT plans, and potentially 4𝜋 plans.  
B.   Dosimetric Accuracy 
Another source for improvement in FIDAO is in the selection of its dose calculation 
algorithm. SVD dose calculation algorithms are commonly used in plan optimization due 
to their superior speed [15]. However, SVD’s superior speed comes at the cost of reduced 
dosimetric accuracy when compared to slower dose calculation algorithms such as 
collapsed cone convolution (CCC) and Monte Carlo simulation [16,17]. The time gained 
with FIDAO’s fast optimization could be re-allocated to executing slower, but more 
accurate, dose computation algorithm for calculating 𝜶 and 𝛽. Alternatively, some 
commercial DAO algorithms first perform an accurate dose calculation (e.g. CCC) of the 
plan prior to DAO. They then use the more approximate SVD dose engine to ‘perturb’ 
the dose distribution based on the difference between the current plan parameters and 
plan parameters at the time of the accurate dose calculation [15,17]. This allows for fast 
DAO with only a slight loss of dosimetric accuracy. A future study could evaluate 
whether this ‘perturbation’ approach is applicable to FIDAO. 
C.   Commercial Software Platforms 
The interior-point DAO algorithm that has been used as a benchmark for FIDAO thus 
far, may not be representative of the optimization times or the plan quality we would 
obtain with a commercial treatment planning system. Therefore, another step in FIDAO’s 
development is to implement FIDAO within a commercial treatment planning system and 
to compare its performance to well established DAO algorithms like the simulated 
annealing DAO algorithm in Eclipse (Varian Medical Systems, Inc., Palo Alto CA) [18] 
or direct machine parameter optimization (DMPO) [15] in Pinnacle3 (Philips Healthcare, 
Fitchburg, USA) and RayStation (RaySearch Laboratories AB, Stockholm SE). 
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D.   Future Applications of FIDAO 
With FIDAO implemented in a commercial treatment planning system, one intriguing 
study would be to compare FIDAO and the commercial DAO algorithm on stereotactic 
radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) cases. As discussed in 
Section 3.4, it is recommended that the dose voxel size in SRS and SBRT plans be 2mm 
or less [19]. These high-resolution dose grids will result in the standard DAO algorithm 
running substantially slower. However, only the calculation times for 𝜶 and 𝛽 will be 
affected by the dose grid resolution in FIDAO. Therefore, a large difference in the 
optimization time could be observed in SRS and SBRT cases. 
Another future study will implement FIDAO on high-performance GPUs and 
investigate its performance to a standard DAO method on a GPU. If ultra-fast 
optimization times are achieved, this GPU-based FIDAO algorithm could be used for on-
line adaptive radiotherapy using the on-line PSC CBCTs or MRI data-sets. It could also 
be used to speed up multi-criteria optimization (MCO), or for interactive treatment 
planning like dose-painting. Specifically, in dose painting, the treatment planner could 
‘paint’ a desired dose distribution on the planning CT, or they could drag a point on the 
DVH interactively instead of modifying IMRT objectives. The DAO algorithm would 
then immediately update the treatment plan and dose distribution, ideally in real-time.  
Finally, with the real-time imaging capabilities of MR-linacs, it may also be possible 
to do intrafraction treatment adaptation with FIDAO. That is, during treatment delivery, 
the undelivered beams could be re-optimized to compensate for any anatomical changes 
that have occurred moments earlier during treatment delivery (e.g. changes in patient 
positioning, their respiratory cycle, or gas passing through the rectum) [20]. This 
intrafraction adaptive radiotherapy could potentially eliminate the need for certain 
immobilization equipment, such as the very invasive head frames used for brain SRS (i.e. 
frame-less SRS) [19]. 
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6.2.3 PSC 
A.   Limited Field-of-View 
CBCTs have a limited field-of-view relative to planning CTs and do not provide 
sufficient anatomical information of the patient, at the time of treatment, for on-line 
adaptive radiotherapy. Therefore, methods of extending CBCT’s limited field-of-view, 
rather than relying on the fusion with the planning CT scans, will be beneficial [21]. 
B.   Artifacts 
In addition to preserving the patient’s anatomical information, the PSC calibration 
method also preserves any noise and imaging artifacts present in the CBCT. Iterative 
reconstruction technique could be used instead of filtered back-projection to improve the 
CBCT image quality, reduce artifacts, and potentially improve the dosimetric accuracy of 
PSC [22]. Similarly, scatter-correction techniques – such as those using convolution 
neural networks – could also enhance the PSC method by improving the CBCT image 
quality, dosimetric accuracy, or calibration time [23-25].  
C.   Additional work 
With these improvements, a future study could re-evaluate the dosimetric accuracy of 
the PSC method in the head-and-neck site, relative to the gold-standard re-planning CT 
and other CBCT calibration techniques. A future study could also assess the dosimetric 
accuracy in other anatomical sites such as the pelvis, thorax, and abdomen sites. Finally, 
a study could evaluate the feasibility of the PSC method for rapid on-line treatment 
adaptation and re-optimization using FIDAO and/or UIMAT. 
6.2.4 Summary 
Medical linear accelerators have evolved rapidly over the last few decades, with the 
integration of MLC systems, the addition of dynamic delivery capabilities (e.g. fixed-
gantry IMRT and rotational-VMAT) and on-board 3D imaging systems (i.e. CT, CBCT, 
MRI, and soon PET). At the time of writing this thesis, EBRT has yet to utilize these 
linac features to their fullest potential. Therefore, this research set out to introduce a 
number of improvements to the EBRT process that enhance the use of modern-day linear 
accelerators. Specifically, we hypothesized that a fast plan optimization algorithm that 
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unifies rotational VMAT and fixed-gantry IMRT will improve radiotherapy plan quality, 
planning and delivery efficiency, and will provide a stepping-stone towards future on-line 
(interactive) plan adaptation.  
This was demonstrated with a new UIMAT planning algorithm that combines the 
optimization and delivery of rotational VMAT and fixed-gantry IMRT. This UIMAT 
algorithm demonstrated lower normal tissue doses and improved delivery efficiency 
compared to conventional IMRT and VMAT treatment plans. Next, a fast-direct aperture 
optimization algorithm was established and applied to both IMRT and VMAT planning. 
This algorithm exhibited superior plan optimization speed on both IMRT and VMAT 
plans, and potential for implementation in UIMAT. Finally, a patient-specific CBCT 
calibration technique was developed and tested on head-and-neck cases. This calibration 
technique demonstrated high dosimetric accuracy and potential for on-line plan 
adaptation. Collectively, these projects improve radiotherapy plan quality, planning and 
delivery efficiency, as well as establish the foundation for an on-line plan adaptation 
procedure. Additional applications of these projects include dose-painting, multi-criteria 
optimization, as well as inter- and intra-fraction on-line adaptive radiotherapy in response 
to anatomical changes. Ultimately, these developments could enhance the quality of life 
and the survival rates of cancer patients, using existing technology that is widely 
available today.  
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Appendix A – Feasibility of a unified approach to intensity-
modulated radiation therapy and volumetric modulated arc 
therapy optimization and delivery 
This chapter was adapted from the published article entitled “Feasibility of a unified 
approach to intensity-modulated radiation therapy and volumetric modulated arc therapy 
optimization and delivery” by Douglas A. Hoover, Michael MacFarlane, Eugene Wong, 
Jerry J. Battista, and Jeff Z. Chen, Medical Physics, 42 (2): 726-34 (2015). Permission to 
reproduce this article was granted by John Wiley and Sons, and is provided in Appendix 
B.5. 
A.1  Introduction 
Volumetric-modulated arc therapy (VMAT) has been rapidly adopted by the 
radiotherapy community due primarily to its delivery speed and monitor unit (MU) 
efficiency, as well as the quality of conformal dose distributions achievable [1-3]. On the 
other hand, intensity-modulated radiotherapy (IMRT) with its static beam directions 
might be advantageous in cases where steep dose gradients or highly intensity-modulated 
beam intensities are required in preferred directions [4]. While the community tends to 
regard these two delivery techniques as disparate entities, they are in reality special cases 
of one another. More specifically, there exists a unifying delivery technique which 
bridges the gap between static-gantry IMRT and rotating-gantry VMAT. Such a unified 
delivery, if properly implemented into an inverse-planning algorithm, would in general 
lead to improved dose delivery capabilities as the algorithm could naturally optimize the 
beam within a given arc range to be more IMRT-like, if greater beam intensity 
modulation is required, or more VMAT-like, if increased conformity is required with less 
beam intensity modulation. This combined approach would take advantage of the two 
modes of beam delivery for targeting and normal tissue sparing. 
IMRT or VMAT delivery is typically represented by control points—or multi-leaf 
collimator (MLC) segments—which are essentially snapshots of the positions of the 
relevant linear accelerator components taken at regular intervals. For example, a VMAT 
beam can be stored as a series of control points specifying the machine parameters at 
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regular 2 or 4 degree intervals of the rotating gantry. Due to the large number of degrees-
of-freedom required to specify a VMAT beam, all VMAT radiotherapy plans are created 
using specialized optimization software, such as SmartArc in Pinnacle (Philips 
Healthcare, Fitchburg, USA) or RapidArc in Eclipse (Varian Medical Systems, Palo Alto, 
USA). Both commercial treatment planning systems optimize beam parameters 
specifically for equally-spaced gantry positions. In addition to commercially-available 
software, a number of research prototypes have been developed to test novel optimization 
algorithms including the concept of unequally-spaced control points [5,6]. In principle, 
VMAT and IMRT with and without gantry rotation, respectively, can be unified during 
optimization and delivery. Instead of forcing the beam angle increments for arc therapy, 
the fixed-gantry IMRT parameters can add additional degrees of freedom available to the 
optimization engine. 
The idea to combine VMAT and IMRT deliveries is not new, and various ideas have 
been implemented to improve the current clinically-available VMAT implementations. 
One suggestion, termed dense angularly sampled and sparse intensity modulated 
radiation therapy (DASSIM-RT), proposes a method to search more thoroughly through 
the parameter space of machine-deliverable radiotherapy plans [7]. One major hurdle 
towards the clinical implementation of this method is that the scale of the optimization 
problem is now immense and so much greater computer memory is required [8]. Another 
proposal, Arc Modulated Radiation Therapy (AMRT), builds on previous work in 
intensity modulated arc therapy (IMAT) [1]. AMRT is a sequencing algorithm that 
allows multiple IMAT arcs to be delivered by a single arc. In one study, AMRT plans 
required on the order of 200-400 segments and achieved similar plan quality to IMRT 
[9]. 
Yet another proposal, termed FusionArc, has recently been published [10]. This paper 
describes an in-house optimization software that begins with a full VMAT optimization 
followed by an iterative conversion, at select gantry angles, from uniform to intensity-
modulated fluence. Gantry angles are selected for conversion based on a gradient 
function which attempts to predict conversions that will lead to the greatest reduction in 
the cost function. Brainlab (Feldkirchen, Germany) has introduced a commercial platform 
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which first optimizes a dynamic conformal arc delivery phase followed by an 
optimization of an IMRT phase. However, the arc phase is restricted by constant angular 
speed and dose rate. Furthermore, the arc ranges, the number of uniformly spaced IMRT 
fields, and the relative weighting of arc and fixed-gantry IMRT phases must all be chosen 
from the outset of optimization [11]. The quality of HybridArc plans has been shown to 
depend on a proper selection of these initial parameters [12]. 
None of the solutions described above has yet embodied the fully-integrated and 
unified approach that we advocate here. The purpose of this work is to create, as a proof-
of-principle, a unified intensity-modulated arc therapy (UIMAT) that combines IMRT 
and VMAT optimization and delivery in order to produce efficient and superior radiation 
treatment plans in a single optimization with concurrent VMAT and IMRT features 
A.2  Material and Methods 
A.2.1 Inverse Planning for UIMAT 
Custom software was developed and integrated into a commercial treatment planning 
system, Pinnacle3 v9.6 Radiation Therapy Planning Systems (Philips Healthcare, 
Fitchburg, USA) for the purpose of testing whether UIMAT is superior to either standard 
VMAT or IMRT. This software extends Pinnacle’s built-in VMAT optimization in a few 
key ways. Firstly, it removes the restriction that control points within a dynamic arc must 
have a uniform angular spacing. Importantly, this allows arc segments that would benefit 
from increased intensity modulation to have more densely packed control points. 
Furthermore, angles requiring this increased modulation are selected automatically during 
the initial optimization stage, and this can be thought of as a form of beam-angle 
optimization.  
Our optimization algorithm begins by creating static beams uniformly distributed 
between start and stop arc angles with an initially coarse control point spacing of twenty-
four degrees, as suggested by Bzdusek [13]. Using Pinnacle’s inverse-planning system, 
an optimized fluence pattern is determined for these initial beams. In general, these 
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fluence patterns will not be machine-deliverable and so a sequencing step is then 
performed which converts the fluence patterns into executable MLC control points. 
Custom software is then initiated which reads in this beam information from Pinnacle 
software. As a preparatory step, the code first re-orders the control points within each 
individual beam, anticipating that these control points may later be distributed—or 
fanned out—into other gantry angles to form an arc segment. The goals of this re-
ordering step are: (1) to preferentially place higher-weighted control points towards the 
middle of the order, thereby minimizing the dosimetric differences between the original 
and the fanned-out beams (see Figure A.1); and (2) to minimize MLC motion between 
control points, thereby improving delivery efficiency. Note that for any given solution, 
there will always be a “symmetric” solution having the reverse control point order. 
However, this symmetry is broken once neighboring beams are considered, and so for 
each beam the software determines whether the original or reverse order will result in the 
least MLC motion between the first and last control points of neighboring beams. 
 
Figure A.1: Schematic showing how the control points from the initial fixed-beam 
optimization are distributed into VMAT and IMRT phases. Control points within each 
beam have been re-ordered to minimize MLC motion. As well, higher-weighted control 
points are preferentially placed in the middle of the ordering to minimize the difference 
between the initial and final gantry angles. Interpolated MLC segments are inserted as 
necessary to maintain a maximum control point spacing of four degrees. 
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The algorithm next determines which of these beams should remain as IMRT fields 
and which should be converted into arc segments. In our current implementation, we 
chose to convert those beams having fewer than four control points (low modulation) into 
a “VMAT phase”, while those beams with four or more control points were retained for 
the “IMRT phase” (high modulation). In this study, the threshold to distinguish between 
low and high modulation corresponds approximately to the average number of control 
points per beam which in turn depends on the MLC sequencing parameters chosen. Based 
on the parameters we chose, on average, we had 4 control points per beam which we 
found to work well practically for the anatomical sites tested. 
Finally, the algorithm modifies the gantry angle associated with each beam segment 
as shown in Figure A.1. Beams that have low modulation become VMAT phases where 
their control points are distributed uniformly within the 24 degree spacing. In order to 
maintain approximately four-degree spacing between control points, linear interpolation 
of MLC leaves is used to create new interlaced control points as needed. Beams that have 
high modulation become IMRT phases. In this case, the first and last control points have 
their gantry angles shifted 8 degrees on either side of the initial gantry angle, as shown in 
Figure A.1. These two boundary control points, together with linearly interpolated control 
points, are used to facilitate a smooth transition from VMAT to IMRT phases. Next, the 
central control points of high-modulation beams are fanned out around the initial gantry 
angle in 0.2° increments. Interpolated control points are then added between these central 
control points to arrive at a 0.1° spacing for the IMRT phase. The small gantry rotation 
(almost stalled) for the IMRT phase approximates a static-gantry IMRT field and is a 
work-around for the fact that Pinnacle v9.6 does not allow simultaneous DMPO 
optimization of static-gantry IMRT and VMAT beams. At this stage, the beam control 
points are re-imported into Pinnacle for a final optimization using the DMPO algorithm. 
As an example, the start and stop angles for these partial arcs, as well as the angular 
location of the IMRT phases, are shown in Figure A.2. 
Certain “soft” deliverability constraints are relaxed for the IMRT-like portions of 
delivery. Specifically, for the IMRT phases the maximum MU per degree is increased 
from 20 to 200, and the gantry acceleration limit is removed. Within Pinnacle software, 
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this is accomplished by defining a separate machine having these special properties and 
associating the IMRT phases with this virtual machine. This is required in order to have a 
reasonable number of MUs delivered during the more highly-modulated IMRT phase, 
which may have up to ten control points within one degree angular spacing. It is 
important to note that such a beam is still machine-deliverable as it does not violate any 
physical constraints of the accelerator.  
 
Figure A.2: A typical UIMAT plan. The angular ranges for three VMAT phases are 
represented by arc segments while the fixed gantry angles corresponding to four IMRT 
phases are represented by straight line pairs. 
From this point on, optimization proceeds using the standard functionality within 
Pinnacle. Machine parameters for both IMRT phases and VMAT phases are optimized at 
the same time as multiple dynamic arcs in Pinnacle software. DMPO optimization is 
continued until a clinically-acceptable plan is obtained using standard dose-volume 
histogram (DVH) constraints. During optimization, the VMAT and IMRT phases are 
treated as separate beams, and after optimization is complete, our custom software is used 
to combine the VMAT and IMRT phases into a single UIMAT arc with variable gantry 
speed for final dose calculation and delivery. The final dose is calculated by collapsed-
cone convolution algorithm in the Pinnacle treatment planning system. 
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A.2.2 Treatment Plan Evaluation  
In order to test our optimization algorithm, CT scans from 15 previously treated 
patients were selected for planning comparison purposes. Five cases each were randomly 
selected from head-and-neck, lung, and prostate sites to represent a variety of anatomy, 
complexity levels, and delivery modalities. All clinical treatment plans were optimized 
using the Pinnacle treatment planning system. A summary of the selected patient plans is 
provided in Table A.1 with the estimated delivery times obtained from Pinnacle. Since 
Pinnacle does not provide an estimate for step-and-shoot beams, the delivery time for 
IMRT plans was measured on a Varian linear accelerator. The IMRT delivery time is 
defined here as the total time from when the first beam turns on until the last beam turns 
off and so includes the “mode-up” time as well as the time required to move to the 
various gantry positions. Beams were ordered for the most efficient delivery. A paired, 
two-tailed t-test was used to assess for statistically significant differences in delivery 
times. 
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Table A.1: Comparison of clinically-delivered treatments with UIMAT treatment plans. Note 
that some patients had multiple target volumes with distinct dose levels (e.g. Patient 3 had 
both a 70 Gy and a 56 Gy target volume). Approximate treatment delivery times are given. 
 
Patient Site 
Dose 
Pres. 
Beam Arrangement Delivery Time [s] 
   [Gy] Clinical UIMAT Clinical UIMAT 
H
ea
d
 &
 N
ec
k 
1 Lt. Parotid 64/60/54 2x 210° (108 CP) 1x 210° (65 CP) 91 64 
2 Rt. Parotid 60 2x 225° (116 CP) 1x 225° (55 CP) 95 68 
3 Larynx/Neck 70/56 2x 360° (182 CP) 1x 360° (87 CP) 151 171 
4 Parotids/Neck 70/56 2x 360° (182 CP) 1x 360° (89 CP) 151 201 
5 Larynx 61/50 5 Fields (23 CP) 1x 260° (77 CP) 182 109 
Lu
n
g 
6 Lt. Lung 60 5 Fields (17 CP)  1x 230° (73 CP) 167 64 
7 Lt. Lung 60 2x 225° (116 CP) 1x 225° (63 CP) 94 67 
8 Rt. Lung 60 6 Fields (21 CP) 1x 192° (61 CP) 237 126 
9 Rt. Lung 60 2x 210° (108 CP) 1x 210° (63 CP) 90 98 
10 
Lt. Lung & 
Mediastinum 
50 2x 360° (181 CP) 1x 360° (93 CP) 149 100 
P
ro
st
at
e 
11 Prostate 76 1x 360° (91 CP) 1x 360° (99 CP) 79 129 
12 Prostate Bed 66 2x 360° (182 CP) 1x 360° (97 CP) 151 200 
13 Prostate 45 2x 360° (182 CP) 
1x 360° (103 
CP) 
150 236 
14 Prostate Bed 76/50.4 2x 360° (182 CP) 1x 360° (93 CP) 154 241 
15 Prostate 66 2x 360° (182 CP) 1x 360° (96 CP) 151 139 
Abbreviations: Pres, prescription; Rt, right; Lt, left; UIMAT, unified intensity modulated arc therapy; 
CP, control points 
The UIMAT plans were optimized based on our local treatment planning guidelines 
used to generate the clinical plans. Without exception, critical structure tolerances such as 
the spinal cord and brainstem were respected. For lung cases, the volume of both lungs 
receiving at least 20 Gy (V20) was kept below 35% and a mean lung dose of < 20 Gy 
was also maintained. The dose coverage goal for the planning target volume (PTV) was 
to cover at least 95% of the PTV by at least 95% of the prescription dose. For non-critical 
structures, DVH criteria from RTOG 0126 and QUANTEC [14] were used to guide the 
planning process. All UIMAT plans were restricted to a single arc. Dynamic jaw 
movements were allowed in order to facilitate the goal of a single-arc delivery. Dynamic 
jaws were required when treating large volumes with a single arc due to the finite speed 
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and length of the MLC leaves. It is noted that the clinical plans did not require dynamic 
jaws, as all complicated VMAT plans standardly use two arcs. 
To compare a UIMAT plan with the corresponding clinical VMAT or IMRT plan for 
each patient, various dose metrics were selected and subjected to a paired, one-tailed t-
test to assess statistically significant differences. Mean doses for PTVs and conformity 
index (CI) were analyzed for all cases. The conformity index has been previously defined 
as [15]: 
𝐶𝐼 = (𝐶𝑜𝑣𝑒𝑟 𝑓𝑎𝑐𝑡𝑜𝑟) × (𝑆𝑝𝑖𝑙𝑙 𝐹𝑎𝑐𝑡𝑜𝑟) 
= (
𝑉100(𝑃𝑇𝑉)
𝑉𝑃𝑇𝑉
) × (
𝑉100(𝑃𝑇𝑉)
𝑉100(𝐵𝑜𝑑𝑦)
) (1) 
where 𝑉100(𝑃𝑇𝑉) and 𝑉100(𝑏𝑜𝑑𝑦) are the volumes of the 100% prescription dose 
within the PTV and body, respectively, and VPTV is the volume of the PTV. For head-and-
neck cases, mean doses for parotids, oral cavity, larynx, and maximum doses for cord, 
brainstem, and larynx were analyzed. For lung cases, mean doses for lung, esophagus, 
and heart were recorded as well as the lung V20 and the maximum cord dose. For 
prostate cases, mean doses for rectum, bladder, bowel, and femurs were analyzed. The 
threshold for statistical significance was set at a p-value of 0.05. 
The deliverability of UIMAT plans was tested on a Varian TrueBeam linear 
accelerator (Varian Medical Systems, Palo Alto, USA). The accuracy of dose calculations 
and delivery was verified by measurements with the ArcCheck Phantom (Sun Nuclear, 
USA). 
A.3  Results 
A.3.1 Feasibility 
The UIMAT plans were generated for 15 cases, as summarized in Table A.1. UIMAT 
plans employed only one arc, while most of the clinical VMAT plans required two arcs. 
The number of MLC control points in the UIMAT plans were less than the VMAT plans 
for all but one case (see Table A.1), but more than in the IMRT plans. The estimated 
delivery times for UIMAT plans were not significantly different from the VMAT plans 
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(p=0.22) but they were significantly faster than multiple-field IMRT plans (p=0.01). No 
significant difference in delivery time was observed between the UIMAT plans and the 
VMAT and IMRT plans taken together (p=0.75).  
An ArcCheck measurement in each treatment site was made to verify the accuracy of 
UIMAT dose calculation and feasibility of delivery. All tested plans had a gamma 
passing rate [16] of greater than 95% using our standard clinical parameters of 3% dose 
difference and 3 mm distance-to-agreement. 
A.3.1 Plan Comparison 
A.3.1.a - Head and Neck 
The dose metrics used in the evaluation of the head-and-neck cases are presented in Table 
A.2. Plans which have multiple PTVs, as listed in Table A.1, have one conformity index 
(CI) reported for each PTV. For patient 5, the low doses associated with most OARs are 
related to the small treatment volume which is restricted to the laryngeal region of the 
neck. For the five head-and-neck cases, the overall average of the mean OAR doses in 
Table A.2 was reduced by 8.4% (p<0.001) using UIMAT plans compared to the clinical 
VMAT or IMRT plans. As a specific example, comparison of the dose distributions and 
DVHs between a UIMAT and a VMAT plan for a head-and-neck case is shown in Figure 
A.3. It shows that the UIMAT plan produced lower OAR doses with similar PTV 
coverage compared with the clinical VMAT plan. 
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Table A.2: Dose volume parameters of interest for five head-and-neck cases. The mean PTV dose is represented as a 
percentage of the prescription dose. Certain OARs were not contoured for some patients, either because the OAR was well 
outside the treatment volume or because it was completely enclosed within the PTV. The conformity indices correspond to 
the target volumes listed in the third-last column, and similarly for the mean PTV doses. Since not all patients had the same 
number of PTV dose levels, P values and average doses for PTVs were calculated for the highest dose level only. 
No. Plan 
Oral 
Cavity 
?̅? [Gy] 
Left 
Parotid 
?̅? [Gy] 
Right 
Parotid 
?̅? [Gy] 
Larynx 
?̅?  
[Gy] 
Larynx 
𝐷𝑚𝑎𝑥 
[Gy] 
Brainstem 
𝐷𝑚𝑎𝑥 [Gy] 
Cord 
𝐷𝑚𝑎𝑥 
[Gy] 
PTV(s) 
Pres. 
[Gy] 
Conformity 
Index 
PTV(s) 
?̅? [%] 
1 
Clinical 28.4 6.9 -- 31.8 62.3 15.0 22.4 64/60/5
4 
0.21/0.77/0.63 99.8/101.5/103.5 
UIMAT 22.6 2.4 -- 26.8 61.2 9.5 24.5 0.14/0.79/0.63 101.9/102.6/103.7 
2 
Clinical 30.0 5.9 61.0 27.8 62.6 13.8 36.7 
60 
0.85 101.3 
UIMAT 27.7 3.3 60.8 26.3 63.1 10.9 37.4 0.80 101.5 
3 
Clinical 33.2 25.9 25.6 -- -- 32.2 36.9 
70/56 
0.83/0.79 100.0/101.8 
UIMAT 29.9 23.1 22.4 -- -- 33.3 44.3 0.70/0.70 101.7/102.6 
4 
Clinical 39.3 25.3 25.4 48.6 65.1 44.3 44.8 
70/56 
0.78/0.72 100.6/104.5 
UIMAT 37.3 22.5 22.9 47.7 58.0 46.0 23.4 0.82/0.71 100.7/103.6 
5 
Clinical 0.2 0.2 0.2 55.5 64.2 0.2 0.2 
61/50 
0.89/0.73 101.0/109.6 
UIMAT 0.2 0.2 0.2 55.5 64.0 39.8 23.6 0.93/0.73 101.6/108.6 
Avg. 
Clinical 26.2 12.8 28.0 40.9 63.6 21.1 31.8  0.72 102.4 
UIMAT 23.6 10.3 26.6 39.0 61.6 20.0 34.9  0.7 102.9 
P value  0.02 0.01 0.09 0.09 0.17 0.23 0.04  0.11 0.08 
Abbreviations: PTV, planning target volume; OAR, organ at risk; UIMAT, unified intensity modulated arc therapy; ?̅?, mean dose; 
Dmax, maximum dose; Avg, average 
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Figure A.3: Comparison of dose distributions between a clinical VMAT plan (top left) 
and a UIMAT plan (top right) and corresponding dose volume histograms (bottom) for a 
head-and-neck case (patient 1). 
A.3.1.b - Lung 
The dose metrics used in the evaluation of the lung cases are presented in Table A.3.  
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UIMAT yielded significant reductions for the mean doses for heart and esophagus, and 
maximum cord dose compared with clinical IMRT or VMAT plans, while the difference 
in V20, mean lung dose, conformity index, and mean PTV dose is not statistically 
significant. The overall average of the mean OAR doses in Table A.3 was reduced by 
5.7% (p<0.001) using UIMAT plans compared with clinical IMRT or VMAT plans 
Table A.3: Dose volume parameters of interest for five lung cases. The mean 
PTV dose is represented as a percentage of the prescription dose. 
No. Plan 
Lung 
V20 
[%] 
Lung  
?̅? [Gy] 
Esophag
us ?̅? [Gy] 
Heart  
?̅? [Gy] 
Cord 
𝑫𝒎𝒂𝒙 
[Gy] 
CI 
PTV 
?̅? [%] 
6 
Clinical 15.1 9.8 17.1 1.2 29.5 0.72 101.7 
UIMAT 14.9 9.2 15.7 1.0 27.9 0.87 102.0 
7 
Clinical 21.9 14.0 22.4 10.1 35.6 0.87 101.3 
UIMAT 22.1 14.0 21.2 8.3 34.8 0.91 101.3 
8 
Clinical 30.5 17.2 25.0 11.0 47.8 0.79 103.5 
UIMAT 27.8 15.5 22.7 10.6 47.4 0.91 101.5 
9 
Clinical 20.7 11.8 24.4 4.8 43.3 0.78 101.3 
UIMAT 20.7 11.5 23.3 3.8 41.2 0.81 101.3 
10 
Clinical 35.6 18.6 36.2 30.6 43.4 0.92 100.2 
UIMAT 34.4 18.1 35.5 29.4 42.5 0.88 101.0 
Avg. 
Clinical 24.8 14.3 25.0 11.5 39.9 0.82 101.6 
UIMAT 24.0 13.7 23.7 10.6 38.8 0.88 101.4 
P value  0.12 0.05 0.003 0.01 0.01 0.08 0.37 
Abbreviations: PTV, planning target volume; CI, conformity index; V20, percent 
volume of lung receiving at least 20 Gy; ?̅?, mean dose; Dmax, maximum dose; 
UIMAT, unified intensity modulated arc therapy; Avg, average 
As a specific example, comparison of the dose distributions and DVHs between a 
UIMAT and a 5-field IMRT plan for a lung case is shown in Figure A.4. The UIMAT 
plan produced more conformal and uniform dose to the PTV and lower doses to left lung, 
esophagus, and spinal cord compared with the IMRT plan. 
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Figure A.4: Comparison of dose distributions between a clinical IMRT plan (top left) 
and a UIMAT plan (top right) and corresponding dose volume histograms (bottom) for a 
lung case (patient 6). 
A.3.1.b - Prostate 
The dosimetric parameters of UIMAT and clinical VMAT plans for five prostate 
cases are shown in Table A.4. The multiple conformity indices for patient 14 correspond 
to the multiple PTVs within the plan. No significant dosimetric difference was observed 
between UIMAT and VMAT plans for the prostate cases studied. The overall average of 
the mean OAR doses listed in Table A.4 was reduced by 3.5% (p=0.009) using UIMAT 
compared with VMAT plans. As a specific example, comparison of the dose distributions 
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and DVHs between a UIMAT and a VMAT plan for a prostate case is shown in Figure 
A.5. In this case, the UIMAT plan is dosimetrically similar to the clinical VMAT plan.  
 
 
Figure A.5: Comparison of dose distributions between a clinical VMAT plan (top left) 
and a UIMAT plan (top right) and corresponding dose volume histograms (bottom) for a 
prostate case (patient 14). 
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Table A.4: Dose volume parameters of interest for five prostate cases. The bowel was not contoured for 
two patients as it lay well outside the treatment volume. The conformity indices correspond to the target 
volumes listed in the third-last column, and similarly for the mean PTV doses. Since not all patients had 
the same number of PTV dose levels, P values for PTVs were calculated for the highest dose level only. 
No. Plan 
Rectum 
?̅? [Gy] 
Bladder 
?̅? [Gy] 
Bowel 
?̅? [Gy] 
Lt. Femur 
?̅? [Gy] 
Rt. Femur 
?̅? [Gy] 
PTV(s) 
Pres. [Gy] 
Conformity 
Index 
PTV 
?̅? [%] 
11 
Clinical 41.4 15.0 -- 19.0 22.6 
76 
0.83 101.4 
UIMAT 39.2 12.3 -- 16.3 17.6 0.85 101.9 
12 
Clinical 41.4 54.3 53.1 22.4 16.5 
66 
0.82 98.2 
UIMAT 42.8 55.5 52.2 20.8 20.8 0.87 98.1 
13 
Clinical 34.2 34.2 28.8 16.1 15.3 
45 
0.78 103.4 
UIMAT 32.2 33.4 26.3 16.2 13.8 0.84 101.9 
14 
Clinical 45.6 45.5 31.6 22.9 21.5 
76/50.4 
0.91/.0.60 102.0/107.0 
UIMAT 46.4 43.8 29.7 19.4 21.6 0.88/0.59 102.2/106.6 
15 
Clinical 32.3 17.9 -- 23.4 23.3 
66 
0.91 100.9 
UIMAT 32.1 17.8 -- 21.7 22.5 0.84 100.9 
Average 
Clinical 39.0 33.4 37.85 20.8 19.8  0.81 102.1 
UIMAT 38.6 32.6 36.1 18.9 19.3 0.81 101.9 
P value  0.29 0.16 0.03 0.02 0.37  0.39 0.26 
Abbreviations: PTV, planning target volume; Lt, left; Rt, right; Pres, prescription; ?̅?, mean dose; UIMAT, unified 
intensity modulated arc therapy 
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A.4  Discussion 
We have shown that it is feasible to optimize and deliver UIMAT which combines 
VMAT and IMRT within the same arc. We have also shown how the degree of intensity 
modulation can be naturally incorporated into an algorithm which dynamically varies the 
angular density of the beam control points. Compared with clinical VMAT or IMRT 
plans, UIMAT has the potential to produce efficient and superior radiation dose 
distributions, especially for complex anatomy such as in head-and-neck cancers. On the 
other hand, for the sites with more rotational symmetry, such as prostate, UIMAT may 
not yield significant advantages as it resulted in plans with comparable dosimetric 
performance but less efficient delivery compared with VMAT. 
One of the virtues of our proposal is that the switch from the current VMAT 
technique to our unified approach would, in principle, be seamless. Treatment planning 
for UIMAT would be the same as for VMAT as no selection of static beam directions is 
required. Similarly, radiation therapists delivering the treatment would not need to 
perform any additional steps beyond what is commonly done for stand-alone VMAT 
delivery, although they must be made aware of the stopped gantry during IMRT phases 
of UIMAT delivery. Another benefit of our proposal is the ease at which it can be 
incorporated into a working clinical system, thus decreasing both cost and time between 
conception and clinical implementation. Of course, in practice, the introduction of this 
technique, as with all new techniques, would require additional quality assurance and 
testing.  
Compared with other IMRT/VMAT combination techniques [7-12], our proposal 
offers simplicity in integration, optimization, and delivery. Our UIMAT proposal is not 
simply an IMRT/VMAT hybrid technique. It would be more correct to refer to it as a 
more fully-realized implementation of VMAT with fuller range of gantry speed that even 
permits gantry stalls, thus allowing for optimal beam modulation. What we have 
demonstrated is one specific implementation of UIMAT, and in principle, it could be 
generalized further. UIMAT could be further developed with more robust segmentation 
and optimization algorithms, as well as more degrees of freedom such as collimator 
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angle, couch position, and couch angle. Such future developments could hopefully 
address certain limitations within our initial implementation of UIMAT. For example, 
once the initial gantry directions are chosen for IMRT phases at the start of optimization, 
they cannot be altered at a later point in the optimization. For most cases this should not 
be a problem, except if the objective function changes dramatically between initial and 
final optimization. It should be noted that the same is true for VMAT and IMRT 
planning. After the fluence map conversion takes place, it becomes much easier for the 
optimization routine to become trapped in local minima.  
In the planning comparison portion of this work, we acknowledge the usual biases 
and confounders inherent in such an approach. For example, there is a natural tendency 
towards demonstrating that a new treatment is superior to the standard-of-care. More 
effort may be spent optimizing the new technique, or choosing comparison endpoints that 
naturally favor the new method. Unfortunately, requiring the matching of equal planning 
effort is not practical, but we were conscious in avoiding “over-optimizing” the UIMAT 
plans. In this retrospective study, the actual difference in planning time was not logged 
precisely. Depending on the complexity of the case, clinical planning in our experience 
requires 1 to 4 hours. To ensure a fair planning comparison, we restricted UIMAT 
planning times to fall within a similar range. 
We acknowledge that the number of cases tested in this feasibility study is very 
limited and so the statistics reported only highlight general trends. More cases are needed 
for each treatment site to confirm the conclusions reached. Finally, as mentioned earlier, 
dynamic jaws are needed when treating large volumes with a single arc due to the finite 
speed and length of the MLC leaves. This is an obvious advantage for UIMAT as it 
allows more freedom for collimating the beam; however comparable degrees of freedom 
were still available in our clinical plans but required more than one arc with differing jaw 
positions. 
Compared to other published techniques [7-12] combining IMRT and VMAT, 
UIMAT is unique in that it possesses all of the following features: 1) it creates VMAT 
and IMRT phases automatically; 2) it optimizes VMAT and IMRT phases 
 130 
 
simultaneously; 3) the VMAT and IMRT phases are combined and delivered in a single 
dynamic arc; 4) the algorithm has been implemented on a commercial treatment planning 
system; 5) the UIMAT plans have been validated using the ArcCheck phantom, delivered 
in clinical mode on a Varian TrueBeam linear accelerator. Theoretically, it is known that 
the increased degrees of freedom afforded by the IMRT phases of the arc will in principle 
lead to a superior plan, all other things being equal. What we have shown is that this 
appears to be the case, even with this simple initial implementation. Further 
improvements in the optimization beyond what is possible within a commercial treatment 
planning software should lead to even better results. Last but not least, our work shows 
that the UIMAT delivery speed is improved over IMRT or when multiple VMAT arcs are 
required. 
A.5  Conclusion 
We have demonstrated the feasibility of a novel radiation therapy delivery technique 
termed UIMAT. This technique combines VMAT and IMRT optimization concurrently 
and delivers radiation in a single arc. The optimal fixed-gantry IMRT phases are chosen 
automatically during the optimization. Optimization of both the VMAT and fixed-gantry 
IMRT phases of delivery occur simultaneously and the final plan is an integrated UIMAT 
plan. Initial results show that the UIMAT has the potential to be superior to either stand-
alone IMRT or VMAT in terms of dose distribution quality and efficiency of delivery.  
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Supplemental Figure 2.1: OAR dose-volume histograms averaged over: a) & b) all 
cases; c) & d) VMAT cases only; e) & f) IMRT cases only.  
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Supplementary Table 2.1: Summary of UIMAT and clinically delivered treatment plans. Patients with 
several prescriptions had multiple target volumes, each with the listed dose levels. 
  
Dose 
Prescription  
Beam Arrangement Delivery Time [s] IMRT QA [%] 
Patient   Site [Gy] Clinical UIMAT Clinical UIMAT Clinical UIMAT 
1 Right Parotid 64/60/54 2 - 210o Arcs 1 - 360o Arc 115 145 99.4 97.5 
2 Right Parotid 60 2 - 225o Arcs 1 - 230o Arc 121 161 99.3 99.5 
3 Neck/Parotids 70/56 2 - 360o Arcs 1 - 360o Arc 194 180 98.5 97.6 
4 Larynx/Neck 70/56 2 - 360o Arcs 1 - 360o Arc 177 176 94.4 96.9 
5 Right Parotid 50 2 - 180o Arcs 1 - 190o Arc 92 135 98.3 98.7 
6 Left Neck 66/64/60/54 2 - 360o Arcs 1 - 360o Arc 182 131 99.6 98.5 
7 Whole Neck 70/56 2 - 360o Arcs 1 - 360o Arc 174 198 96.0 96.1 
8 Left Parotid 50 2 - 180o Arcs 1 - 180o Arc 109 81 99.4 97.5 
9 Hypopharynx 66/60/56 2 - 360o Arc 1 - 360o Arc 166 125 99.3 98.0 
10 Right Neck 54 2 - 360o Arcs 1 - 360o Arc 171 159 97.2 96.6 
11 Left Neck 50 2 - 210o Arcs 1 - 190o Arc 120 154 99.6 97.4 
12 Right Neck 72/65 2 - 360o Arcs 1 - 210o Arc 168 82 98.3 97.8 
13 Right Neck 55/45 2 - 180o Arcs 1 - 210o Arc 101 135 100.0 98.0 
14 Oral Cavity 66/64/60/54 2 - 360o Arcs 1 - 360o Arc 174 97 97.7 96.0 
15 Larynx/Neck 70/56 2 - 360o Arcs 1 - 360o Arc 168 123 98.8 97.2 
16 Left Neck 64/60 4F SS-IMRT 1 - 190o Arc 188 108 99.8 97.9 
17 Left Head 64/60/54 4F SS-IMRT 1 - 190o Arc 204 144 98.0 97.8 
18 Ethmoid 70/63/56 4F SS-IMRT 1 - 210o Arc 127 109 99.6 97.2 
19 Left Parotid 50 4F SS-IMRT 1 - 210o Arc 224 167 99.3 97.8 
20 Right Neck 50/45 5F SS-IMRT 1 - 230o Arc 269 182 99.3 98.9 
21 Right Neck 70/56 5F SS-IMRT 1 - 240o Arc 313 94 99.8 96.7 
22 Left Neck 60/54 6F SS-IMRT 1 - 360o Arc 339 136 99.2 97.6 
23 Hypopharynx 70/63/56 6F SS-IMRT 1 - 360o Arc 320 214 98.9 95.1 
24 Hypopharynx 70/56 6F SS-IMRT 1 - 360o Arc 348 147 98.4 95.7 
25 Larynx/Neck 70/63/56 6F SS-IMRT 1 - 360o Arc 287 111 97.9 99.6 
26 Right Neck 50/45 4F SS-IMRT 1 - 360o Arc 235 148 98.0 97.9 
27 Hypopharynx 60/54 6F SS-IMRT 1 - 360o Arc 358 192 93.4 94.7 
28 Left Neck 64/60/54 4F SS-IMRT 1 - 360o Arc 262 202 99.4 97.5 
29 Tonsils 70/63/56 6F SS-IMRT 1 - 360o Arc 296 117 97.6 98.3 
30 Right Neck 60/54 4F SS-IMRT 1 - 360o Arc 244 154 99.4 96.4 
*Abbreviations: UIMAT, unified intensity-modulated arc therapy; nF SS-IMRT, n-field step-and-shoot 
intensity-modulated radiation therapy. 
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Supplementary Table 2.2: Comparison of dose metrics between the unified plans and the clinically delivered VMAT plans. PTV mean doses and D95 (dose 
to 95% of the volume) are given as percentages of the prescribed dose to the target volume(s). Max doses are defined as the dose to 2% of the volume. Missing 
dose metrics are a result of OARs which were not contoured, for example due to an OAR being completely enclosed within the PTV. 
  Planning Target Volume(s) 
Oral 
Cavity 
Left 
Parotid 
Right 
Parotid Larynx Cord Brainstem 
Left 
Cochlea 
Right 
Cochlea 
No. Plan Conformity Index Mean (%) D95 (%) 
Mean 
(Gy) 
Mean 
(Gy) 
Mean 
(Gy) 
Mean 
(Gy) 
Max 
(Gy) 
Max  
(Gy) 
Max 
(Gy) 
Max  
(Gy) 
1 
VMAT 0.21/0.77/0.63 99/101/103 97/97/97 28.3 6.9 - 33.8 20.4 14.0 6.2 25.3 
Unified 0.16/0.80/0.63 101/102/104 99/97/98 15.6 2.0 - 26.2 13.5 6.0 2.1 17.6 
2 
VMAT 0.87 101 98 30.0 5.9 60.9 27.9 31.9 11.1 5.6 27.6 
Unified 0.86 101 97 23.1 2.6 60.8 22.2 23.4 5.1 1.6 10.6 
3 
VMAT 0.78/0.71 101/105 99/98 39.5 25.3 25.5 48.7 37.0 40.4 27.3 32.4 
Unified 0.74/0.66 101/106 99/99 35.0 22.6 22.6 45.5 32.4 31.4 13.5 26.3 
4 
VMAT 0.83/0.79 100/102 98/97 33.2 25.9 25.6 - 35.8 25.7 3.8 2.9 
Unified 0.82/0.78 101/103 99/99 21.3 26.1 24.6 - 29.4 11.0 4.0 2.3 
5 
VMAT 0.74 101 98 5.8 2.0 - 0.4 16.5 20.3 2.3 50.0 
Unified 0.76 102 99 5.0 2.6 - 0.4 9.2 11.7 2.5 50.0 
6 
VMAT 0.19/0.44/0.77/0.67 102/102/102/103 99/99/98/99 39.5 39.9 30.6 50.5 39.8 42.3 25.2 19.8 
Unified 0.15/0.37/0.73/0.65 101/102/103/103 99/99/97/99 35.8 39.8 30.8 52.2 35.1 39.8 19.5 20.0 
7 
VMAT 0.84/0.75 101/106 98/98 30.5 29.7 30.4 64.7 37.0 35.0 19.0 9.8 
Unified 0.85/0.75 102/107 98/98 22.7 31.0 32.1 65.2 31.2 24.6 9.6 4.6 
8 
VMAT 0.72 102 99 5.2 43.9 1.3 0.2 7.3 6.2 17.1 1.2 
Unified 0.68 104 99 3.6 44.3 1.1 0.2 5.6 2.8 9.4 1.0 
9 
VMAT 0.75/0.55/0.72 100/103/107 97/99/98 37.7 37.3 32.9 65.8 37.5 39.6 11.9 12.2 
Unified 0.74/0.54/0.71 101/105/106 97/101/97 35.7 34.0 29.5 66.7 36.7 31.0 7.3 7.5 
10 
VMAT 0.92 101 97 4.7 6.6 20.3 0.7 41.6 40.5 4.3 7.9 
Unified 0.87 101 97 3.0 4.2 16.1 1.0 36.8 32.4 1.8 6.2 
11 
VMAT 0.80 101 98 18.1 - 7.8 31.0 18.3 21.5 50.8 8.2 
Unified 0.79 101 98 14.8 - 2.2 24.1 14.3 7.5 51.6 2.0 
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  Planning Target Volume(s) 
Oral 
Cavity 
Left 
Parotid 
Right 
Parotid Larynx Cord Brainstem 
Left 
Cochlea 
Right 
Cochlea 
No. Plan Conformity Index Mean (%) D95 (%) 
Mean 
(Gy) 
Mean 
(Gy) 
Mean 
(Gy) 
Mean 
(Gy) 
Max 
(Gy) 
Max  
(Gy) 
Max 
(Gy) 
Max  
(Gy) 
12 
VMAT 0.52/0.83 101/101 97/96 22.6 4.7 - 36.1 19.7 18.6 5.2 25.0 
Unified 0.45/0.85 101/102 98/96 10.2 2.8 - 28.0 14.5 7.9 1.6 12.1 
13 
VMAT 0.68/0.73 100/109 96/105 8.9 - 46.4 27.8 25.0 4.3 3.1 12.3 
Unified 0.58/0.66 101/110 97/98 8.0 - 46.5 24.1 20.1 4.4 3.1 6.9 
14 
VMAT 0.42/0.26/0.71/0.65 100/101/102/103 90/99/97/98 44.0 33.4 28.8 55.0 40.2 57.3 64.6 35.0 
Unified 0.27/0.24/0.68/0.66 100/102/103/103 89/99/96/96 43.0 33.2 26.3 55.5 37.7 56.9 65.5 29.5 
15 
VMAT 0.74/0.73 103/105 101/100 29.2 24.3 25.0 - 37.9 37.1 13.8 16.1 
Unified 0.71/0.70 103/107 100/100 22.7 19.5 20.0 - 32.9 29.7 5.9 8.2 
Med. 
VMAT 0.73 101.5 98.0 29.2 25.3 27.2 33.8 35.8 25.7 11.9 16.1 
Unified 0.70 102.3 98.2 21.3 22.6 25.5 26.2 29.4 11.7 5.9 8.2 
P-value 0.003 0.001 0.695 0.002 0.173 0.071 0.173 0.001 0.001 0.011 0.001 
*Abbreviations: D95, dose to 95% of the volume; VMAT, volumetric modulated arc therapy; Med, Median. 
† P-values were calculated using the Wilcoxon signed-rank test. 
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Supplemental Table 2.3: Comparison of dose metrics between the unified plans and the clinically delivered IMRT plans. PTV mean doses and D95 (dose to 
95% of the volume) are given as percentages of the prescribed dose to the target volume(s). Max doses are defined as the dose to 2% of the volume. Missing 
dose metrics are a result of OARs which were not contoured, for example due to an OAR being completely enclosed within the PTV. 
  Planning Target Volume(s) 
Oral 
Cavity 
Left 
Parotid 
Right 
Parotid Larynx 
 
Cord Brainstem 
Left 
Cochlea 
Right 
Cochlea 
No. Plan Conformity Index Mean (%) D95 (%) 
Mean 
(Gy) 
Mean 
(Gy) 
Mean 
(Gy) 
Mean 
(Gy) 
Max 
(Gy) 
Max  
(Gy) 
Max 
(Gy) 
Max  
(Gy) 
16 
IMRT 0.19/0.11 101/102 96/96 33.9 - 10.2 41.0 40.4 32.1 29.9 5.0 
Unified 0.18/0.11 101/102 96/96 27.5 - 7.8 41.1 37.3 24.2 25.7 4.5 
17 
IMRT 0.17/0.67/0.60 100/102/102 96/97/97 20.5 - 9.9 32.0 33.9 22.2 40.2 13.4 
Unified 0.16/0.60/0.60 101/102/103 98/99/97 16.7 - 4.9 27.0 28.9 22.2 29.2 7.0 
18 
IMRT 0.76/0.63/0.54 100/102/112 95/98/103 34.1 28.0 6.3 0.6 34.6 44.0 59.9 25.2 
Unified 0.81/0.65/0.55 101/102/109 96/99/101 32.8 27.1 5.2 0.6 27.0 41.0 56.3 17.7 
19 
IMRT 0.81 101 95 14.0 - 7.9 24.8 30.9 20.7 23.8 8.2 
Unified 0.83 101 96 12.4 - 3.9 22.3 24.8 8.0 14.1 4.0 
20 
IMRT 0.81/0.59 101/102 97/99 16.2 8.0 - 34.6 27.6 18.9 8.5 22.9 
Unified 0.79/0.61 101/102 96/99 13.8 3.7 - 30.5 15.9 6.4 2.5 9.7 
21 
IMRT 0.85/0.63 101/105 95/99 29.5 - 58.0 40.0 25.3 14.6 1.5 24.3 
Unified 0.86/0.68 102/104 97/99 23.3 - 58.1 38.5 23.3 6.6 1.4 11.4 
22 
IMRT 0.70/0.68 101/103 97/97 41.0 28.3 25.0 55.2 37.1 36.5 13.6 13.8 
Unified 0.76/0.70 101/102 98/97 40.1 26.4 15.7 54.1 30.6 23.5 5.3 5.2 
23 
IMRT 0.71/0.67/0.53 100/103/104 95/95/97 51.3 33.0 30.2 71.3 41.5 45.0 7.2 9.8 
Unified 0.71/0.68/0.56 99/103/105 95/95/99 45.6 31.0 28.4 70.6 39.4 38.8 5.1 6.2 
24 
IMRT 0.84/0.60 100/106 95/98 46.0 52.0 39.4 - 40.9 46.9 6.1 6.8 
Unified 0.83/0.63 102/107 97/99 35.4 48.3 36.6 - 39.0 35.9 5.9 5.7 
25 
IMRT 0.82/0.66/0.71 100/102/105 95/98/96 37.4 25.2 29.4 - 40.5 25.4 8.1 17.5 
Unified 0.83/0.62/0.69 102/104/106 97/100/99 27.7 20.9 26.1 - 39.6 20.2 8.2 11.2 
26 
IMRT 0.71/0.64 102/105 99/98 39.0 42.7 8.6 37.4 25.3 19.9 26.3 2.0 
Unified 0.78/0.69 102/104 98/99 30.8 40.0 3.2 30.9 21.3 10.6 23.3 1.3 
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 Planning Target Volume(s) 
Oral 
Cavity 
Left 
Parotid 
Right 
Parotid Larynx Cord Brainstem 
Left 
Cochlea 
Right 
Cochlea 
No. 
Plan Conformity Index Mean (%) D95 (%) 
Mean 
(Gy) 
Mean 
(Gy) 
Mean 
(Gy) 
Mean 
(Gy) 
Max 
(Gy) 
Max  
(Gy) 
Max 
(Gy) 
Max  
(Gy) 
27 
IMRT 0.74/0.61 99/103 95/97 33.2 29.9 30.7 25.3 38.0 34.4 4.8 3.3 
Unified 0.74/0.59 101/102 97/99 23.5 25.3 26.0 15.3 36.7 32.8 4.5 3.1 
28 
IMRT 0.54/0.61/0.56 100/101/101 96/97/96 27.7 - 4.7 39.6 34.5 23.5 2.2 0.9 
Unified 0.47/0.67/0.56 102/102/101 98/98/99 23.7 - 2.7 37.6 28.8 11.6 2.1 0.9 
29 
IMRT 0.76/0.58/0.57 101/106/103 97/101/98 61.3 37.8 29.6 58.1 39.6 46.6 32.8 9.5 
Unified 0.77/0.56/0.59 103/105/104 98/102/98 57.7 36.1 21.0 55.8 35.3 32.4 16.5 7.0 
30 
IMRT 0.75/0.59 100/102 96/98 23.1 3.4 58.6 30.3 35.3 3.4 0.7 2.4 
Unified 0.73/0.56 101/103 97/100 10.0 2.6 58.3 20.9 30.3 4.5 0.6 2.0 
Med. 
IMRT 0.67 101.8 96.7 33.9 29.1 27.2 37.4 35.3 25.4 8.5 9.5 
Unified 0.67 102.2 98.0 27.5 26.7 18.4 30.9 30.3 22.2 5.9 5.7 
P-value 0.256 0.011 0.004 0.001 0.005 0.001 0.002 0.001 0.001 0.001 0.001 
*Abbreviations: D95, dose to 95% of the volume; IMRT, intensity-modulated radiation therapy; Med, Median.  
† P-values were calculated using the Wilcoxon signed-rank test. 
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Appendix D – Supplemental Data for Chapter 3 
This content of this appendix was previously published with the article “A fast 
inverse direct aperture optimization algorithm for intensity-modulated radiation therapy” 
by Michael MacFarlane, Douglas Hoover, Eugene Wong, Pedro Goldman, Jerry J. 
Battista, and Jeff Z. Chen, Medical Physics, Early View (2019). Permission to reproduce 
this article was granted by John Wiley and Sons and is provided in Appendix B.3. 
 
 
Supplemental Figure 3.1: Dose-volume histograms of the prostate case after undergoing 
FMO and aperture sequencing (dotted) and when optimized with the FIDAO (solid) and 
the standard (dashed) DAO algorithms. 
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Supplemental Figure 3.2: Dose-volume histograms of the liver case after undergoing 
FMO and aperture sequencing (dotted) and when optimized with the FIDAO (solid) and 
the standard (dashed) DAO algorithms. 
 
Supplemental Figure 3.3: Dose-volume histograms of the head-and-neck case after 
undergoing FMO and aperture sequencing (dotted) and when optimized with the FIDAO 
(solid) and the standard (dashed) DAO algorithms. 
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Supplemental Table 3.1: PTV dosimetric and volume statistics for each plan. Note that P.S. stands for the Post Sequencing plan. R50 is defined as the ratio 
of the 50% prescription isodose line to the PTV volume. 
Case 
 No. Of 
Voxel 
Volume 
[cc] 
D98 [Gy] D02 [Gy] Conformity Index 
Homogeneity 
Index R50 
PTV P.S. Std. FIDAO P.S. Std. FIDAO P.S. Std. FIDAO P.S. Std. FIDAO P.S. Std. FIDAO 
TG119 PTV50 7429 94.7 40.0 46.3 46.3 50.8 52.8 52.8 0.4 0.7 0.8 17.4 9.0 9.5 4.5 4.8 4.7 
Prostate PTV56 9491 1020.7 32.3 53.0 52.5 54.4 60.4 60.6 0.0 0.2 0.2 33.4 8.4 9.1 9.8 12.8 12.9 
 PTV68 6770 259.6 50.2 64.0 64.2 68.0 69.7 69.9 0.3 0.6 0.6 20.9 6.1 6.1 6.7 10.0 10.1 
Liver PTV45 6954 156.5 38.7 43.2 43.4 46.2 46.1 46.2 0.8 0.7 0.8 11.4 4.1 4.2 3.2 5.4 5.4 
Head-
and-
neck 
PTV56 2104 94.7 38.5 54.9 54.8 53.4 57.1 57.3 0.0 0.0 0.0 20.1 2.9 3.2 18.5 40.5 40.5 
PTV63 22682 1020.7 26.4 59.1 58.8 60.9 67.5 67.4 0.0 0.5 0.5 44.4 9.7 9.9 1.5 3.5 3.5 
PTV70 5768 259.6 45.6 67.4 67.3 68.2 71.4 71.4 0.1 0.7 0.7 26.1 4.5 4.5 5.2 12.6 12.6 
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Supplemental Table 3.2: OAR dose statistics for each plan and structure. 
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Appendix E – Supplemental Data for Chapter 5 
This content of this appendix was previously published with the article “Patient-specific 
calibration of cone-beam computed tomography data sets for radiotherapy dose 
calculations and treatment plan assessment” by Michael MacFarlane, Daniel Wong, 
Douglas A. Hoover, Eugene Wong, Carol Johnson, Jerry J. Battista, and Jeff Z. Chen, 
Journal of Applied Clinical Medical Physics, 19 (2): 249-257 (2018). Permission to 
reproduce this article was granted by John Wiley and Sons and is provided in Appendix 
B.4.  
 
Supplemental Table 5.1: Summary of Patient Treatment Information 
No. 
Primary 
Disease Site Delivery Method Re-planned After 
1 Tongue 2 Coplanar 360o Arcs 18/35 Fxns 
2 Mouth Floor 2 Coplanar 360o Arcs 9/30 Fxns 
3 Right Neck 2 Coplanar 360o Arcs 27/35 Fxns 
4 Tongue 2 Coplanar 360o Arcs 29/35 Fxns 
5 Oropharynx 2 Coplanar 360o Arcs 17/35 Fxns 
6 Mouth 2 Coplanar 180o Arcs 12/30 Fxns 
7 Tonsils 2 Coplanar 360o Arcs 21/35 Fxns 
8 Tonsils 2 Coplanar 360o Arcs 17/35 Fxns 
9 Tongue 2 Coplanar 360o Arcs 14/35 Fxns 
10 Tonsils 2 Coplanar 360o Arcs 26/35 Fxns 
11 Tonsils 2 Coplanar 360o Arcs 20/35 Fxns 
12 Tongue 2 Coplanar 360o Arcs 27/35 Fxns 
13 Tongue 2 Coplanar 360o Arcs 24/35 Fxns 
14 Neck 2 Coplanar 360o Arcs 21/35 Fxns 
15 Nasal Cavity 2 Non-coplanar Arcs 17/30 Fxns 
Abbreviations: Fxns, fractions. 
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Supplemental Table 5.2: Summary of the planning CT acquisition. 
No. Device 
Acquisition 
Date 
Energy 
[kV] 
X-Ray 
Current 
[mA] 
Exposure 
Time 
[ms] 
Exposure 
[mAs] Slices 
Voxel Size 
[mm] 
1 Brilliance Big Bore 11/27/2012 120 283 1060 300 146 1.01 x 1.01 x 3 
2 Brilliance Big Bore 4/5/2016 120 245 1224 300 141 1.10 x 1.10 x 3 
3 Brilliance Big Bore 5/15/2015 120 281 1068 300 135 1.00 x 1.00 x 3 
4 Brilliance Big Bore 5/11/2016 120 242 1240 300 155 1.22 x 1.22 x 3 
5 Brilliance Big Bore 8/14/2013 120 283 1060 300 126 1.02 x 1.02 x 3 
6 Brilliance Big Bore 9/25/2013 120 281 1068 300 151 0.97 x 0.97 x 3 
7 Brilliance Big Bore 12/9/2013 120 244 1230 300 140 1.09 x 1.09 x 3 
8 Brilliance Big Bore 12/3/2013 120 281 1068 300 158 1.00 x 1.00 x 3 
9 Brilliance Big Bore 1/27/2014 120 281 1068 300 136 0.93 x 0.93 x 3 
10 Brilliance Big Bore 5/13/2014 120 283 1060 300 134 1.02 x 1.02 x 3 
11 Brilliance Big Bore 6/8/2015 120 244 1230 300 120 1.18 x 1.18 x 3 
12 Brilliance Big Bore 6/24/2015 120 208 1447 301 135 1.30 x 1.30 x 3 
13 Brilliance Big Bore 4/11/2016 120 281 1068 300 140 0.93 x 0.93 x 3 
14 Brilliance Big Bore 4/11/2016 120 283 1060 300 121 0.93 x 0.93 x 3 
15 Brilliance Big Bore 9/23/2015 120 244 1230 300 124 1.05 x 1.05 x 3 
 
Supplemental Table 5.3: Summary of the re-planning CT acquisition. 
No. Device 
Acquisition 
Date 
Energy 
[kV] 
X-Ray 
Current 
[mA] 
Exposure 
Time 
[ms] 
Exposure 
[mAs] Slices 
Voxel Size 
[mm] 
1 Brilliance Big Bore 1/8/2013 120 244 1230 300 153 1.20 x 1.20 x 3 
2 Brilliance Big Bore 5/26/2016 120 244 1230 300 137 1.08 x 1.08 x 3 
3 Brilliance Big Bore 7/8/2015 120 244 1230 300 167 1.13 x 1.13 x 3 
4 Brilliance Big Bore 6/29/2016 120 244 1230 300 131 1.10 x 1.10 x 3 
5 Brilliance Big Bore 9/19/2013 120 244 1230 300 158 1.13 x 1.13 x 3 
6 Brilliance Big Bore 10/21/2013 120 281 1068 300 144 1.04 x 1.04 x 3 
7 Brilliance Big Bore 1/28/2014 120 244 1230 300 156 1.19 x 1.19 x 3 
8 Brilliance Big Bore 1/10/2014 120 281 1068 300 153 0.98 x 0.98 x 3 
9 Brilliance Big Bore 2/28/2014 120 244 1230 300 137 1.16 x 1.16 x 3 
10 Brilliance Big Bore 6/27/2014 120 281 1068 300 134 1.03 x 1.03 x 3 
11 Brilliance Big Bore 7/24/2015 120 244 1230 300 146 1.05 x 1.05 x 3 
12 Brilliance Big Bore 8/11/2015 120 281 1068 300 137 0.97 x 0.97 x 3 
13 Brilliance Big Bore 5/26/2016 120 244 1230 300 143 1.15 x 1.15 x 3 
14 Brilliance Big Bore 5/10/2016 120 281 1068 300 145 1.03 x 1.03 x 3 
15 Brilliance Big Bore 11/3/2015 120 245 1224 300 125 1.11 x 1.11 x 3 
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Supplemental Table 5.4: Summary of the CBCT acquisition. 
No. Device 
Acquisition 
Date 
Energy 
[kV] 
X-Ray 
Current 
[mA] 
Exposure 
Time 
[ms] 
Exposure 
[mAs] Slices Voxel Size [mm] 
1 Clinac iX 1/8/2013 100 20 7000 140 70 0.65 x 0.65 x 2.5 
2 Truebeam 5/26/2016 100 20 7450 149 93 0.51 x 0.51 x 2.0 
3 Truebeam 7/15/2015 100 20 7450 149 93 0.51 x 0.51 x 2.0 
4 Truebeam 7/5/2016 100 20 7500 150 93 0.51 x 0.51 x 2.0 
5 Clinac iX  9/19/2013 100 20 7050 141 70 0.65 x 0.65 x 2.5 
6 Truebeam  10/21/2013 100 20 7250 145 89 0.51 x 0.51 x 2.0 
7 Clinac iX  1/28/2014 100 20 7000 140 70 0.65 x 0.65 x 2.5 
8 Truebeam 1/10/2014 100 10 7200 72 70 0.49 x 0.49 x 2.5 
9 Clinac iX  2/28/2014 100 10 7000 70 70 0.65 x 0.65 x 2.5 
10 Clinac iX  6/26/2014 100 20 7250 145 70 0.65 x 0.65 x 2.5 
11 Clinac iX  7/23/2015 100 20 6950 139 70 0.65 x 0.65 x 2.5 
12 Clinac iX  8/11/2015 100 20 7200 144 70 0.65 x 0.65 x 2.5 
13 Clinac iX  5/26/2016 100 10 7000 70 70 0.65 x 0.65 x 2.5 
14 Clinac iX  5/10/2016 100 20 7200 144 70 0.65 x 0.65 x 2.5 
15 Clinac iX  11/3/2015 100 20 7000 140 70 0.65 x 0.65 x 2.5 
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